image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
193ee6cf1d72b80bab84c9e60e663741e99e04fb370a9bb20eaef52612bcd26f.png | simple | <table><tr><td>Properties</td><td>Year</td><td>Crop</td><td>Stages</td><td>pH</td><td>Organic C</td><td>K<sub>2</sub>O</td><td>S</td><td>Zn</td><td>Fe</td><td>Mn</td><td>Mineral- N</td><td>Actinomycetes population</td></tr><tr><td>Year</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Crop</td><td>0.00</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Stages</td><td>0.00</td><td>0.00</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>pH</td><td>-0.01</td><td>0.25</td><td>0.64**</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Organic C</td><td>0.58</td><td>0.24</td><td>0.52**</td><td>0.71**</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>K<sub>2</sub>O</td><td>-0.21</td><td>0.21</td><td>0.02</td><td>0.62**</td><td>0.32</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>S</td><td>-0.09</td><td>0.13</td><td>0.09</td><td>0.11</td><td>0.30</td><td>0.09</td><td>1</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Zn</td><td>-0.02</td><td>0.34</td><td>0.37</td><td>0.66**</td><td>0.93**</td><td>0.45**</td><td>0.40</td><td>1</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Fe</td><td>-0.98</td><td>0.24</td><td>0.35</td><td>0.52*</td><td>0.73**</td><td>0.11</td><td>0.25</td><td>0.67</td><td>1</td><td> </td><td> </td><td> </td></tr><tr><td>Mn</td><td>-0.00</td><td>0.14</td><td>0.54*</td><td>0.79**</td><td>0.71**</td><td>0.15</td><td>0.37</td><td>0.63**</td><td>0.81**</td><td>1</td><td> </td><td> </td></tr><tr><td>Mineral-N</td><td>-0.00</td><td>-0.03</td><td>0.30</td><td>0.81**</td><td>0.92**</td><td>0.27</td><td>0.24</td><td>0.85**</td><td>0.74**</td><td>0.81**</td><td>1</td><td> </td></tr><tr><td>Actinomycetes population</td><td>-0.06</td><td>0.11</td><td>0.82</td><td>0.54**</td><td>0.82**</td><td>0.45**</td><td>0.04</td><td>0.84**</td><td>0.64**</td><td>0.56**</td><td>0.85**</td><td>1</td></tr></table> |
c92dc921e457c1e455040d2661a1389a8306abdd65128a1a29f4ea25e7b2cc5c.png | simple | <table><tr><td>Citation</td><td>Type of study</td><td>Sample</td><td>Gene</td><td>Clinical assessments</td><td>Main findings</td></tr><tr><td>Tsao <i>et al</i>. 2006 [22]</td><td>Case-control and follow-up</td><td>20 MDD22 Controls</td><td><i>5-HTT</i><i>IL-1β</i><i>IL-6</i><i>TNF-α</i><i>IFN-α</i></td><td>Diagnosis based on DSM-IV criteriaHDRS</td><td>Higher expression of <i>5-HTT, IL-1β, IL-6, TNF-α </i>and <i>IFN-α </i>in patients with MDD compared with controls. Significant decreased in expression of <i>5-HTT </i>and <i>IFN-α </i>after 3 months of fluoxetine treatment.</td></tr><tr><td>Cattaneo <i>et al</i>. 2012 [23]</td><td>Case-control and follow-up</td><td>74 MDD34 Controls</td><td><i>IL-1α</i><i>IL-1β</i><i>IL-4</i><i>IL-6</i><i>IL-7</i><i>IL-8</i><i>IL-10</i><i>MIF</i><i>TNF-α</i></td><td>Diagnosis based on DSM-IV or ICD-10 criteriaSCAN</td><td>Higher expression of <i>IL-1β, IL-6, MIF </i>and <i>TNF-α </i>and lower expression of <i>IL-4 </i>in patients with MDD compared with controls.<i>IL-β, TNF-α </i>and <i>MIF </i>expression predicted antidepressant response.Significant decrease in <i>IL-6 </i>expression after 8 weeks of antidepressant treatment (escitalopram or nortriptyline) in responders only.</td></tr><tr><td>Suzuki <i>et al</i>. 2010 [25]</td><td>Case-control</td><td>43 MDD43 Controls</td><td><i>ApoER2</i><i>VLDLR</i></td><td>Diagnosis based on DSM-IV criteriaHAM-DBPRS</td><td>Lower expression of <i>ApoER2 </i>in patients with MDD compared with controls.No significant difference in expression of <i>VLDLR</i>.</td></tr><tr><td>Galecki <i>et al</i>. 2012 [29]</td><td>Case-control</td><td>181 rDD149 Controls</td><td><i>COX-2</i><i>MPO</i><i>NOS2A</i><i>PLA2G2A</i></td><td>Diagnosis based on DSM-IV criteriaor ICD-10 criteriaCIDI</td><td>Higher expression of <i>COX-2, MPO</i>,<i>NOS2A </i>and <i>PLA2G2A </i>in patients with rDD compared with controls.</td></tr><tr><td>Weigelt <i>et al</i>. 2011 [33]</td><td>Case-control</td><td>24 MDD22 BPD45 Controls</td><td><i>TREM-1</i><i>DAP12</i><i>PU.1</i><i>ATF3</i><i>EGR3</i><i>MXD1</i><i>MAFF</i><i>NAB2</i></td><td>Diagnosis based on DSM-IV criteriaSCID-I</td><td>Higher expression of <i>TREM-1 </i>and <i>NAB2 </i>in patients with BPD only.Higher expression of <i>PU.1 </i>in patients with MDD and a trend for higher expression of <i>TREM-1</i>.Higher expression of <i>ATF3, EGR3, MAFF </i>and <i>MXD1 </i>in patients with both MDD and BPD.No significant difference in expression of <i>DAP12 </i>in either patient group.</td></tr></table> |
5e78a861f201d930e7e3a485756f897049e5cd29fac265d21425101c1b3a1397.png | complex | <table><tr><td>Symptoms</td><td>Mild</td><td>Moderate</td><td>Severe</td><td>Total</td></tr><tr><td>Age groups (year)</td><td>frequency (%)</td><td>frequency (%)</td><td>frequency (%)</td><td>frequency (%)</td></tr><tr><td><10</td><td>89 (8.3)</td><td>2 (9.5)</td><td>3 (4.9)</td><td>94 (8.2)</td></tr><tr><td>10–19</td><td>168 (15.7)</td><td>3 (14.3)</td><td>9 (14.8)</td><td>180 (15.6)</td></tr><tr><td>20–29</td><td>355 (33.2)</td><td>5 (23.8)</td><td>22 (36.1)</td><td>382 (33.2)</td></tr><tr><td>30–39</td><td>165 (15.4)</td><td>6 (28.6)</td><td>8 (13.1)</td><td>179 (15.6)</td></tr><tr><td>40–49</td><td>116 (10.9)</td><td>2 (9.5)</td><td>10 (16.4)</td><td>128 (11.1)</td></tr><tr><td>50–50</td><td>92 (8.6)</td><td>2 (9.5)</td><td>2 (3.3)</td><td>96 (8.3)</td></tr><tr><td>>60</td><td>84 (7.9)</td><td>1 (4.8)</td><td>7 (11.5)</td><td>92 (7.9)</td></tr><tr><td>Total</td><td>1069 (100)</td><td>21 (100)</td><td>61 (100)</td><td>1151 (100)</td></tr><tr><td>Statistical test</td><td colspan="4"><i>χ</i><sup>2</sup> = 11.11 <i>p</i> = 0.677</td></tr></table> |
518b120a1b6d2b023dd8eb3406075e25299daf49be04dc2e7778b9d1a8ddb4aa.png | complex | <table><tr><td></td><td colspan="3">Number of patients</td><td colspan="3">Number of procedures</td><td colspan="2">Efficiency</td></tr><tr><td></td><td>2010</td><td>2011</td><td>Total</td><td>2010</td><td>2011</td><td>Total</td><td>2010</td><td>2011</td></tr><tr><td>EPS 1</td><td>242</td><td>350</td><td>592</td><td>7425</td><td>9253</td><td>16678</td><td>0,863</td><td>0,822</td></tr><tr><td>EPS 2</td><td>102</td><td>84</td><td>186</td><td>1566</td><td>1185</td><td>2751</td><td>0,651</td><td>0,562</td></tr></table> |
71a480e811d613cc3167d87f1630f2f1e28665a8fc5bb47927ffd6bc2c2372a6.png | complex | <table><tr><td>Signaling questions</td><td>Answer</td><td>Risk of bias/applicability</td><td>Planned adjustment</td></tr><tr><td>Domain 1: Patient selection</td><td> </td><td> </td><td> </td></tr><tr><td>Risk of bias</td><td> </td><td>Low risk</td><td> </td></tr><tr><td>Is a consecutive sample of patients enrolled?</td><td>Yes</td><td> </td><td> </td></tr><tr><td>Is a case-control design avoided?</td><td>Yes</td><td> </td><td> </td></tr><tr><td>Does the study avoid inappropriate exclusions?</td><td>Yes</td><td> </td><td> </td></tr><tr><td>Applicability</td><td> </td><td>High concern</td><td>- Magnitude will be evaluated</td></tr><tr><td>Are there concerns that the included patients and setting do not match the topic of our study (patients had symptoms suggestive of inflammatory bowel disease in primary care)?</td><td> </td><td> </td><td> </td></tr><tr><td>Domain 2: Index test</td><td> </td><td> </td><td> </td></tr><tr><td>Risk of bias</td><td> </td><td>Low Risk</td><td> </td></tr><tr><td>Are the index test results interpreted without knowledge of the results of the reference standard?</td><td>Yes</td><td> </td><td> </td></tr><tr><td>If a threshold was used, is it pre-specified?</td><td>Yes</td><td> </td><td> </td></tr><tr><td>Applicability</td><td> </td><td>Low Concern</td><td> </td></tr><tr><td>Are there concerns that the index test, its conduct, or interpretation differ from the topic of our study (fecal calprotectin was measured with ELISA)?</td><td> </td><td> </td><td> </td></tr><tr><td>Domain 3: Reference standard</td><td> </td><td> </td><td> </td></tr><tr><td>Risk of bias</td><td> </td><td>High risk</td><td> </td></tr><tr><td rowspan="2">Is the reference standard likely to correctly classify the target condition?</td><td rowspan="2">No</td><td rowspan="2"> </td><td>- Probably not clinically relevant</td></tr><tr><td>- Adjustment in analysis[30,31]</td></tr><tr><td>Are the reference standard results interpreted without knowledge of the results of the index test?</td><td>Yes</td><td> </td><td> </td></tr><tr><td>Domain 4: Flow and timing</td><td> </td><td> </td><td> </td></tr><tr><td>Risk of bias</td><td> </td><td>High risk</td><td> </td></tr><tr><td rowspan="2">Is there an appropriate interval between index test and reference standard?</td><td rowspan="2">No</td><td rowspan="2"> </td><td>- Represents care as usual</td></tr><tr><td>- Repeated measurement index test before endoscopy</td></tr><tr><td>Do all patients receive a reference standard?</td><td>Yes</td><td> </td><td> </td></tr><tr><td>Do all patients receive the same reference standard?</td><td>No</td><td> </td><td>- Adjustment in analysis[30,31]</td></tr></table> |
d555ad9a841400f8edfcfb5ad357b4fb3f386a2bbee3ca2c543c96280c679061.png | simple | <table><tr><td>Variable</td><td>Magnesium (% (<i>n</i>))</td><td>Control (% (<i>n</i>))</td><td><i>x</i><sup>2 </sup>value</td><td><i>P </i>value</td><td>Total prevalence (% (<i>n</i>))</td></tr><tr><td>Diabetes mellitus [11,24-26]</td><td>22.4 (68/304)</td><td>21.9 (70/319)</td><td>0.016</td><td>0.9</td><td>22.2 (138/623)</td></tr><tr><td>Hypertension [24-26]</td><td>31.2 (43/138)</td><td>27.1 (38/140)</td><td>0.543</td><td>0.5</td><td>29.1 (81/278)</td></tr><tr><td>β-blocker [21-25]</td><td>45.6 (146/320)</td><td>48.6 (152/313)</td><td>0.548</td><td>0.5</td><td>47.1 (298/633)</td></tr></table> |
f3629e08b3bc9c8dcaa4b5852205a6d14f4ebebb958286fe1a96d426bfce36ba.png | complex | <table><tr><td> </td><td colspan="6">Number (%) of mice with viable GAS in tissues</td></tr><tr><td> </td><td colspan="2">Blood</td><td colspan="2">Spleen</td><td colspan="2">Liver</td></tr><tr><td>Time (h) from defined injury to infection</td><td>Trauma</td><td>Control</td><td>Trauma</td><td>Control</td><td>Trauma</td><td>Control</td></tr><tr><td>0*</td><td>4/5(80%)</td><td>4/4(100%)</td><td>4/5(80%)</td><td>(3/4)(75%)</td><td>3/5(60%)</td><td>2/4(50%)</td></tr><tr><td>24</td><td>3/6(50%)</td><td>4/6(67%)</td><td>5/6(83%)</td><td>5/6(83%)</td><td>4/6(67%)</td><td>4/6(67%)</td></tr><tr><td>48**</td><td>4/4(100%)</td><td>5/5(100%)</td><td>4/4(100%)</td><td>5/5(100%)</td><td>2/4(50%)</td><td>5/5(100%)</td></tr></table> |
a18b8c3c318991dfec71b16d56b3aed18d7e0acf7df5dbf260aa24d3556311a4.png | complex | <table><tr><td><i>Strategy</i></td><td colspan="3"><i>Clusters of terms</i></td></tr><tr><td> </td><td><i>#clusters</i></td><td><i>Interval</i></td><td><i>Mean</i></td></tr><tr><td>Semantic distance</td><td>7,564</td><td>[2; 1,354]</td><td>132.67</td></tr><tr><td>Terminology structuring</td><td>748</td><td>[1; 119]</td><td>3.82</td></tr><tr><td>(hierarchical+synonymy)</td><td> </td><td> </td><td> </td></tr><tr><td>Merging (semantic distance +</td><td>7,684</td><td>[1; 1,354]</td><td>130.75</td></tr><tr><td>hierarchical + synonymy)</td><td> </td><td> </td><td> </td></tr></table> |
b9d50b11a3f3512b0a6dcce540c33f2e5f530323c152f5778a5fb18ad26ad0db.png | complex | <table><tr><td rowspan="2"> </td><td colspan="4">Original Network</td><td colspan="4">Simplified Network</td></tr><tr><td><i>Se</i></td><td><i>Sp</i></td><td><i>Pr</i></td><td><i>F</i></td><td><i>Se</i></td><td><i>Sp</i></td><td><i>Pr</i></td><td><i>F</i></td></tr><tr><td>Proposed Method</td><td>0.63</td><td>1.0</td><td>1.0</td><td>0.77</td><td>0.67</td><td>1.0</td><td>1.0</td><td>0.80</td></tr><tr><td>TDARACNE</td><td>0.63</td><td>0.88</td><td>0.71</td><td>0.67</td><td>0.67</td><td>0.90</td><td>0.80</td><td>0.73</td></tr><tr><td>BNFinder+BDe</td><td>0.13</td><td>0.82</td><td>0.25</td><td>0.17</td><td>0.17</td><td>0.80</td><td>0.33</td><td>0.22</td></tr><tr><td>BNFinder+MDL</td><td>0.13</td><td>0.82</td><td>0.25</td><td>0.17</td><td>0.17</td><td>0.80</td><td>0.33</td><td>0.22</td></tr><tr><td>BANJO</td><td>0.25</td><td>0.76</td><td>0.33</td><td>0.27</td><td>0.50</td><td>0.70</td><td>0.50</td><td>0.50</td></tr></table> |
63ec3b2f8214a596e145d632825227847b309b4b32578ba03d4ffdaf70404987.png | complex | <table><tr><td></td><td colspan="2">Males (n = 518)</td><td colspan="2">Females (n = 626)</td></tr><tr><td></td><td><i>BP < 140/90 n = 195</i></td><td><i>SBP ≥ 140 or DBP ≥ 90 n = 323</i></td><td><i>BP=<140/90 n = 183</i></td><td><i>SBP ≥ 140 or DBP ≥ 90 n = 443</i></td></tr><tr><td>Cardiovascular disease</td><td>130 (66.7)</td><td>131 (40.6)**</td><td>73 (39.9)</td><td>118 (26.6)**</td></tr><tr><td>Diabetes mellitus</td><td>23 (12.3)</td><td>33 (10.4)</td><td>15 (8.5)</td><td>50 (11.5)</td></tr><tr><td>Family history of early CVD</td><td>50 (25.6)</td><td>99 (30.7)</td><td>62 (33.9)</td><td>150 (33.9)</td></tr><tr><td>Daily smoking</td><td>23 (11.9)</td><td>34 (10.8)</td><td>16 (9.1)</td><td>41 (10.0)</td></tr><tr><td>Quit smoking</td><td>133 (67.5)</td><td>218 (68.2)</td><td>50 (27.3)</td><td>120 (27.1)</td></tr><tr><td>Alcohol > 14 times/month</td><td>16 (9.4)</td><td>32 (11.5)</td><td>2 (1.4)</td><td>11 (3.2)</td></tr><tr><td>No physical exercise</td><td>29 (15.7)</td><td>43 (13.9)</td><td>39 (23.9)</td><td>86 (21.4)</td></tr><tr><td>Hard physical exercise</td><td>44 (25.0)</td><td>90 (30.6)</td><td>24 (15.4)</td><td>64 (17.3)</td></tr><tr><td>BMI => 27 kg/m<sup>2</sup></td><td>63 (32.3)</td><td>147 (45.5)**</td><td>80 (43.7)</td><td>234 (52.8)*</td></tr><tr><td>Education < 12 years</td><td>68 (65.4)</td><td>113 (64.9)</td><td>81 (86.2)</td><td>223 (86.4)</td></tr><tr><td>Depressed mood</td><td>5 (3.1)</td><td>6 (2.1)</td><td>11 (8.1)</td><td>21 (6.3)</td></tr><tr><td>Less than good general health</td><td>76 (40.2)</td><td>104 (33.0)</td><td>94 (53.1)</td><td>191 (43.8)*</td></tr><tr><td>Statin treatment</td><td>60 (30.8)</td><td>68 (21.1)*</td><td>58 (31.7)</td><td>96 (21.7)*</td></tr></table> |
ca801fab6099f58d29ca76a5ec089229bd41ea1eaffa682d3399b2ef61b25d30.png | simple | <table><tr><td>Land cover class</td><td>Description</td></tr><tr><td>Crops, agricultural and open savannah</td><td>Agricultural land or grassland with occasional trees/bushes (not seasonally flooding)</td></tr><tr><td>Woodland and dense savannah</td><td>Grassland with dense trees/bushes (not seasonally flooding) and patches of woodland</td></tr><tr><td>Built up and bare ground</td><td>Towns or villages with high building density or bare murrum or mud</td></tr><tr><td>Open water</td><td>Areas of open water</td></tr><tr><td>Lake fringe swamps</td><td>Lake edges with a high density of papyrus, water hyacinth and water lilies</td></tr><tr><td>Seasonally flooded grassland</td><td>Savannah which floods during the wet season, with occasional trees/bushes</td></tr></table> |
6103beab13f8f8cfa9e66e9ded97c08e77421062e7a7b3881c8e06f0071451d7.png | simple | <table><tr><td>No. of suicide attempts by self-poisoning per case (<i>i</i>)</td><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>≥7</td></tr><tr><td>No. of cases (<i>n<sub>i</sub></i>)</td><td>---</td><td>1,069</td><td>334</td><td>156</td><td>78</td><td>32</td><td>15</td><td>30</td></tr></table> |
f6cb15fa1f9f468b9e8f2c5dac8c858e7718173c1c01dac997f9481690e989f9.png | simple | <table><tr><td>Trait</td><td>Montbéliarde</td><td>Normande</td><td>Holstein</td></tr><tr><td> </td><td>[HPD95%]</td><td>[HPD95%]</td><td>[HPD95%]</td></tr><tr><td>Milk</td><td>0.33 / 0.30*</td><td>0.33/ 0.30*</td><td>0.37 / 0.30*</td></tr><tr><td> </td><td>[0.29 ; 0.38]</td><td>[0.29 ; 0.38]</td><td>[0.33 ; 0.41]</td></tr><tr><td>Fat content</td><td>0.42/ 0.50*</td><td>0.44 / 0.50*</td><td>0.48 / 0.50*</td></tr><tr><td> </td><td>[0.36 ; 0.46]</td><td>[0.39 ; 0.49]</td><td>[0.45 ; 0.51]</td></tr><tr><td>Fertility</td><td>0.05 / 0.02*</td><td>0.06 / 0.02*</td><td>0.08 / 0.02*</td></tr><tr><td> </td><td>[0.04 ; 0.06]</td><td>[0.04 ; 0.07]</td><td>[0.06 ; 0.09]</td></tr></table> |
ce2b7b91f9cb664595e067e83f1885a558c5bf34cce9707c464893324348bbf2.png | complex | <table><tr><td>Variable</td><td colspan="2">Study group</td><td><i>P </i>value</td></tr><tr><td></td><td>Hyal-Joint<sup>® </sup>(<i>n </i>= 11)</td><td>Placebo (<i>n </i>= 9)</td><td></td></tr><tr><td>Men/women</td><td>4/7</td><td>5/4</td><td>0.653</td></tr><tr><td>Age, years, mean (SD)</td><td>57.7 (10.1)</td><td>54.6 (7.7)</td><td>0.448</td></tr><tr><td>Ethnicity</td><td></td><td></td><td>0.361</td></tr><tr><td> Black</td><td>0</td><td>1</td><td></td></tr><tr><td> Caucasian</td><td>1</td><td>1</td><td></td></tr><tr><td> Hispanic</td><td>10</td><td>6</td><td></td></tr><tr><td>Height, cm, mean (SD)</td><td>164.7 (6.1)</td><td>164.1 (10.8)</td><td>0.889</td></tr><tr><td>Weight, kg, mean (SD</td><td>79.1 (26.3)</td><td>80.9 (20.7)</td><td>0.867</td></tr><tr><td>Heart rate, beats/min, mean (SD)</td><td>75.5 (12.3)</td><td>75.7 (12.4)</td><td>0.970</td></tr><tr><td>Systolic BP, mm Hg, mean (SD)</td><td>122.8 (16.4)</td><td>135.6 (21.7)</td><td>0.152</td></tr><tr><td>Diastolic BP, mm Hg, mean (SD)</td><td>77.8 (8.9)</td><td>84.3 (10.4)</td><td>0.148</td></tr><tr><td>Rescue medication use (paracetamol 500 mg)*</td><td></td><td></td><td></td></tr><tr><td> No. capsules (range)</td><td>4 (0–19)</td><td>9 (0–29)</td><td>0.425</td></tr><tr><td> Mean (SD)</td><td>6.8 (7.3)</td><td>9.9 (9.6)</td><td></td></tr><tr><td>WOMAC scores, mean (SD)</td><td></td><td></td><td></td></tr><tr><td> Pain</td><td>10.4 (3.0)</td><td>10.1 (2.7)</td><td>0.848</td></tr><tr><td> Stiffness</td><td>4.4 (1.0)</td><td>4.4 (1.0)</td><td>0.862</td></tr><tr><td> Physical function</td><td>37.7 (7.4)</td><td>35.4 (11.5)</td><td>0.597</td></tr><tr><td> Aggregated total symptoms</td><td>52.5 (10.8)</td><td>50.0 (14.4)</td><td>0.667</td></tr><tr><td>SF-36v2 scores, mean (SD)</td><td></td><td></td><td></td></tr><tr><td> Physical functioning</td><td>30.8 (8.5)</td><td>27.1 (8.5)</td><td>0.342</td></tr><tr><td> Role-physical</td><td>35.3 (8.3)</td><td>41.9 (7.8)</td><td>0.084</td></tr><tr><td> Bodily pain</td><td>33.2 (4.8)</td><td>36.9 (4.8)</td><td>0.100</td></tr><tr><td> General health</td><td>44.1 (12.3)</td><td>45.4 (10.3)</td><td>0.814</td></tr><tr><td> Vitality</td><td>49.0 (11.3)</td><td>50.4 (11.7)</td><td>0.791</td></tr><tr><td> Social functioning</td><td>37.5 (12.0)</td><td>43.5 (11.3)</td><td>0.268</td></tr><tr><td> Role-emotional</td><td>36.1 (12.6)</td><td>40.3 (12.9)</td><td>0.467</td></tr><tr><td> Mental health</td><td>40.3 (19.7)</td><td>47.5 (9.5)</td><td>0.326</td></tr><tr><td> Physical component summary (PCS-36)</td><td>34.8 (6.3)</td><td>34.6 (6.4)</td><td>0.947</td></tr><tr><td> Mental component summary (MCS-36)</td><td>43.6 (17.5)</td><td>50.6 (11.2)</td><td>0.317</td></tr></table> |
61e7884bd84980aa976b5e4ffedf30023144ae77b8d1f020d518615c1d63b8be.png | complex | <table><tr><td></td><td>Min</td><td>Q1</td><td>Median</td><td>Q3</td><td>Max</td></tr><tr><td colspan="6"><i>Village prevalence (%)</i></td></tr><tr><td>Situation 1 <sup>a</sup></td><td>0.32</td><td>2.39</td><td>3.72</td><td>5.23</td><td>12.1</td></tr><tr><td>Situation 2 <sup>b</sup></td><td>0.95</td><td>2.07</td><td>4.5</td><td>5.79</td><td>12.3</td></tr><tr><td colspan="6"><i>City prevalence (%)</i></td></tr><tr><td>Situation 1 <sup>a</sup></td><td>2.39</td><td>2.51</td><td>3.54</td><td>4.17</td><td>6.72</td></tr><tr><td>Situation 2 <sup>b</sup></td><td>1.52</td><td>2.41</td><td>4.06</td><td>4.72</td><td>7.26</td></tr></table> |
05da0a473078abcdb157eaf0dd1d19d43e37153389184802e3fc68ab49a87fc9.png | complex | <table><tr><td></td><td colspan="2">Baseline</td><td colspan="2">Endline</td></tr><tr><td>Messages</td><td>Nutrition-focused MNCH<sup>2</sup> (<i>n</i> = 747)</td><td>Standard MNCH (<i>n</i> = 767)</td><td>Nutrition-focused MNCH<sup>2</sup> (<i>n</i> = 622)</td><td>Standard MNCH (<i>n</i> = 685)</td></tr><tr><td>Proper diet every day during pregnancy ensures weight gain of pregnant woman</td><td>77.5</td><td>78.5</td><td>97.1*</td><td>87.7</td></tr><tr><td>Proper diet every day during pregnancy ensures adequate growth of baby inside the womb</td><td>83.7</td><td>82.0</td><td>97.3*</td><td>90.4</td></tr><tr><td>Proper diet every day can ensure quick recovery of mothers after delivery</td><td>75.5</td><td>72.1</td><td>95.3*</td><td>86.0</td></tr><tr><td>Proper diet every day during pregnancy can save costs on doctor and medicine for both mother and child</td><td>46.3</td><td>49.3</td><td>84.7**</td><td>58.1</td></tr><tr><td>Proper diet during pregnancy will ensure that the child will be brainy</td><td>49.7</td><td>53.7</td><td>86.0**</td><td>61.9</td></tr><tr><td>Pregnant women should consume ≥5 different food groups daily</td><td>20.6</td><td>24.0</td><td>83.6***</td><td>16.4</td></tr><tr><td>Nutritious food is not always expensive</td><td>46.9</td><td>46.9</td><td>75.2***</td><td>46.1</td></tr><tr><td>During pregnancy, take 1 IFA tablet every day</td><td>83.7</td><td>78.6</td><td>95.8***</td><td>84.1</td></tr><tr><td>During pregnancy, take 1 calcium tablet every day</td><td>84.5*</td><td>79.4</td><td>96.6***</td><td>84.7</td></tr><tr><td>During pregnancy, take ≥2 h of rest every afternoon</td><td>75.2</td><td>70.9</td><td>91.6***</td><td>72.1</td></tr><tr><td>Avoid tea/coffee</td><td>14.1</td><td>13.0</td><td>50.3***</td><td>14.9</td></tr><tr><td>During pregnancy, a woman should gain 10–12 kg</td><td>17.1</td><td>26.0</td><td>83.6***</td><td>21.8</td></tr><tr><td>A pregnant woman should be weighed each month</td><td>30.5</td><td>36.4</td><td>84.9***</td><td>32.7</td></tr><tr><td>Total awareness score (range: 1–10)<sup>3</sup></td><td>5.42 ± 2.12</td><td>5.47 ± 2.45</td><td>8.63 ± 1.89***</td><td>5.82 ± 2.12</td></tr></table> |
4eef5e4a88ca8dc43d1e1f4669d138214f7d5f4eb906eccaa041cb17529ad578.png | simple | <table><tr><td>Case</td><td>Age (years)</td><td>Sex</td><td>Physical activity</td><td>Level affected</td></tr><tr><td>1</td><td>9</td><td>Girl</td><td>Jumping rope</td><td>T5</td></tr><tr><td>2</td><td>9</td><td>Boy</td><td>Jumping rope</td><td>T6</td></tr><tr><td>3</td><td>10</td><td>Boy</td><td>Handstand</td><td>T11</td></tr><tr><td>4</td><td>11</td><td>Boy</td><td>Jumping rope</td><td>T7</td></tr><tr><td>5</td><td>12</td><td>Boy</td><td>Physical education</td><td>T4</td></tr><tr><td>6</td><td>13</td><td>Boy</td><td>Japanese box vaulting</td><td>T6</td></tr></table> |
7c304f2b97d8607ab98cc7a17d28db9de4bcd84986d7426a66ceebbaed5385e3.png | simple | <table><tr><td>Characteristics</td><td>Mean</td><td>Standard deviation</td></tr><tr><td>Age (years)</td><td>25</td><td>1,0</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>23,9</td><td>1,9</td></tr><tr><td>Waist size (cm)</td><td></td><td></td></tr><tr><td> Male</td><td>79</td><td>5,0</td></tr><tr><td> Female</td><td>76</td><td>2,0</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>114</td><td>10,0</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>69</td><td>10,0</td></tr><tr><td>Estimated GFR (ml/min)</td><td>97,3</td><td>5,8</td></tr><tr><td>Alanine amino-transférase (UI)</td><td>28,1</td><td>1,7</td></tr></table> |
d65a08fb681dc1aca03a5b178be094df5a9d45752ccb720d55566f84b0bca30c.png | complex | <table><tr><td rowspan="2">Macaque (sequence)</td><td rowspan="2">Tissue<sup><i>a</i></sup></td><td rowspan="2">No. of sequences</td><td colspan="2">Genetic diversity (DNAsp)</td><td rowspan="2">Population recombination rate (LDhat), rho</td><td rowspan="2">Molecular adaptation (HyPhy), ω/sites</td><td rowspan="2">Stop codons, N/h</td></tr><tr><td>Pi</td><td>Theta</td></tr><tr><td rowspan="9">H1 (2,694 bp)</td><td>T</td><td>21</td><td>0.002</td><td>0.005</td><td>0</td><td>0.648/0</td><td>1</td></tr><tr><td>EPh</td><td>18</td><td>0.011</td><td>0.011</td><td>9</td><td>0.484/1</td><td>0</td></tr><tr><td>EPb</td><td>17</td><td>0.003</td><td>0.005</td><td>5</td><td>0.927/0</td><td>0</td></tr><tr><td>EPt</td><td>18</td><td>0.014</td><td>0.014</td><td>42</td><td>0.38/2</td><td>0</td></tr><tr><td>VD</td><td>25</td><td>0.008</td><td>0.011</td><td>26</td><td>0.498/3</td><td>0</td></tr><tr><td>SV</td><td>20</td><td>0.01</td><td>0.013</td><td>25</td><td>0.519/3</td><td>1</td></tr><tr><td>PR</td><td>21</td><td>0.013</td><td>0.014</td><td>26</td><td>0.588/4</td><td>0</td></tr><tr><td>UR</td><td>22</td><td>0.005</td><td>0.006</td><td>0</td><td>0.499/1</td><td>3 (1)</td></tr><tr><td>LN</td><td>7</td><td>0.014</td><td>0.014</td><td>100</td><td>0.530/2</td><td>1</td></tr><tr><td rowspan="9">H2 (2,658 bp)</td><td>T</td><td>1</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>EPh</td><td>17</td><td>0.005</td><td>0.004</td><td>0</td><td>0.571/0</td><td>1</td></tr><tr><td>EPb</td><td>20</td><td>0.01</td><td>0.013</td><td>100</td><td>0.466/7</td><td>0</td></tr><tr><td>EPt</td><td>27</td><td>0.005</td><td>0.006</td><td>2</td><td>0.417/0</td><td>0</td></tr><tr><td>VD</td><td>17</td><td>0.006</td><td>0.008</td><td>3</td><td>0.613/0</td><td>4 (2)</td></tr><tr><td>SV</td><td>19</td><td>0.01</td><td>0.009</td><td>17</td><td>0.487/2</td><td>1</td></tr><tr><td>PR</td><td>19</td><td>0.01</td><td>0.014</td><td>100</td><td>0.534/3</td><td>0</td></tr><tr><td>UR</td><td>22</td><td>0.007</td><td>0.007</td><td>5</td><td>0.522/1</td><td>0</td></tr><tr><td>LN</td><td>18</td><td>0.011</td><td>0.012</td><td>98</td><td>0.479/4</td><td>0</td></tr><tr><td rowspan="9">M1 (2,688 bp)</td><td>T</td><td>1</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>EPh</td><td>8</td><td>0.012</td><td>0.013</td><td>21</td><td>0.354/2</td><td>0</td></tr><tr><td>EPb</td><td>12</td><td>0.012</td><td>0.013</td><td>24</td><td>0.336/1</td><td>0</td></tr><tr><td>EPt</td><td>10</td><td>0.011</td><td>0.013</td><td>53</td><td>0.324/2</td><td>0</td></tr><tr><td>VD</td><td>16</td><td>0.012</td><td>0.015</td><td>100</td><td>0.35/3</td><td>0</td></tr><tr><td>SV</td><td>16</td><td>0.013</td><td>0.014</td><td>100</td><td>0.310/3</td><td>0</td></tr><tr><td>PR</td><td>12</td><td>0.012</td><td>0.014</td><td>11</td><td>0.392/0</td><td>0</td></tr><tr><td>UR</td><td>10</td><td>0.01</td><td>0.011</td><td>4</td><td>0.375/2</td><td>0</td></tr><tr><td>LN</td><td>15</td><td>0.012</td><td>0.015</td><td>100</td><td>0.331/3</td><td>0</td></tr></table> |
d7d04b1713a372623390dffe6b6abe6cf1622ffe9a74ea03de449e436dd43312.png | simple | <table><tr><td>Clone name</td><td>Comment</td></tr><tr><td>Rp11-91k4</td><td>Segmental duplication identified by BLASTN</td></tr><tr><td>Rp11-208g16</td><td>Segmental duplication identified by BLASTN</td></tr><tr><td>Rp11-119l2</td><td>Segmental duplication identified by BLASTN</td></tr><tr><td>RP11-168f7</td><td>Localization on other chromosome (chr19)</td></tr><tr><td>CDT-2278f18</td><td>Segmental duplication identified by BLASTN</td></tr><tr><td>RP11-129g16</td><td>Misplacement in database; real localization on 3q</td></tr><tr><td>RP11-79o5</td><td>Segmental duplication identified by BLASTN</td></tr><tr><td>RP11-666d14</td><td>Not functioning probe in any experiment</td></tr><tr><td>Rp11-153k19</td><td>Probe localized on other chromosome</td></tr><tr><td>Rp11-994b16</td><td>Segmental duplication identified by BLASTN</td></tr><tr><td>Rp11-732m7</td><td>Misplacement in database; real localization on 3p</td></tr><tr><td>Rp11-80p4</td><td>Localization on other chromosome (chr4)</td></tr><tr><td>Rp11-125e8</td><td>Segmental duplication identified by BLASTN</td></tr></table> |
050f6884240f7166216c974871393f0ba979d9511c520b28eb05b9f3363b178c.png | complex | <table><tr><td></td><td colspan="3">Unadjusted models</td><td colspan="3">Adjusted model</td></tr><tr><td></td><td>OR</td><td>95 % CI</td><td><i>p</i> value</td><td>OR</td><td>95 % CI</td><td><i>p</i> value</td></tr><tr><td>Age (years)</td><td>1.07</td><td>1.02 to 1.11</td><td>0.004</td><td></td><td></td><td></td></tr><tr><td>IQCODE</td><td>4.56</td><td>2.43 to 8.52</td><td><0.001</td><td>5.81</td><td>2.77 to 12.21</td><td>0.001</td></tr><tr><td>APACHE II score</td><td>1.11</td><td>0.96 to 1.27</td><td>0.15</td><td></td><td></td><td></td></tr><tr><td>Independent in ADL</td><td>0.24</td><td>0.12 to 0.49</td><td><0.001</td><td></td><td></td><td></td></tr><tr><td>Time from admission to surgery, hours</td><td>1.02</td><td>1.00 to 1.05</td><td>0.046</td><td>1.04</td><td>1.01 to 1.07</td><td>0.017</td></tr><tr><td>Living in an institution</td><td>4.61</td><td>1.80 to 11.76</td><td>0.001</td><td></td><td></td><td></td></tr><tr><td>CSF Neopterin, nmol/L<sup>a</sup></td><td>3.67</td><td>1.58 to 8.47</td><td>0.002</td><td>3.31</td><td>1.24 to 8.86</td><td>0.017</td></tr><tr><td>Centre (reference: Oslo)</td><td>0.59</td><td>0.30 to 1.19</td><td>0.14</td><td>0.58</td><td>0.22 to 1.52</td><td>0.27</td></tr></table> |
fc323e528997f92c8c3ad3618fc315a6b3cd901da62da06c1bb42305ec025a85.png | complex | <table><tr><td rowspan="2">Period</td><td colspan="3">O<sub>3</sub></td><td rowspan="2">NO</td><td rowspan="2">NO<sub>2</sub></td><td rowspan="2">NO<sub>X</sub></td><td rowspan="2">O<sub>X</sub></td></tr><tr><td>O<sub>3_mean</sub></td><td>O<sub>3_1-h max</sub></td><td>O<sub>3_8-h max</sub></td></tr><tr><td>2008: 06/01–09/30</td><td>75 ± 25</td><td>157 ± 55</td><td>129 ± 46</td><td>5 ± 4</td><td>41 ± 10</td><td>46 ± 13</td><td>116 ± 27</td></tr><tr><td>2009: 07/13–09/30</td><td>69 ± 29</td><td>161 ± 54</td><td>126 ± 52</td><td>7 ± 5</td><td>43 ± 10</td><td>50 ± 13</td><td>113 ± 28</td></tr><tr><td>2010: 06/01–09/30</td><td>53 ± 22</td><td>120 ± 50</td><td>97 ± 42</td><td>6 ± 5</td><td>47 ± 13</td><td>54 ± 14</td><td>100 ± 32</td></tr><tr><td>2011: 06/01–08/10</td><td>79 ± 35</td><td>178 ± 75</td><td>143 ± 64</td><td>4 ± 4</td><td>39 ± 10</td><td>44 ± 12</td><td>118 ± 36</td></tr><tr><td>Mean</td><td>69 ± 28</td><td>154 ± 61</td><td>124 ± 51</td><td>5 ± 5</td><td>43 ± 11</td><td>49 ± 13</td><td>112 ± 31</td></tr></table> |
0e63310c3babecd3bd4b8d6a9854e2651864e02270ef22669f9f2bbc44320cb6.png | simple | <table><tr><td> </td><td>Sum of squares</td><td>df</td><td>Mean square</td><td><i>F</i></td><td><i>P</i></td></tr><tr><td>Between group</td><td>2984.547</td><td>5</td><td>596.909</td><td>1.115</td><td>.359</td></tr><tr><td>Within group</td><td>45,518.750</td><td>85</td><td>535.515</td><td> </td><td> </td></tr><tr><td>Total</td><td>48,503.297</td><td>90</td><td> </td><td> </td><td> </td></tr></table> |
6aa400f5db796325fb90a8f00749a773ce643bda98d1f31310140c98dccc28e2.png | simple | <table><tr><td></td><td>Field hunting</td><td>Platform</td><td>Open room</td><td>Mantis</td><td>Net hole</td></tr><tr><td>Clutter</td><td><10<sup>−10</sup></td><td><0.00005</td><td>0.58</td><td>0.07</td><td><0.001</td></tr><tr><td>Net hole</td><td><10<sup>−10</sup></td><td><0.00005</td><td><0.001</td><td>0.33</td><td></td></tr><tr><td>Mantis</td><td><10<sup>−10</sup></td><td><0.00005</td><td>0.2</td><td></td><td></td></tr><tr><td>Open room</td><td><10<sup>−10</sup></td><td><0.00005</td><td></td><td></td><td></td></tr><tr><td>Platform</td><td><10<sup>−10</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Field hunting</td><td></td><td></td><td></td><td></td><td></td></tr></table> |
5862eb5cf8efb7022a5d3cc11b0a2add6355907c32e82d1f01641349ed73f9fa.png | complex | <table><tr><td></td><td colspan="3">Allicor</td><td colspan="3">Placebo</td></tr><tr><td>Time</td><td>All</td><td>Men</td><td>Women</td><td>All</td><td>Men</td><td>Women</td></tr><tr><td></td><td>(n = 26)</td><td>(n = 14)</td><td>(n = 12)</td><td>(n = 25)</td><td>(n = 14)</td><td>(n = 11)</td></tr><tr><td colspan="7">Absolute risk, %</td></tr><tr><td>At the baseline</td><td>13.1 ± 3.8</td><td>22.3 ± 6.0</td><td>2.3 ± 0.6<sup>$</sup></td><td>8.9 ± 2.4</td><td>14.3 ± 3.7</td><td>2.0 ± 0.7<sup>$</sup></td></tr><tr><td>After 12 months</td><td>8.9 ± 2.3*</td><td>15.1 ± 3.5*</td><td>1.8 ± 0.6<sup>$</sup></td><td>7.8 ± 2.4*</td><td>12.4 ± 3.9*</td><td>1.9 ± 0.6<sup>$</sup></td></tr><tr><td colspan="7">Relative risk</td></tr><tr><td>At the baseline</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>After 12 months</td><td>0.81 ± 0.08*</td><td>0.76 ± 0.08*</td><td>0.88 ± 0.15</td><td>1.05 ± 0.13</td><td>0.81 ± 0.10</td><td>1.36 ± 0.23<sup>$</sup></td></tr></table> |
d17231e2d99c231301eb87ac5f122dec0d8ce788b53348a2fef042a70e20a78c.png | simple | <table><tr><td>Images</td><td>Training samples</td><td>Testing samples</td><td>Total</td></tr><tr><td>Liver cancer </td><td>40</td><td>40</td><td>80</td></tr><tr><td>Normal cancer</td><td>60</td><td>60</td><td>120</td></tr><tr><td>Liver cirrhosis</td><td>60</td><td>60</td><td>120</td></tr><tr><td>Liver cyst</td><td>60</td><td>60</td><td>120</td></tr></table> |
b837490355ba9d2a549dabbec08f6697648df6a965977d26a0d0a1c166c76e33.png | simple | <table><tr><td></td><td>Atrial Fibrillation (AF)*</td><td>Supraventricular tachycardia (SVT)**</td><td>Atrial Flutter***</td><td>Ventricular Ectopics</td></tr><tr><td>Female, n (%)</td><td>7 (28 %)</td><td>5 (20 %)</td><td>2 (8 %)</td><td>1 (4 %)</td></tr><tr><td>Male, n (%)</td><td>7 (28 %)</td><td>0</td><td>3 (12 %)</td><td>0</td></tr></table> |
71c5fdf4564902c6426408b5b8708bcc26af9f570430c831d09391d7ccfa1dad.png | simple | <table><tr><td>No.</td><td>Factor (g/L) </td><td>Low level (-)</td><td>High level (+)</td></tr><tr><td>1</td><td>Isoeugenol</td><td>1</td><td>5</td></tr><tr><td>2</td><td>Dry Biomass</td><td>2.5</td><td>5</td></tr><tr><td>3</td><td>Tween 20</td><td>0</td><td>0.5</td></tr><tr><td>4</td><td>Tween 80</td><td>0</td><td>0.5</td></tr><tr><td>5</td><td>Glycerol</td><td>0</td><td>0.1</td></tr><tr><td>6</td><td>Yeast extract</td><td>0</td><td>0.1</td></tr><tr><td>7</td><td>Trypton</td><td>0</td><td>0.1</td></tr><tr><td>8</td><td>Cu<sup>+2</sup></td><td>0</td><td>0.05</td></tr><tr><td>9</td><td>Zn<sup>+2</sup></td><td>0</td><td>0.05</td></tr><tr><td>10</td><td>NaCl</td><td>0</td><td>50</td></tr></table> |
f8a028b19dcb78f3e574458fba33a618fac4acbb0b1aad77ea73ce52eb3e7bf0.png | complex | <table><tr><td>Applications</td><td>Examples</td><td>References</td></tr><tr><td>Oil recovery</td><td>Microbial enhanced oil recovery (MEOR)Increase amount of recoverable oil aided by rhamnolipid-producing microorganisms</td><td>[73][2, 74]</td></tr><tr><td rowspan="3">Bioremediation</td><td>Bioremediation of petroleum at contaminated sitesAddition of rhamnolipids improves solubility of hydrocarbons to facilitate degradation</td><td>[46, 75–78]</td></tr><tr><td>Bioremediation of heavy metal at contaminated lands or in water treatment plant; rhamnolipids can be applied in foaming-surfactant technology to remove heavy metal contaminants</td><td>[2, 11, 79]</td></tr><tr><td>Bioremediation of pesticides at agricultural fields; addition of rhamnolipids can enhance degradation of chemical pesticides</td><td>[11, 79]</td></tr><tr><td rowspan="2">Pest control</td><td>As emulsifier, spreaders and dispersing agent in pesticide formulations</td><td>[2, 79]</td></tr><tr><td>As bio-pesticide against agricultural pests; rhamnolipids have insecticidal activity against green peach aphids and <i>Aedes aegypti</i> larvae</td><td>[43, 80]</td></tr><tr><td rowspan="2">Crop protection</td><td>As biocontrol agent against several phytopathogenic fungi; addition of rhamnolipids or rhamnolipid-containing cell-free broth are effective in inhibiting growth of phytopathogens, e.g. <i>F. oxysporum</i>, <i>B. cinerea</i>, <i>Mucor</i> spp. and many more</td><td>[1, 7, 81–84]</td></tr><tr><td>As stimulant for plant immunity; induced genes involved in plant’s defense system in tobacco, wheat and <i>Arabidopsis thaliana</i>; induced biosynthesis of plant hormones important for signaling pathways involved in plant immunity</td><td>[43]</td></tr><tr><td rowspan="3">Food processing</td><td>As food ingredients or additives functioning as emulsifier, solubilizer, foaming and wetting agent</td><td>[7]</td></tr><tr><td>As antimicrobial agent preventing food spoilage and for sanitization; rhamnolipids inhibit growth of foodborne pathogenic bacteria, e.g. <i>L. monocytogenes</i>, <i>B. subtilis</i>; rhamnolipids also prevent formation of biofilms due to their anti-adhesive nature</td><td>[1, 85, 86]</td></tr><tr><td>As a source of (l)-rhamnose; enzymatic hydrolysis of rhamnolipids to obtain (l)-rhamnose, a raw material for production of flavor compounds</td><td>[42, 87]</td></tr><tr><td rowspan="2">Medical use</td><td>As biofilm control agent to prevent medical device-related infections; inhibit biofilm formation; synergistic effect with caprylic acid to inhibit biofilms of more resistant pathogens, e.g. <i>P. aeruginosa</i> and <i>S. aureus</i></td><td>[2, 88, 89]</td></tr><tr><td>As anticancer agent; rhamnolipids inhibit growth of many human cancer cell lines, e.g. HI-60, BV-173, SKW-3, JMSU-1 and Hela cells</td><td>[2, 19]</td></tr><tr><td>Protein folding</td><td>Aid in folding of outer membrane protein A</td><td>[90]</td></tr><tr><td>Microbial fuel cells</td><td>Improve power density output of microbial fuel cells</td><td>[91]</td></tr><tr><td>Synthesis of nanoparticles</td><td>As structure-directing agent in nanoparticle synthesis</td><td>[92]</td></tr></table> |
0fe76d3bcd7df10b6f8525eb60cf5b42b49140aa31bfab4bb8a975a28e661976.png | complex | <table><tr><td rowspan="2">Parameters</td><td colspan="2">Anemic patients</td><td colspan="2">Non-anemic patients</td></tr><tr><td>N</td><td>Number (%) or mean ± SD</td><td>N</td><td>Number (%) or mean ± SD</td></tr><tr><td>Demographics</td><td></td><td></td><td></td><td></td></tr><tr><td>Age, years</td><td>162</td><td>68.8 ± 13.2</td><td>295</td><td>66 ± 13.8</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td></tr><tr><td>(Female/Male)</td><td>162</td><td>91 (56.2) / 71 (43.8)</td><td>295</td><td>124 (42.0) / 171 (58.0)</td></tr><tr><td>Race</td><td></td><td></td><td></td><td></td></tr><tr><td>Chinese/Malay/Indian/Others</td><td>162</td><td>99 (61.1) / 34 (21.0) / 16 (9.9) / 13 (8.0)</td><td>295</td><td>202 (68.5) / 56 (19.0) / 18 (6.1) / 19 (6.4)</td></tr><tr><td>Clinical data</td><td></td><td></td><td></td><td></td></tr><tr><td>Weight, kg</td><td>67</td><td>61.8 ± 13.1</td><td>137</td><td>68.1 ± 15</td></tr><tr><td>Height, m</td><td>65</td><td>1.6 ± 0.1</td><td>135</td><td>1.6 ± 0.1</td></tr><tr><td>Body mass index, kg/m2</td><td>65</td><td>25.4 ± 4.8</td><td>133</td><td>27 ± 5.3</td></tr><tr><td>CKD stage</td><td></td><td></td><td></td><td></td></tr><tr><td>Stage 1/2/3/4/5</td><td>162</td><td>3 (1.9) / 8 (4.9) / 29 (17.9) / 52 (32.1) / 70 (43.2)</td><td>295</td><td>45 (15.3) / 0 (0.0) / 127 (43.1) / 104 (35.3) / 19 (6.4)</td></tr><tr><td>Laboratory data (serum levels), units</td><td></td><td></td><td></td><td></td></tr><tr><td>Current Hb, g/dL</td><td>162</td><td>9.2 ± 0.7</td><td>295</td><td>12.6 ± 1.7</td></tr><tr><td>Previous Hb, g/dL</td><td>162</td><td>9.9 ± 1.3</td><td>295</td><td>12.6 ± 1.7</td></tr><tr><td>Sodium, mmol/L</td><td>161</td><td>137.7 ± 3.8</td><td>292</td><td>138.1 ± 3.1</td></tr><tr><td>Potassium, mmol/L</td><td>161</td><td>4.5 ± 2.6</td><td>292</td><td>4.3 ± 0.5</td></tr><tr><td>Chloride, mmol/L</td><td>136</td><td>107 ± 5.8</td><td>257</td><td>106.1 ± 4</td></tr><tr><td>Bicarbonate, mmol/L</td><td>150</td><td>22.9 ± 3.9</td><td>270</td><td>24.7 ± 3.1</td></tr><tr><td>Urea, mmol/L</td><td>161</td><td>15.1 ± 8</td><td>292</td><td>10.5 ± 5.5</td></tr><tr><td>Creatinine, μmol/L</td><td>161</td><td>257 ± 188.7</td><td>293</td><td>174.3 ± 87.9</td></tr><tr><td>Calcium, mmol/L</td><td>150</td><td>2.2 ± 0.2</td><td>269</td><td>2.2 ± 0.1</td></tr><tr><td>Corrected calcium, mmol/L</td><td>99</td><td>2.3 ± 0.1</td><td>206</td><td>2.3 ± 0.1</td></tr><tr><td>Phosphate, mmol/L</td><td>148</td><td>1.3 ± 0.3</td><td>262</td><td>1.2 ± 0.2</td></tr><tr><td>Alkaline phosphatase, U/L</td><td>149</td><td>86.1 ± 58.5</td><td>262</td><td>73.4 ± 42.6</td></tr><tr><td>Albumin, g/L</td><td>145</td><td>34 ± 5.5</td><td>239</td><td>37.7 ± 4.2</td></tr><tr><td>Total cholesterol, mmol/L</td><td>128</td><td>4.6 ± 1.5</td><td>258</td><td>4.7 ± 1.3</td></tr><tr><td>Triglycerides, mmol/L</td><td>128</td><td>1.6 ± 0.8</td><td>258</td><td>1.8 ± 1.7</td></tr><tr><td>High-density lipoprotein, mmol/L</td><td>128</td><td>1.2 ± 0.4</td><td>257</td><td>1.2 ± 0.4</td></tr><tr><td>Low-density lipoprotein, mmol/L</td><td>128</td><td>2.7 ± 1.3</td><td>254</td><td>2.7 ± 1.1</td></tr><tr><td>White blood cells, x109/L</td><td>162</td><td>8.1 ± 4</td><td>295</td><td>7.8 ± 2.9</td></tr><tr><td>HbA1c, %</td><td>127</td><td>7 ± 1.5</td><td>193</td><td>7.4 ± 1.6</td></tr><tr><td>Iron, μmol/L</td><td>94</td><td>10.3 ± 5.7</td><td>80</td><td>11.4 ± 5.6</td></tr><tr><td>Ferritin, μg/L</td><td>97</td><td>397.9 ± 490.8</td><td>85</td><td>275.5 ± 520.0</td></tr><tr><td>Transferrin, mg/dL</td><td>94</td><td>186 ± 50.5</td><td>80</td><td>205.1 ± 53.6</td></tr><tr><td>Total iron binding capacity, μmol/L</td><td>94</td><td>48.4 ± 13.1</td><td>79</td><td>54.1 ± 12.7</td></tr><tr><td>Transferrin saturation, %</td><td>93</td><td>22.6 ± 11.9</td><td>79</td><td>22.2 ± 12.0</td></tr><tr><td>Intact parathyroid hormone, pmol/L</td><td>81</td><td>16.3 ± 15.4</td><td>129</td><td>11.9 ± 13.7</td></tr><tr><td>25-hydroxyvitamin D, μg/L</td><td>34</td><td>17.1 ± 11</td><td>60</td><td>22.4 ± 11.8</td></tr><tr><td>Folate, nmol/L</td><td>39</td><td>52.7 ± 71.2</td><td>44</td><td>27.8 ± 33.4</td></tr><tr><td>Vitamin B12, pmol/L</td><td>42</td><td>488.7 ± 260.4</td><td>50</td><td>450.6 ± 292.9</td></tr></table> |
a71e5b811954466a979ed95d0e647fec5e93a3c8a6ead5c7e10cf8468ede6a2e.png | complex | <table><tr><td colspan="2">Variables</td><td>N (%)</td></tr><tr><td rowspan="2">Sex</td><td>Female</td><td>16 (34.8%)</td></tr><tr><td>Male</td><td>30 (65.2%)</td></tr><tr><td rowspan="2">Age 30.5 ± 6.9 (mean ± SD)</td><td>23–28 year</td><td>26 (56.5%)</td></tr><tr><td>29–51 year</td><td>20 (43.5%)</td></tr><tr><td rowspan="3">Educational level</td><td>Diploma</td><td>20 (43.5%)</td></tr><tr><td>BPharm degree</td><td>25(54.3%)</td></tr><tr><td>MSc degree</td><td>1 (2.2%)</td></tr><tr><td rowspan="2">Work experience in community pharmacy (years) 5.6 ± 3.9 (mean ± SD)</td><td>1–4 year</td><td>22 (47.8%)</td></tr><tr><td>5–16 year</td><td>24 (52.2%)</td></tr><tr><td rowspan="2">Additional work experience</td><td>Yes</td><td>18 (39.1%)</td></tr><tr><td>No</td><td>28 (60.9%)</td></tr><tr><td rowspan="2">Employment status</td><td>Owner</td><td>18 (39.1%)</td></tr><tr><td>Employee</td><td>28 (60.9%)</td></tr><tr><td rowspan="2">Membership to any professional organization</td><td>Yes</td><td>15 (32.6%)</td></tr><tr><td>No</td><td>31 (67.4%)</td></tr><tr><td rowspan="2">Awareness of CPD concept</td><td>Yes</td><td>20 (43.5%)</td></tr><tr><td>No</td><td>26 (56.5%)</td></tr></table> |
99b84a1fc170680f6ade57fbcaba32eb71544e9fbed83dd406fa268036270a73.png | simple | <table><tr><td>Treatment</td><td>COC</td><td>GV</td><td>GVBD</td><td>MI</td><td>MII</td></tr><tr><td> </td><td>(n)</td><td>(%)</td><td>(%)</td><td>(%)</td><td>(%)</td></tr><tr><td><i>SOF</i></td><td>75</td><td>11/78 (14.6)</td><td>9/75 (12.0)</td><td>14/75 (18.7)</td><td>41/75 (54.7)</td></tr><tr><td><i>SOF + GM-CSF (1 ng/ml)</i></td><td>71</td><td>11/71 (15.5)</td><td>5/71 (7.0)</td><td>13/71 (18.3)</td><td>42/71 (59.2)</td></tr><tr><td><i>SOF + GM-CSF (10 ng/ml)</i></td><td>59</td><td>8/59 (13.6)</td><td>4/59 (6.8)</td><td>15/59 (25.4)</td><td>32/59 (54.2)</td></tr><tr><td><i>SOF + GM-CSF (100 ng/ml)</i></td><td>89</td><td>14/89 (15.7)</td><td>4/89 (4.5)</td><td>18/89 (20.2)</td><td>53/89 (59.6)</td></tr><tr><td><i>TCM</i></td><td>95</td><td>1/95 (1.0)</td><td>4/95 (4.2)</td><td>11/95 (11.6)</td><td>79/95 (83.2*)</td></tr></table> |
1019e774c572d66a4b254207f9dbc5d0ac230eaba7eeaf1d317db3551ce448a4.png | complex | <table><tr><td>Sl. No:</td><td>Factors</td><td>Level description</td><td>Level</td><td>Contribution</td></tr><tr><td>1</td><td>Temperature (°C)</td><td>28</td><td>2</td><td>0.025</td></tr><tr><td>2</td><td>pH</td><td>5</td><td>2</td><td>0.081</td></tr><tr><td>3</td><td>Galactose (%)</td><td>0.8</td><td>1</td><td>0.223</td></tr><tr><td>4</td><td>Cupric sulphate (mM)</td><td>3</td><td>2</td><td>1.023</td></tr><tr><td>5</td><td>Inoculum concentration</td><td>6</td><td>2</td><td>0.117</td></tr><tr><td>6</td><td>Substrate length (m)</td><td>0.05</td><td>2</td><td>0.558</td></tr><tr><td colspan="4">Total contribution from all factors</td><td>2.025</td></tr><tr><td colspan="4">Current grand average of performance</td><td>54.743</td></tr><tr><td colspan="4">Expected result at optimum condition</td><td>56.769</td></tr></table> |
bb2f26dcf6d4151603d5dbb0da486bec6eb438c7bc22688aef37dbc07985fe42.png | complex | <table><tr><td rowspan="2">Variable (number of patients evaluated)</td><td rowspan="2"></td><td colspan="2">PD-L1 expression</td><td rowspan="2"><i>p</i>-value</td></tr><tr><td>Positive</td><td>Negative</td></tr><tr><td>Tumor stage (99)</td><td>High</td><td>2</td><td>14</td><td>0.66</td></tr><tr><td></td><td>Low</td><td>8</td><td>75</td><td></td></tr><tr><td></td><td><i>NA</i></td><td><i>0</i></td><td><i>4</i></td><td></td></tr><tr><td>Depth of stromal invasion (87)</td><td>> 1mm</td><td>4</td><td>32</td><td>0.16</td></tr><tr><td></td><td>≤ 1mm</td><td>1</td><td>50</td><td></td></tr><tr><td></td><td><i>NA</i></td><td><i>5</i></td><td><i>11</i></td><td></td></tr><tr><td>Lymph node involvement (71)</td><td>Present</td><td>4</td><td>27</td><td>0.69</td></tr><tr><td></td><td>Absent</td><td>3</td><td>37</td><td></td></tr><tr><td></td><td><i>NA</i></td><td><i>3</i></td><td><i>29</i></td><td></td></tr><tr><td>Metastasis (99)</td><td>Present</td><td>1</td><td>4</td><td>0.42</td></tr><tr><td></td><td>Absent</td><td>9</td><td>85</td><td></td></tr><tr><td></td><td><i>NA</i></td><td><i>0</i></td><td><i>4</i></td><td></td></tr><tr><td>Tumor grade (102)</td><td>High</td><td>9</td><td>81</td><td>1.00</td></tr><tr><td></td><td>Low</td><td>1</td><td>11</td><td></td></tr><tr><td></td><td><i>NA</i></td><td><i>0</i></td><td><i>1</i></td><td></td></tr><tr><td>Lymphovascular space invasion (88)</td><td>Present</td><td>0</td><td>8</td><td>0.59</td></tr><tr><td></td><td>Absent</td><td>10</td><td>70</td><td></td></tr><tr><td></td><td><i>NA</i></td><td><i>0</i></td><td><i>15</i></td><td></td></tr><tr><td>Haemangioinvasion (88)</td><td>Present</td><td>0</td><td>6</td><td>1.00</td></tr><tr><td></td><td>Absent</td><td>10</td><td>72</td><td></td></tr><tr><td></td><td><i>NA</i></td><td><i>0</i></td><td><i>15</i></td><td></td></tr></table> |
175db5d915a086e864b1e266c6d28511240fa5a1c0151c5b8f95400cba890477.png | complex | <table><tr><td> </td><td>EW</td><td>DW</td><td>p</td></tr><tr><td>n (%)</td><td>80 (79.2%)</td><td>21 (20.8%)</td><td> </td></tr><tr><td rowspan="2">GA, mean ± SD (range), wk</td><td>30.3 ± 2.5</td><td>27.5 ± 2.1</td><td rowspan="2">< 0.0001</td></tr><tr><td>(24 – 35)</td><td>(23 – 31)</td></tr><tr><td rowspan="2">BW, mean ± SD (range), g</td><td>1198 ± 270</td><td>894 ± 251</td><td rowspan="2">< 0.0001</td></tr><tr><td>(450 – 1590)</td><td>(475 – 1520)</td></tr><tr><td>Male, n (%)</td><td>39 (48.7%)</td><td>9 (42.9%)</td><td>0.81</td></tr><tr><td>SGA, n (%)</td><td>19 (23.7%)</td><td>5 (23.8%)</td><td>1</td></tr><tr><td>Necrotizing enterocolitis, n (%)</td><td>0</td><td>3 (14.3%)</td><td>< 0.0001</td></tr><tr><td>Sepsis, n (%)</td><td>5 (6.3%)</td><td>11 (52.4%)</td><td>< 0.0001</td></tr><tr><td>Intraventricular hemorrhage, n (%)</td><td>4 (5%)</td><td>4 (19.0%)</td><td>< 0.05</td></tr><tr><td>Chronic lung disease, n (%)</td><td>0</td><td>7 (33.3%)</td><td>< 0.0001</td></tr></table> |
ea517555285dc8f7aa4870a946e6be631def44602f4abc6a4dfddb06bf543501.png | simple | <table><tr><td>Study </td><td>Asthma therapy</td><td>Number of subjects</td><td>Results </td></tr><tr><td>Farah et al., 2011 [36]</td><td>Fluticasone/salmeterol</td><td>49</td><td>Similar improvements in asthma control, spirometry, airway inflammation, and airway hyperresponsiveness across BMI groups</td></tr><tr><td>Sutherland et al., 2010 [46]</td><td>Fluticasone, montelukast</td><td>1052</td><td>Fluticasone greater improvement across all BMI categories when compared to montelukast</td></tr><tr><td>Sutherland et al., 2008 [37] </td><td>Glucocorticoids</td><td>45</td><td>Decreased in vitro response to glucocorticoids in obese asthmatics</td></tr><tr><td>Boulet and Franssen 2007 [35]</td><td>Fluticasone with or without salmeterol</td><td>1242</td><td>Fluticasone with salmeterol resulted in improved asthma control in both groups compared to fluticasone alone but overall decreased effectiveness with both regimens in obese patients</td></tr><tr><td>Dixon et al., 2006 [38]</td><td>Theophylline, montelukast, placebo</td><td>488</td><td>Increased risk of exacerbations in obese subjects treated with theophylline but no difference in montelukast treatment groups</td></tr><tr><td>Peters-Golden et al., 2006 [34] </td><td>Beclomethasone, montelukast, placebo</td><td> 3073</td><td>Less improvement in asthma control days with inhaled corticosteroid with increasing BMI, no difference with montelukast</td></tr></table> |
8bb91cc2f1b8c6c803ac73c3a407708bd863813a01fe78ad467e8f5605dcafbf.png | simple | <table><tr><td>Quantity</td><td>Value</td><td>Description</td></tr><tr><td><i>z</i><sub>1</sub></td><td>8 mm</td><td>Distance between the stem and the point light source [12]</td></tr><tr><td><i>z</i><sub>2</sub></td><td>297 mm</td><td>Distance between the stem and the screen [12]</td></tr><tr><td>Δ<i>x</i></td><td>229 mm (for the stem width = 6 mm)</td><td>Width of the geometrical shadow [12]</td></tr><tr><td>Δ<i>p</i></td><td>5.2 μm</td><td>Camera pixel size</td></tr><tr><td><i>N</i></td><td>7 pixels</td><td>Response of a fringe position to the stem margin shift by 1 μm</td></tr><tr><td><i>C</i></td><td>38.125</td><td>Sensitivity of the optical set-up</td></tr></table> |
a0fbb8b03bf767aafd2b19257d2043532439a0d6fe07a27f2dd6574b6be07a4a.png | complex | <table><tr><td rowspan="3">Age</td><td colspan="2">women with breast cancer</td></tr><tr><td>n</td><td>%</td></tr><tr><td>≤30</td><td>4</td><td>4.0</td></tr><tr><td>31-49</td><td>43</td><td>43.0</td></tr><tr><td>50-59</td><td>32</td><td>32.0</td></tr><tr><td>60-69</td><td>13</td><td>13.0</td></tr><tr><td>≥70</td><td>8</td><td>8.0</td></tr><tr><td><i>Total</i></td><td>100</td><td>100.0</td></tr><tr><td></td><td colspan="2">Mean=51.8 (±11.23)*Min 28; Max 77</td></tr></table> |
266f1f360f6eb7dd3ca5d3312f5ff66c4442fc390d15b46e47aa19ce32a71a2f.png | simple | <table><tr><td>ID</td><td>Farm</td><td>Age (months)</td><td>Sex</td><td>Weight (kg)</td><td>Previous episodes of BRD</td><td>Spontaneous cough</td><td>Nasal discharge</td><td>Abnormal lung sounds</td><td>Read number NS sample</td><td>Read number TTA sample</td></tr><tr><td>1<sup>a</sup></td><td>TO1</td><td>14</td><td>M</td><td>400</td><td>3 months before sampling</td><td>Repeated</td><td>Cloudy and bilateral</td><td>Wheezes and crackles on the left side of the thorax</td><td>NP</td><td>53,494</td></tr><tr><td>2<sup>b</sup></td><td>CN1</td><td>6</td><td>M</td><td>180</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>NP</td><td>7902</td></tr><tr><td>3<sup>a</sup></td><td>CN1</td><td>6</td><td>M</td><td>180</td><td>1 month before sampling</td><td>Occasional</td><td>Absent</td><td>Wheezes and crackles on both sides of the thorax</td><td>NP</td><td>47,115</td></tr><tr><td>4<sup>b</sup></td><td>CN1</td><td>6</td><td>M</td><td>180</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>NP</td><td>18,855</td></tr><tr><td>5<sup>b</sup></td><td>CN1</td><td>6</td><td>M</td><td>180</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>NP</td><td>81,564</td></tr><tr><td>6<sup>a</sup></td><td>CN2</td><td>6</td><td>M</td><td>180</td><td>No</td><td>Absent</td><td>Cloudy and unilateral</td><td>Absent</td><td>36,160</td><td>129,750</td></tr><tr><td>7<sup>b</sup></td><td>CN2</td><td>6</td><td>M</td><td>180</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>28,543</td><td>118,454</td></tr><tr><td>8<sup>b</sup></td><td>CN2</td><td>6</td><td>M</td><td>180</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>31,232</td><td>61,778</td></tr><tr><td>9<sup>a</sup></td><td>CN2</td><td>6</td><td>M</td><td>180</td><td>No</td><td>Absent</td><td>Cloudy and bilateral</td><td>Wheezes and crackles on both sides of the thorax</td><td>DNA < 5 ng/μl</td><td>DNA < 5 ng/μl</td></tr><tr><td>10<sup>a</sup></td><td>VC1</td><td>5</td><td>F</td><td>150</td><td>No</td><td>Repeated</td><td>Absent</td><td>Wheezes and crackles on both sides of the thorax</td><td>40,694</td><td>142,459</td></tr><tr><td>11<sup>a</sup></td><td>VC1</td><td>5</td><td>F</td><td>150</td><td>2 months before sampling</td><td>Absent</td><td>Absent</td><td>Wheezes and crackles on both sides of the thorax</td><td>12,952</td><td>DNA < 5 ng/μl</td></tr><tr><td>12<sup>b</sup></td><td>VC1</td><td>5</td><td>F</td><td>150</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>5988</td><td>DNA < 5 ng/μl</td></tr><tr><td>13<sup>a</sup></td><td>VC1</td><td>5</td><td>M</td><td>150</td><td>No</td><td>Absent</td><td>Absent</td><td>Wheezes and crackles on both sides of the thorax</td><td>24,070</td><td>26,910</td></tr><tr><td>14<sup>b</sup></td><td>TO2</td><td>6</td><td>M</td><td>200</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>DNA < 5 ng/μl</td><td>68,954</td></tr><tr><td>15<sup>b</sup></td><td>TO2</td><td>6</td><td>F</td><td>200</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>20,464</td><td>40,790</td></tr><tr><td>16<sup>a</sup></td><td>TO2</td><td>6</td><td>F</td><td>200</td><td>No</td><td>Absent</td><td>Absent</td><td>Wheezes and crackles on the right side of the thorax</td><td>167,198</td><td>107,679</td></tr><tr><td>17<sup>a</sup></td><td>TO2</td><td>6</td><td>F</td><td>200</td><td>No</td><td>Absent</td><td>Cloudy and bilateral</td><td>Absent</td><td>DNA < 5 ng/μl</td><td>143,886</td></tr><tr><td>18<sup>b</sup></td><td>TO2</td><td>6</td><td>M</td><td>200</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>3932</td><td>55,630</td></tr><tr><td>19<sup>b</sup></td><td>TO2</td><td>6</td><td>M</td><td>200</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>DNA < 5 ng/μl</td><td>1,825<sup>c</sup></td></tr><tr><td>20<sup>b</sup></td><td>TO2</td><td>6</td><td>M</td><td>200</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>154,004</td><td>4585</td></tr><tr><td>21<sup>b</sup></td><td>TO3</td><td>5</td><td>M</td><td>170</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>1,536<sup>c</sup></td><td>6833</td></tr><tr><td>22<sup>b</sup></td><td>TO3</td><td>5</td><td>M</td><td>170</td><td>No</td><td>Absent</td><td>Absent</td><td>Absent</td><td>159<sup>c</sup></td><td>189<sup>c</sup></td></tr></table> |
bfb4489cf7acd4c586d7f86224c8368aa28ae7605d3d6b1ae4e998d1f910ecc3.png | simple | <table><tr><td>CombinedPrograms</td><td>Single Program</td><td>t-value</td><td>Single Program</td><td>t-value</td></tr><tr><td>USR + GZD</td><td>USR</td><td><underline>1.414</underline></td><td>GZD</td><td>0.150</td></tr><tr><td>USR + PS</td><td>USR</td><td><underline>1.373</underline></td><td>PS</td><td><underline>1.369</underline></td></tr><tr><td>USR + ROCS</td><td>USR</td><td>2.489</td><td>ROCS</td><td><underline>1.409</underline></td></tr><tr><td>GZD + PS</td><td>GZD</td><td><underline>1.409</underline></td><td>PS</td><td>2.014</td></tr><tr><td>GZD + ROCS</td><td>GZD</td><td>2.402</td><td>ROCS</td><td>0.137</td></tr><tr><td>PS + ROCS</td><td>PS</td><td>3.547</td><td>ROCS</td><td>0.452</td></tr></table> |
5197a892f374bc768731a04fe3e3a82727298c0bcd784a2df770f6f2100d4f5a.png | simple | <table><tr><td>S.No.</td><td>Angiogenesis analyzer parameter</td><td>FRG1 overexpression vector</td><td>Control vector</td><td><i>P-</i>value</td></tr><tr><td>1</td><td>Number of extremities</td><td>132 ± 25</td><td>107 ± 14</td><td>0.026</td></tr><tr><td>2</td><td>Number of nodes</td><td>263 ± 98</td><td>371 ± 96</td><td>0.039</td></tr><tr><td>3</td><td>Number of junctions</td><td>79 ± 28</td><td>110 ± 28</td><td>0.041</td></tr><tr><td>4</td><td>Number of master junctions</td><td>32 ± 16</td><td>46 ± 15</td><td>0.073</td></tr><tr><td>5</td><td>Number of master segments</td><td>51 ± 29</td><td>80 ± 28</td><td>0.057</td></tr><tr><td>6</td><td>Total master segment length</td><td>6288 ± 2837</td><td>9571 ± 2576</td><td>0.028</td></tr><tr><td>7</td><td>Number of meshes</td><td>16 ± 12</td><td>27 ± 12</td><td>0.057</td></tr><tr><td>8</td><td>Total mesh area</td><td>127029 ± 120136</td><td>306016 ± 163722</td><td>0.022</td></tr><tr><td>9</td><td>Number of pieces</td><td>183 ± 33</td><td>218 ± 36</td><td>0.052</td></tr><tr><td>10</td><td>Number of segments</td><td>83 ± 41</td><td>130 ± 43</td><td>0.039</td></tr><tr><td>11</td><td>Number of branches</td><td>69 ± 7</td><td>70 ± 8</td><td>0.41</td></tr><tr><td>12</td><td>Number of isolated segments</td><td>30 ± 11</td><td>17 ± 8</td><td>0.025</td></tr><tr><td>13</td><td>Total length</td><td>13624 ± 1677</td><td>15602 ± 1613</td><td>0.029</td></tr><tr><td>14</td><td>Total branching length</td><td>11200 ± 2393</td><td>14257 ± 2200</td><td>0.029</td></tr><tr><td>15</td><td>Total segment length</td><td>5964 ± 2756</td><td>9165 ± 2562</td><td>0.029</td></tr><tr><td>16</td><td>Total branch length</td><td>5236 ± 683</td><td>5091 ± 777</td><td>0.36</td></tr><tr><td>17</td><td>Total isolated branches length</td><td>2424 ± 867</td><td>1345 ± 620</td><td>0.014</td></tr><tr><td>18</td><td>Branching interval</td><td>87 ± 43</td><td>132 ± 41</td><td>0.046</td></tr><tr><td>19</td><td>Mesh index</td><td>200 ± 26</td><td>212 ± 28</td><td>0.22</td></tr><tr><td>20</td><td>Mean mesh size</td><td>6830 ± 1740</td><td>10358 ± 3523</td><td>0.024</td></tr></table> |
e990db6677ee9edb32a9700a9b7bccc04a9cd7cabb53863af357fac77ffda211.png | complex | <table><tr><td><i>cis</i>-element</td><td>Position (From ATG)</td><td>Sequence (5′-3′)</td></tr><tr><td colspan="3">Light regulation elements</td></tr><tr><td> 3-AF1 binding site</td><td>−1444(+)</td><td>ATGAGATATTT</td></tr><tr><td> ACE</td><td>−1387(−)</td><td>CAAACGTATT</td></tr><tr><td> AT1-motif</td><td>−511(+)</td><td>AATTATTATTTATT</td></tr><tr><td> Box 4</td><td>−126(+),−560(+),−615(+),−752(+),−1183(+)</td><td>ATTAAT</td></tr><tr><td> Box I</td><td>−390(+),−1363(+)</td><td>TTTCAAA</td></tr><tr><td> G-Box</td><td>−156(+)</td><td>TACGTG</td></tr><tr><td> I-box</td><td>−841(−)</td><td>GTAAAAGGCC</td></tr><tr><td> LAMP-element</td><td>−63(+)</td><td>CTTTATCA</td></tr><tr><td> chs-CMA1a</td><td>−1452(−)</td><td>TTACTTAA</td></tr><tr><td colspan="3">Tissue-specific and development-related elements</td></tr><tr><td> GCN4_motif</td><td>−1023(+)</td><td>TGAGTCA</td></tr><tr><td> Skn-1_motif</td><td>−230(+),-1020(+),−1111(+)</td><td>GTCAT</td></tr><tr><td> Circadian</td><td>−1220(+)</td><td>AAAAGATATC</td></tr><tr><td> GARE-motif</td><td>−880(−)</td><td>AAACAGA</td></tr><tr><td> TCA</td><td>−199(−)</td><td>GAGAATAATA</td></tr><tr><td> ABRE</td><td>−156(+)</td><td>TACGTG</td></tr><tr><td colspan="3">Abiotic stress response elements</td></tr><tr><td> MBS</td><td>−1081(−),−649(+)</td><td>(C/T)AACTG</td></tr><tr><td> HSE</td><td>−1307(−),−628(+)</td><td>A(A/G)AAAATTT(A/G)</td></tr><tr><td> DRE</td><td>−170(+)</td><td>TACCGACAT</td></tr><tr><td> TC-rich repeats</td><td>−1230(+)</td><td>ATTTTCTTAA</td></tr></table> |
719926668a6e33415eccf9fa9fab1da857e02ba76d8bb5c47f7d377f23e48794.png | complex | <table><tr><td></td><td colspan="2">Dentistry (<i>N</i> = 31)</td><td colspan="2">Health Sciences (<i>N</i> = 22)</td><td colspan="2">Pharmacy (<i>N</i> = 28)</td></tr><tr><td>Items</td><td>Mean</td><td>Agreement (%)</td><td>Mean</td><td>Agreement (%)</td><td>Mean</td><td>Agreement (%)</td></tr><tr><td>Q3_well_organized</td><td>3.14</td><td>100</td><td>3.38</td><td>100</td><td>3.23</td><td>92.4</td></tr><tr><td>Q4_safe_environment*</td><td>3.34</td><td>100</td><td>3.68</td><td>100</td><td>3.62</td><td>100</td></tr><tr><td>Q5_sufficient_information*</td><td>3.03</td><td>86.2</td><td>3.45</td><td>95.5</td><td>3.40</td><td>100</td></tr><tr><td>Q6_helpful_information**</td><td>3.11</td><td>96.4</td><td>3.68</td><td>100</td><td>3.58</td><td>100</td></tr><tr><td>Q7_engagement</td><td>3.89</td><td>88.9</td><td>3.9</td><td>90.5</td><td>4.00</td><td>100</td></tr></table> |
18f7aee53c5a515de5f8d4c929e77dd8f78f0cfaaf08f1137c784cc80b270c36.png | complex | <table><tr><td>Focus of Review</td><td colspan="4">Methodological Rating</td></tr><tr><td></td><td>Strong</td><td>Moderate</td><td>Weak</td><td>Total</td></tr><tr><td>Chronic Diseases (All)</td><td><i>329</i></td><td><i>144</i></td><td><i>141</i></td><td>614</td></tr><tr><td>Adult Health (All)</td><td><i>244</i></td><td><i>117</i></td><td><i>98</i></td><td>459</td></tr><tr><td>Child Health</td><td><i>208</i></td><td><i>86</i></td><td><i>75</i></td><td>369</td></tr><tr><td>Nutrition (All)</td><td><i>187</i></td><td><i>96</i></td><td><i>83</i></td><td>366</td></tr><tr><td>Addiction/Substance Use (All)</td><td><i>152</i></td><td><i>79</i></td><td><i>81</i></td><td>312</td></tr><tr><td>Physical Activity (All)</td><td><i>148</i></td><td><i>79</i></td><td><i>78</i></td><td>305</td></tr><tr><td>Adolescent Health</td><td><i>139</i></td><td><i>71</i></td><td><i>80</i></td><td>290</td></tr><tr><td>Mental Health (All)</td><td><i>156</i></td><td><i>75</i></td><td><i>53</i></td><td>284</td></tr><tr><td>Parenting, Infants and Children (All)</td><td><i>152</i></td><td><i>67</i></td><td><i>52</i></td><td>271</td></tr><tr><td>Injury Prevention/Safety (All)</td><td><i>166</i></td><td><i>57</i></td><td><i>43</i></td><td>266</td></tr><tr><td>Communicable Disease/Infection (All)</td><td><i>134</i></td><td><i>56</i></td><td><i>51</i></td><td>241</td></tr><tr><td>Reproductive Health (All)</td><td><i>131</i></td><td><i>43</i></td><td><i>40</i></td><td>214</td></tr><tr><td>Sexually Transmitted Infections (All)</td><td><i>81</i></td><td><i>48</i></td><td><i>58</i></td><td>187</td></tr><tr><td>Sexual Health (All)</td><td><i>87</i></td><td><i>46</i></td><td><i>38</i></td><td>171</td></tr><tr><td>Infant Health</td><td><i>81</i></td><td><i>32</i></td><td><i>23</i></td><td>136</td></tr><tr><td>Senior Health (All)</td><td><i>84</i></td><td><i>27</i></td><td><i>22</i></td><td>133</td></tr><tr><td>Healthy Communities (All)</td><td><i>43</i></td><td><i>26</i></td><td><i>29</i></td><td>98</td></tr><tr><td>Environmental Health (All)</td><td><i>39</i></td><td><i>10</i></td><td><i>14</i></td><td>63</td></tr><tr><td>Social Determinants of Health (All)</td><td><i>30</i></td><td><i>13</i></td><td><i>8</i></td><td>51</td></tr><tr><td>Dental Health (All)</td><td><i>28</i></td><td><i>9</i></td><td><i>10</i></td><td>47</td></tr><tr><td>Food Safety & Inspection (All)</td><td><i>8</i></td><td><i>2</i></td><td><i>2</i></td><td>12</td></tr></table> |
64fccdce6feaf47d9da9307fc780bda030e210f18ec176bdc95f9e77c003f55c.png | complex | <table><tr><td>Concentrations of Paclitaxel (nM)</td><td colspan="2">BIM/GAPDH</td><td colspan="2">PTEN/GAPDH</td></tr><tr><td></td><td>m-PTIP-GFP</td><td>m-PTIP-Sponge all</td><td>m-PTIP-GFP</td><td>m-PTIP-Sponge all</td></tr><tr><td>0</td><td>70.59 ± 3.4215</td><td>107.70 ± 2.3265 *</td><td>122.77 ± 2.3265</td><td>137.67 ± 1.2452</td></tr><tr><td>20</td><td>94.13 ± 5.3265</td><td>154.08 ± 2.2641 *</td><td>98.15 ± 5.8736</td><td>121.96 ± 1.4737</td></tr><tr><td>100</td><td>123.72 ± 3.1749</td><td>136.83 ± 1.5821 *</td><td>122.59 ± 3.5521</td><td>130.93 ± 1.2481</td></tr><tr><td>200</td><td>109.54 ± 1.1399</td><td>164.46 ± 3.7326 *</td><td>116.54 ± 1.3357</td><td>125.28 ± 3.2158</td></tr></table> |
9efcccc857bf94b01b8c5073e833f58d5475a6bd375511591997cb7c2dd178e9.png | complex | <table><tr><td>Outcome measures</td><td>Operationalisation</td><td colspan="3">Measurement</td></tr><tr><td> </td><td> </td><td>SCR</td><td>Qt</td><td>TIp</td></tr><tr><td><i>Usefulness</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Population reached</td><td>General characteristics of the participants and trainers</td><td>+</td><td> </td><td> </td></tr><tr><td> </td><td>Target population and proportion of the intended target population</td><td>+</td><td>+</td><td> </td></tr><tr><td> </td><td>Number of participants that refused, dropped out or completed training and reasons for withdrawal</td><td> </td><td>+</td><td> </td></tr><tr><td>Self-reported benefit or achievement</td><td>Benefit regarding the training according to trainers</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Benefit regarding the training according to participants</td><td> </td><td> </td><td>+</td></tr><tr><td> </td><td>Use of identification cane in daily life</td><td> </td><td>+</td><td>+</td></tr><tr><td> </td><td>Achievement regarding to training goals</td><td> </td><td>+</td><td> </td></tr><tr><td>Experienced barriers and potential solutions</td><td>Deviations of each session element*</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Main goal, strong and weak aspects of the training</td><td> </td><td>+</td><td>+</td></tr><tr><td> </td><td>Hampering and encouraging factors of the standardised training*</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Matters for improvement – materials and standardised training*</td><td> </td><td>+</td><td> </td></tr><tr><td><i>Acceptability</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Extent to which intervention was performed according to protocol</td><td>Format, preparation time and duration of the session</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Per session element: performance, duration and participation by participant*</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Extent to which participant achieved training goals*</td><td> </td><td>+</td><td> </td></tr><tr><td>Participants’ exposure to and engagement in the training</td><td>Total number of sessions</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Use of materials*</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Opinion of trainer/participants regarding participant’s engagement</td><td> </td><td>+</td><td>+</td></tr><tr><td> </td><td>Extent to which participants complied with contracts*</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Quality of action plans formulated by participant*</td><td> </td><td>+</td><td> </td></tr><tr><td>Opinion about the training</td><td>Overall opinion about the training by trainer and participant</td><td> </td><td>+</td><td>+</td></tr><tr><td> </td><td>Opinion regarding number, duration and progress of the sessions by trainer and participant</td><td> </td><td>+</td><td>+</td></tr><tr><td> </td><td>Opinion regarding comprehensibility of the training</td><td> </td><td> </td><td>+</td></tr><tr><td> </td><td>Opinion regarding number of extra sessions needed and whether the participant’s need for mobility support was met</td><td> </td><td>+</td><td>+</td></tr><tr><td> </td><td>Burden experienced by participant</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Recommendation of the training to others</td><td> </td><td>+</td><td> </td></tr><tr><td> </td><td>Overall opinion about the trainer</td><td> </td><td>+</td><td>+</td></tr></table> |
37a63fa171a98fe457fe14c0c3e5ae1f45802499a32b0705b8b26fda7d477f37.png | complex | <table><tr><td colspan="5">HCV-1</td><td colspan="5">HCV-2</td></tr><tr><td>SNP ID</td><td>SVR (+)</td><td>SVR (−)</td><td><i>P</i></td><td>OR (95% CI)</td><td>SNP ID</td><td>SVR (+)</td><td>SVR (−)</td><td><i>P</i></td><td>OR (95% CI)</td></tr><tr><td> </td><td>N (%)</td><td>N (%)</td><td> </td><td> </td><td> </td><td>N (%)</td><td>N (%)</td><td> </td><td> </td></tr><tr><td colspan="5">rs1059513</td><td colspan="5">rs1059513</td></tr><tr><td>A allele</td><td>294 (90.2)</td><td>195 (95.6)</td><td> </td><td>0.42 (0.20, 0.91)</td><td>A allele</td><td>333 (93.5)</td><td>32 (94.1)</td><td> </td><td>0.90 (0.20, 4.01)</td></tr><tr><td>G allele</td><td>32 (9.8)</td><td>9 (4.4)</td><td>0.0235*</td><td>1</td><td>G allele</td><td>23 (6.5)</td><td>2 (5.9)</td><td>0.8954</td><td>1</td></tr><tr><td colspan="5">rs703817<sup>a</sup></td><td colspan="5">rs703817</td></tr><tr><td>A allele</td><td>80 (24.5)</td><td>63 (31.2)</td><td> </td><td>0.72 (0.49, 1.06)</td><td>A allele</td><td>93 (26.1)</td><td>5 (14.7)</td><td> </td><td>2.05 (0.77, 5.45)</td></tr><tr><td>G allele</td><td>246 (75.5)</td><td>139 (68.8)</td><td>0.0948</td><td>1</td><td>G allele</td><td>263 (73.9)</td><td>29 (85.3)</td><td>0.1425</td><td>1</td></tr><tr><td colspan="5">rs324015<sup>a</sup></td><td colspan="5">rs324015</td></tr><tr><td>A allele</td><td>145 (44.5)</td><td>89 (44.1)</td><td> </td><td>1.02 (0.71, 1.45)</td><td>A allele</td><td>172 (48.3)</td><td>20 (58.8)</td><td> </td><td>0.65 (0.32, 1.34)</td></tr><tr><td>G allele</td><td>181 (55.5)</td><td>113 (55.9)</td><td>0.9249</td><td>1</td><td>G allele</td><td>184 (51.7)</td><td>14 (41.2)</td><td>0.2416</td><td>1</td></tr><tr><td colspan="5">rs3024974</td><td colspan="5">rs3024974<sup>b</sup></td></tr><tr><td>C allele</td><td>258 (79.1)</td><td>161 (78.9)</td><td> </td><td>1.01 (0.66, 1.56)</td><td>C allele</td><td>285 (80.5)</td><td>27 (79.4)</td><td> </td><td>1.07 (0.45, 2.56)</td></tr><tr><td>T allele</td><td>68 (20.9)</td><td>43 (21.1)</td><td>0.9518</td><td>1</td><td>T allele</td><td>69 (19.5)</td><td>7 (20.6)</td><td>0.8777</td><td>1</td></tr></table> |
0b76aecb64a63849ad2277041c226f95a12e1a4fb59e1645c7ac187a60b729d6.png | simple | <table><tr><td></td><td>Heart Health Program</td><td>Traditional Hospital Cardiac Programs</td></tr><tr><td>Referral</td><td>No formal process, mostly word of mouth or opportunistic due to location.</td><td>Formal referral from doctor or cardiac nurse post cardiac event.</td></tr><tr><td>Attendance</td><td>As often as wanted, program runs weekly. No specific attendance required.</td><td>Set period, usually 4–6 weeks long. Attendance at every session usually required.</td></tr><tr><td>Health prerequisites</td><td>Nil, program provides information on any health issues requested by participants with primary focus on cardiac issues and diabetes. Do not need to have any chronic diseases or cardiac issues to attend.</td><td>Post cardiac event.</td></tr><tr><td>Transport</td><td>Provided to anyone who requires it at no cost.</td><td>Make own arrangements.</td></tr><tr><td>Food</td><td>Morning tea and lunch provided.</td><td>Not provided.</td></tr><tr><td>Exercise</td><td>Group walk and exercise-physiologist led rehabilitation exercises (walk pending weather).</td><td>Dependent on program.</td></tr><tr><td>Structure</td><td>Diabetes round-table discussion, followed by a group walk and morning tea. Group yarning on weekly health topic (session can be facilitator led, participant led, or a more formal presentation style talk depending on topic and presenter); lunch is provided during this session. Followed by weight exercises. Finished with a cardiac-specific discussion; sharing of personal experiences and asking questions is encouraged. Participants are free to leave at any point. Blood pressure and insulin measured throughout the day.</td><td>Typically PowerPoint presentation while seated at desks.</td></tr></table> |
01d301e8e068602d9e87dd7cb7d69cb931005b96610e02f6205bce3a62ecfd2c.png | simple | <table><tr><td></td><td>Lost to Follow-up N (%)</td><td>Completed Follow-up N (%)</td><td>RR (95% CI)</td></tr><tr><td>Lost to Follow-up Status After Delivery, N</td><td>1,385</td><td>277,733</td><td></td></tr><tr><td>Delivery location</td><td></td><td></td><td></td></tr><tr><td>Hospital</td><td>451 (33.3)</td><td>126,606 (45.6)</td><td>1.0</td></tr><tr><td>Clinic</td><td>394 (29.1)</td><td>68,689 (24.7)</td><td>1.1 (1.0, 1.3)</td></tr><tr><td>Home/Other</td><td>508 (37.5)</td><td>82,303 (29.6)</td><td>1.0 (0.8, 1.1)</td></tr><tr><td>Delivery mode</td><td></td><td></td><td></td></tr><tr><td>Vaginal</td><td>1,110 (82.1)</td><td>231,099 (83.2)</td><td>1.0</td></tr><tr><td>Vaginal assisted</td><td>40 (3.0)</td><td>4,161 (1.5)</td><td>1.1 (0.6, 1.8)</td></tr><tr><td>C-section</td><td>154 (11.4)</td><td>33,052 (11.9)</td><td>1.0 (0.9, 1.2)</td></tr><tr><td>Birth attendant</td><td></td><td></td><td></td></tr><tr><td>Physician</td><td>384 (28.4)</td><td>106,834 (38.5)</td><td>1.0</td></tr><tr><td>Nurse/Midwife/Health worker</td><td>437 (32.3)</td><td>88,316 (31.8)</td><td>1.1 (1.0, 1.2)</td></tr><tr><td>Traditional birth attendant</td><td>450 (33.3)</td><td>63,892 (23.0)</td><td>1.0 (0.8, 1.2)</td></tr><tr><td>Family/Other</td><td>80 (5.9)</td><td>18,593 (6.7)</td><td>0.9 (0.8, 1.1)</td></tr></table> |
b60ecb91b4f51bd88e299a24e30c0622431745dba9555a9cd1cf587ed7475fdb.png | complex | <table><tr><td rowspan="3"></td><td>Participated in FW (<i>n</i> = 2835)</td></tr><tr><td>(Reference category: Did not participate in FW)</td></tr><tr><td>OR (95% CI)</td></tr><tr><td colspan="2">Demographics</td></tr><tr><td colspan="2">Sex</td></tr><tr><td>Man</td><td>1.00</td></tr><tr><td>Woman</td><td>0.92 (0.76–1.13)</td></tr><tr><td> Age</td><td>0.80 (0.78–.0.83)<sup>***</sup></td></tr><tr><td> Total years spent studying</td><td>0.70 (0.67–0.74)<sup>***</sup></td></tr><tr><td colspan="2"> Place of birth</td></tr><tr><td>Born outside of Norway</td><td>1.00</td></tr><tr><td>Born in Norway</td><td>0.79 (0.57–1.09)</td></tr><tr><td colspan="2"> Religious identification</td></tr><tr><td>Nonreligious</td><td>1.00</td></tr><tr><td>Religious</td><td>1.01 (0.84–1.21)</td></tr><tr><td colspan="2"> Relationship status</td></tr><tr><td>In a relationship</td><td>1.00</td></tr><tr><td>Single</td><td>1.29 (1.08–1.53)<sup>**</sup></td></tr><tr><td colspan="2"> Parental status</td></tr><tr><td>Did not have child/children</td><td>1.00</td></tr><tr><td>Had child/children</td><td>0.36 (0.23–0.56)<sup>***</sup></td></tr><tr><td colspan="2"> Educational institution</td></tr><tr><td>Not business school</td><td>1.00</td></tr><tr><td>Business school</td><td>1.60 (1.23–2.08)<sup>***</sup></td></tr><tr><td colspan="2"> Personality</td></tr><tr><td>ExtroversionZ</td><td>1.18 (1.07–1.29)<sup>**</sup></td></tr><tr><td>AgreeablenessZ</td><td>1.08 (0.99–1.19)</td></tr><tr><td>ConscientiousnessZ</td><td>1.01 (0.92–1.10)</td></tr><tr><td>NeuroticismZ</td><td>1.01 (0.90–1.13)</td></tr><tr><td>Intellect/imaginationZ</td><td>0.96 (0.88–1.05)</td></tr><tr><td>Concurrent alcohol use (AUDIT-scoreZ)</td><td>1.28 (1.16–1.41)<sup>***</sup></td></tr><tr><td colspan="2"> Psychological health</td></tr><tr><td>Depression symptomsZ</td><td>1.08 (0.94–1.23)</td></tr><tr><td>Anxiety symptomsZ</td><td>0.93 (0.83–1.05)</td></tr><tr><td><i>Model,</i> df = 16 and <i>p</i> < .001</td><td>Cox & Snell R<sup>2</sup> = .390; Nagelkerke R<sup>2</sup> = .536</td></tr></table> |
d10a73a719e54c4d20341d148008bcb892ec1b84e785bff2424a9e2c22e3b21c.png | simple | <table><tr><td>Antibody</td><td>Identification</td><td>Dilution</td><td>Source</td></tr><tr><td>p16INK4a</td><td>E6H4</td><td>undiluted</td><td>mtm laboratories AG, Heidelberg, Germany</td></tr><tr><td>MMP-7</td><td>Clone ID2</td><td>1:30</td><td>Calbiochem, Merck Chemicals Ltd., Nottingham, UK</td></tr><tr><td>MMP-12</td><td>rabbit polyclonal</td><td>1:50</td><td>Sigma-Aldrich Inc., Saint Louis, MO</td></tr><tr><td>MMP-16</td><td>rabbit polyclonal</td><td>1:50</td><td>Sigma-Aldrich Inc., Saint Louis, MO</td></tr><tr><td>CK8/18</td><td>Clone 5D3</td><td>1:50</td><td>Novocastra Lab’s Ltd., Vision Biosystems, Newcastle, UK</td></tr><tr><td>Laminin</td><td>rabbit polyclonal</td><td>1:350</td><td>DakoCytomation, Glostrup, Denmark</td></tr><tr><td>EDA-Fibronectin</td><td>Clone 52DH1</td><td>1:30</td><td>Dr Ismo Virtanen [15]</td></tr><tr><td>E-cadherin</td><td>Clone 36</td><td>1:200</td><td>BD Transduction Laboratories, Franklin Lakes, NJ</td></tr><tr><td>N-cadherin</td><td>Clone GC-4</td><td>1:30</td><td>Sigma-Aldrich Inc., Saint Louis, MO</td></tr><tr><td>Beta-catenin</td><td>Clone 14</td><td>1:30</td><td>BD Transduction Laboratories, Franklin Lakes, NJ</td></tr></table> |
2cd0d1a30cc1ceea4063fcb89a19ede1daf43bdf97b3a7811cb176ded183d3e8.png | complex | <table><tr><td rowspan="3">Dopant</td><td colspan="6">SnO<sub>2</sub>–d (110) in Å</td></tr><tr><td rowspan="2">Urea</td><td rowspan="2">Ammonia</td><td colspan="2">Chemically Doped</td><td colspan="2">Impregnated Powders</td></tr><tr><td>Urea</td><td>Ammonia</td><td>Urea</td><td>Ammonia</td></tr><tr><td>Undoped</td><td>3.35853</td><td>3.35492</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Cu</td><td>-</td><td>-</td><td>3.3732</td><td>3.36927</td><td>3.3682</td><td>3.3927</td></tr><tr><td>Pt</td><td>-</td><td>-</td><td>3.39422</td><td>3.38839</td><td>3.3801</td><td>3.35427</td></tr><tr><td>Pd</td><td>-</td><td>-</td><td>3.41855</td><td>3.40501</td><td>3.40697</td><td>3.35706</td></tr></table> |
f09534c384c6c683ff2be239f54d83d3cb2337789e026fc822694737e0987115.png | complex | <table><tr><td>Reference, Study Location and data collection period</td><td>Study Design Subject Characteristics and sample size</td><td>Exposure air pollutants</td><td>Health outcomes</td><td>Results</td><td>Adjustment for confounding factors</td><td>Limitations</td></tr><tr><td colspan="7">Cross sectional studies</td></tr><tr><td>Karunasekara KAW et al.[40],Gampaha district.1998</td><td>Children, 5-11 years,asthmatics (n = 441);non asthmatics (n = 1510)</td><td>No specific types are measured</td><td>Asthma</td><td>Prevalence of asthma was significantly higher in the presence of firewood smoke</td><td>Yes</td><td>No measurement of exposure</td></tr><tr><td>Lankatilake KN et al.[20],Kotte Medical Officer of Health area.1999</td><td>Households = 397children = 604women = 130</td><td>Respirable dust</td><td>Respiratory symptoms</td><td>Respiratory symptoms were significantly higher in houses using firewood</td><td>Yes</td><td>Only respirable dust levels were measured</td></tr><tr><td>Pathirane S M et al.[43]Kegalle and Kalutara districts.2004</td><td>New borns (n = 369)</td><td>No specific types</td><td>Low birth weight</td><td>Low birth weight was associated with fuel type and kitchen characteristics</td><td>No</td><td>No measurement of exposure</td></tr><tr><td colspan="7">Case-control Studies</td></tr><tr><td>Karunasekara KAW et al.[39],Colombo North Teaching Hospital1996-1997</td><td>Children 1-10 years,age matched cases and controls (n = 300)</td><td>No specific type</td><td>Asthma</td><td>Dust at home was a significant risk factor for asthma</td><td>Yes</td><td>No measurement of exposure</td></tr><tr><td>Perera MAKK P et al.[42],National Cancer Hospital2004</td><td>Lung cancer patients (n = 128) and controls (n = 128)</td><td>No specific type</td><td>Lung cancer</td><td>No significant association with biomass exposure</td><td>No</td><td>No measurement of exposure</td></tr><tr><td>Ranasinghe MH et al.[41], National Eye Hospital, Colombo2004</td><td>Patients with cataracts (n = 197) and controls (n = 190)</td><td>No specific type</td><td>Cataract</td><td>Cataracts significantly associated with biomass exposure</td><td>No</td><td>No measurement of exposure</td></tr></table> |
a38433e65bd11825e6a8b5cdb9056f7e2a11d4f6993d56d3e1e60dc8d320dae9.png | complex | <table><tr><td rowspan="2">Cropping system cultivar</td><td>Organic</td><td>Conventional</td><td>Average</td><td>Difference in organic</td></tr><tr><td>Mg ha<sup>−1</sup></td><td>Mg ha<sup>−1</sup></td><td> Mg ha<sup>−1</sup></td><td>%</td></tr><tr><td>Matt</td><td>2.13</td><td>2.85</td><td>2.48 b</td><td>−25.0</td></tr><tr><td>Saragolla</td><td>3.62</td><td>4.09</td><td>3.85 a</td><td>−11.4</td></tr><tr><td>Karalis</td><td>2.33</td><td>3.22</td><td>2.78 b</td><td>−27.6</td></tr><tr><td>Pablo</td><td>2.57</td><td>2.99</td><td>2.78 b</td><td>−14.2</td></tr><tr><td>San Carlo</td><td>2.46</td><td>3.45</td><td>2.94 b</td><td>−28.8</td></tr><tr><td> Average</td><td>2.52 b</td><td>3.23 a</td><td>2.87</td><td>−21.0</td></tr></table> |
cb058088a4c4f9db98d906aaf0d8b39f8e7e67729cb21cbb24de4e8325ee7c2d.png | simple | <table><tr><td>Demographics</td><td></td><td></td></tr><tr><td>Age (yrs) (mean ± SD)</td><td></td><td>65.8 ± 8.7</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Male/Female</td><td></td><td>46%/54%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Wealth (%)</td><td></td><td></td></tr><tr><td></td><td>Poorest tertile</td><td>34%</td></tr><tr><td></td><td>Tertile 2</td><td>20%</td></tr><tr><td></td><td>Richest tertile</td><td>45%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>BMI (kg/m<sup>2</sup>) (mean ± SD)</td><td></td><td>28.1 ± 4.9</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Smoking status (%)</td><td>current smoker</td><td>11%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Chronic illness (%)</td><td></td><td>16%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Physical exercise</td><td></td><td></td></tr><tr><td></td><td>Sedentary</td><td>2%</td></tr><tr><td></td><td>Low</td><td>10%</td></tr><tr><td></td><td>Moderate</td><td>52%</td></tr><tr><td></td><td>vigorous</td><td>36%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Alcohol consumption</td><td></td><td></td></tr><tr><td></td><td>Never</td><td>35%</td></tr><tr><td></td><td>Occasionally</td><td>48%</td></tr><tr><td></td><td>Daily</td><td>17%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Depression at baseline</td><td></td><td>11%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>Depression at 4-year follow-up</td><td></td><td>10%</td></tr><tr><td>

</td><td></td><td></td></tr><tr><td>DHEA(S) (μmol/L) (mean ± SD)</td><td></td><td>2.41 ± 1.80</td></tr></table> |
bfcc305cea02cc38f90f31df16555bb210f3b0da6bd298b3364a9b6e1750c502.png | complex | <table><tr><td></td><td></td><td colspan="3">Vascular plants</td><td colspan="3">Bryophytes</td></tr><tr><td></td><td></td><td><i>F</i>-value</td><td><i>P</i>-value</td><td><i>r</i></td><td><i>F</i>-value</td><td><i>P</i>-value</td><td><i>r</i></td></tr><tr><td>MAT</td><td>Plant community</td><td>1.3</td><td>0.26</td><td>−0.07</td><td>1.5</td><td>0.23</td><td>−0.09</td></tr><tr><td></td><td>Cluster I</td><td>19.3</td><td>≤0.001</td><td>−0.51</td><td>10.9</td><td>≤0.01</td><td>−0.41</td></tr><tr><td></td><td>Cluster II</td><td>11.4</td><td>≤0.001</td><td>0.41</td><td>3.7</td><td>0.06</td><td>0.22</td></tr><tr><td>TS</td><td>Plant community</td><td>0.0</td><td>0.83</td><td>0.13</td><td>6.2</td><td>≤0.01</td><td>0.29</td></tr><tr><td></td><td>Cluster I</td><td>29.0</td><td>≤0.001</td><td>0.59</td><td>34.6</td><td>≤0.001</td><td>0.63</td></tr><tr><td></td><td>Cluster II</td><td>39.6</td><td>≤0.001</td><td>−0.66</td><td>4.1</td><td>0.04</td><td>−0.24</td></tr><tr><td>MAP</td><td>Plant community</td><td>0.2</td><td>0.68</td><td>0.12</td><td>1.8</td><td>0.18</td><td>−0.12</td></tr><tr><td></td><td>Cluster I</td><td>5.1</td><td>≤0.05</td><td>−0.27</td><td>11.0</td><td>≤0.001</td><td>−0.40</td></tr><tr><td></td><td>Cluster II</td><td>7.2</td><td>≤0.01</td><td>0.33</td><td>0.1</td><td>0.74</td><td>0.14</td></tr><tr><td>SO<sub><i>x</i></sub></td><td>Plant community</td><td>0.7</td><td>0.39</td><td>−0.06</td><td>0.2</td><td>0.64</td><td>−0.12</td></tr><tr><td></td><td>Cluster I</td><td>2.2</td><td>0.14</td><td>−0.15</td><td>0.8</td><td>0.86</td><td>−0.13</td></tr><tr><td></td><td>Cluster II</td><td>0.2</td><td>0.63</td><td>−0.12</td><td>0.2</td><td>0.68</td><td>−0.13</td></tr><tr><td>NH<sub><i>x</i></sub></td><td>Plant community</td><td>0.3</td><td>0.59</td><td>−0.11</td><td>1.9</td><td>0.18</td><td>−0.13</td></tr><tr><td></td><td>Cluster I</td><td>2.6</td><td>0.11</td><td>−0.17</td><td>1.7</td><td>0.19</td><td>−0.12</td></tr><tr><td></td><td>Cluster II</td><td>0.7</td><td>0.39</td><td>−0.07</td><td>1.9</td><td>0.17</td><td>0.13</td></tr></table> |
22e8ff2243da845f736daa32fec816dbc1e2cb17b3745284952c82577a767c9e.png | complex | <table><tr><td>Treatment Effect</td><td>Control Exacerbation Rate (per‐person year)</td><td>AAR</td><td>ERT</td></tr><tr><td rowspan="3">0.5</td><td>1.3</td><td>0.82</td><td>0.83</td></tr><tr><td>1.8</td><td>0.87</td><td>0.88</td></tr><tr><td>2.3</td><td>0.89</td><td>0.91</td></tr><tr><td rowspan="3">0.7</td><td>1.3</td><td>0.34</td><td>0.35</td></tr><tr><td>1.8</td><td>0.38</td><td>0.39</td></tr><tr><td>2.3</td><td>0.39</td><td>0.42</td></tr><tr><td rowspan="3">1.0 (null case)</td><td>1.3</td><td>0.05</td><td>0.05</td></tr><tr><td>1.8</td><td>0.05</td><td>0.06</td></tr><tr><td>2.3</td><td>0.05</td><td>0.06</td></tr><tr><td rowspan="3">1.5</td><td>1.3</td><td>0.47</td><td>0.49</td></tr><tr><td>1.8</td><td>0.51</td><td>0.54</td></tr><tr><td>2.3</td><td>0.52</td><td>0.56</td></tr></table> |
408b4c55fce789f302d65fc6b02c5e5f1bb0869a466da3bbb09fe2bc536c32f3.png | simple | <table><tr><td>Medium</td><td>Carbon source</td><td>Rationale</td></tr><tr><td>DSMZ 65</td><td>Glucose Switchgrass MCC</td><td>DSMZ recommended <i>T. bispora</i> growth medium prepared with glucose</td></tr><tr><td>I/S</td><td>Glucose Switchgrass MCC</td><td>Previously reported actinobacteria isolation/screening medium prepared with MCC (Waldron and Eveleigh, 1986)</td></tr><tr><td>M9TE</td><td>MCC</td><td>Minimal medium + cellulose (Gladden et al., 2011)</td></tr><tr><td>DSMZ 84</td><td>Rolled oats</td><td>Previous DSMZ recommended <i>T. bispora</i> growth medium prepared with soluble polysaccharides from rolled oats</td></tr></table> |
288d7510d82176dee27d110fa9145d694be9e52f93af52e56a16aeb173ffe76d.png | simple | <table><tr><td>Inclusion criteria</td><td>Exclusion criteria</td></tr><tr><td>1. Written informed consent</td><td>1. Unstable asthma</td></tr><tr><td>2. Age 16 years or older</td><td>2. Presence of active lung disease other than asthma</td></tr><tr><td>3. Diagnosis of asthma by a health professional and duration of asthma symptoms ≥ 1 year.</td><td>3. Mental impairment or language difficulties that make informed consent impossible.</td></tr><tr><td>4. Asthma Control Questionnaire score (6 questions version) greater than or equal to 1 (suggesting poorly controlled asthma)</td><td>4. Terminal illness</td></tr><tr><td>5. Ability to access the internet (excluding via smart phone or tablet).</td><td>5. Cognitive impairment.</td></tr></table> |
fc6901bc0c1499c3837baae7118ed351d6cb1a4927b6513420e31abaee2626a4.png | simple | <table><tr><td>Confounder</td><td>Slope</td><td>95 % CI</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>0.009</td><td>−0.020, 0.039</td><td>0.537</td></tr><tr><td>% Males</td><td>−0.011</td><td>−0.024, 0.002</td><td>0.106</td></tr><tr><td>% Diabetics</td><td>0.003</td><td>−0.002, 0.008</td><td>0.255</td></tr><tr><td>% Smokers</td><td>−0.004</td><td>−0.009, 0.0004</td><td>0.075</td></tr><tr><td>Dose (mg/day)<sup>a</sup></td><td>−0.007</td><td>−0.015, 0.001</td><td>0.091</td></tr><tr><td>Baseline LDL-C (mg/dL)</td><td>0.004</td><td>−0.007, 0.016</td><td>0.435</td></tr></table> |
68075b5db5fff98606b050b2969e1d20d9124a747c5b5ab3f64c85a83545053d.png | complex | <table><tr><td></td><td></td><td colspan="2">Unstable housing</td><td></td><td></td></tr><tr><td>Characteristic</td><td>Total n (%)</td><td>Yes 1713 (69.8)</td><td>No<sup>2</sup>722 (29.4)</td><td>Odds ratio (95% CI)</td><td><i>p</i>-value</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>1620 (66.0)</td><td>1147 (67.0)</td><td>462 (64.0)</td><td rowspan="2">1.14 (0.95-1.37)</td><td rowspan="2">0.158</td></tr><tr><td>Female</td><td>833 (34.0)</td><td>566 (33.0)</td><td>260 (36.0)</td></tr><tr><td>Age, in years (median IQR)</td><td>37.7 (29.7 – 44.1)</td><td>37.8 (30.0 – 44.1)</td><td>37.6 (29.6 – 44.0)</td><td>1.00 (0.99-1.01)</td><td>0.399</td></tr><tr><td>Ancestry</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Caucasian</td><td>1496 (61.0)</td><td>1058 (61.8)</td><td>430 (59.6)</td><td rowspan="2">1.10 (0.92-1.31)</td><td rowspan="2">0.308</td></tr><tr><td>Other</td><td>957 (39.0)</td><td>655 (38.2)</td><td>292 (40.4)</td></tr><tr><td>HIV serostatus</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>758 (30.9)</td><td>551 (32.2)</td><td>200 (27.7)</td><td rowspan="2">1.23 (1.02-1.50)</td><td rowspan="2">0.032</td></tr><tr><td>Negative</td><td>1692 (69.0)</td><td>1161 (67.8)</td><td>520 (72.0)</td></tr><tr><td colspan="2">Sex work involvement<sup>3</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>560 (22.8)</td><td>410 (23.9)</td><td>143 (19.8)</td><td rowspan="2">1.27 (1.03-1.58)</td><td rowspan="2">0.026</td></tr><tr><td>No</td><td>1883 (76.8)</td><td>1296 (75.7)</td><td>576 (79.8)</td></tr><tr><td colspan="2">Daily heroin injection<sup>3</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>909 (37.1)</td><td>660 (38.5)</td><td>242 (33.5)</td><td rowspan="2">1.24 (1.04-1.49)</td><td rowspan="2">0.020</td></tr><tr><td>No</td><td>1538 (62.7)</td><td>1049 (61.2)</td><td>478 (66.2)</td></tr><tr><td colspan="2">Daily cocaine injection<sup>3</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>733 (29.9)</td><td>560 (32.7)</td><td>164 (22.7)</td><td rowspan="2">1.65 (1.35-2.02)</td><td rowspan="2">< 0.001</td></tr><tr><td>No</td><td>1704 (69.5)</td><td>1143 (66.7)</td><td>552 (76.5)</td></tr><tr><td colspan="2">Daily non-injection cocaine use<sup>3</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>590 (24.1)</td><td>496 (29.0)</td><td>90 (12.5)</td><td rowspan="2">2.87 (2.25-3.66)</td><td rowspan="2">< 0.001</td></tr><tr><td>No</td><td>1860 (75.8)</td><td>1214 (70.9)</td><td>632 (87.5)</td></tr><tr><td colspan="2">Enrolment in a methadone program<sup>3</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>559 (22.8)</td><td>373 (21.8)</td><td>184 (25.5)</td><td rowspan="2">0.82 (0.67-1.00)</td><td rowspan="2">0.051</td></tr><tr><td>No</td><td>1885 (76.8)</td><td>1332 (77.8)</td><td>537 (74.4)</td></tr><tr><td colspan="2">Incarceration<sup>3</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>326 (13.3)</td><td>255 (14.9)</td><td>67 (9.3)</td><td rowspan="2">1.71 (1.29-2.28)</td><td rowspan="2"><0.001</td></tr><tr><td>No</td><td>2122 (86.5)</td><td>1454 (84.9)</td><td>654 (90.6)</td></tr><tr><td>HCV serostatus</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>2025 (82.6)</td><td>1450 (84.7)</td><td>562 (77.8)</td><td rowspan="2">1.59 (1.27-1.98)</td><td rowspan="2"><0.001</td></tr><tr><td>Negative</td><td>411 (16.8)</td><td>252 (14.7)</td><td>155 (21.5)</td></tr></table> |
1192fa168a05f0e73cf6568e23fa9be5f6fed1ba4a3154d2dff2c6c2e51015e2.png | simple | <table><tr><td></td><td></td><td>OR (95% CI)</td><td>P</td></tr><tr><td>Tvitals</td><td>Red</td><td>6.57 (2.25-19.17)</td><td>< 0.001</td></tr><tr><td></td><td>Orange</td><td>6.69 (3.29-13.58)</td><td>< 0.0001</td></tr><tr><td></td><td>Yellow</td><td>2.98 (1.31-5.45)</td><td>< 0.001</td></tr><tr><td></td><td>Green</td><td>1.0</td><td></td></tr><tr><td>Tfinal</td><td>Red</td><td>5.43 (1.68-17.52)</td><td>< 0.005</td></tr><tr><td></td><td>Orange</td><td>1.49 (0.62-3.56)</td><td>ns</td></tr><tr><td></td><td>Yellow</td><td>1.34 (0.86-3.08)</td><td>ns</td></tr><tr><td></td><td>Green</td><td>1.0</td><td></td></tr></table> |
414b51d36b3cd896e13845a8c786cc7a742a2e34a451a8b4e9eadaa6ca21b6d7.png | complex | <table><tr><td>Study groups and time points</td><td colspan="4">SF-36v2 scores, mean (SD)</td></tr><tr><td></td><td>Vitality</td><td>Social functioning</td><td>Role-emotional</td><td>Mental health</td></tr><tr><td>Hyal-Joint<sup>® </sup>(<i>n </i>= 8)</td><td></td><td></td><td></td><td></td></tr><tr><td> Baseline</td><td>49.4 (9.9)</td><td>38.4 (10.1)</td><td>36.9 (10.9)</td><td>42.3 (18.8)</td></tr><tr><td> Week 4</td><td>50.9 (4.4)</td><td>46.6 (8.5)</td><td>44.2 (5.5)</td><td>49.7 (13.3)</td></tr><tr><td> Week 8</td><td>52.1 (4.7)</td><td>43.2 (12.4)</td><td>42.3 (10.2)</td><td>44.4 (16.3)</td></tr><tr><td> Change baseline <i>vs </i>week 4</td><td>1.6 (9.9)</td><td>8.2 (8.8)</td><td>7.3 (7.3)</td><td>7.4 (12.2)</td></tr><tr><td><i>P </i>value</td><td>0.669</td><td>0.033</td><td>0.026</td><td>0.131</td></tr><tr><td> Change baseline <i>vs </i>week 8</td><td>2.7 (11.9)</td><td>4.8 (12.5)</td><td>5.4 (8.8)</td><td>2.1 (15.2)</td></tr><tr><td><i>P </i>value</td><td>0.537</td><td>0.318</td><td>0.129</td><td>0.707</td></tr><tr><td>Placebo (<i>n </i>= 8)</td><td></td><td></td><td></td><td></td></tr><tr><td> Baseline</td><td>49.8 (12.3)</td><td>44.6 (11.6)</td><td>39.4 (13.4)</td><td>48.3 (9.9)</td></tr><tr><td> Week 4</td><td>49.4 (9.1)</td><td>49.3 (8.2)</td><td>38.9 (11.6)</td><td>49.7 (10.9)</td></tr><tr><td> Week 8</td><td>53.3 (6.5)</td><td>46.6 (8.9)</td><td>44.7 (9.6)</td><td>52.5 (8.4)</td></tr><tr><td> Change baseline <i>vs </i>week 4</td><td>-0.4 (8.4)</td><td>4.8 (4.5)</td><td>-0.5 (7.0)</td><td>1.4 (9.4)</td></tr><tr><td><i>P </i>value</td><td>0.897</td><td>0.021</td><td>0.843</td><td>0.684</td></tr><tr><td> Change baseline <i>vs </i>week 8</td><td>3.5 (9.3)</td><td>2.0 (7.7</td><td>5.3 (6.2)</td><td>4.2 (9.7)</td></tr><tr><td><i>P </i>value</td><td>0.323</td><td>0.477</td><td>0.045</td><td>0.258</td></tr></table> |
7c02d38eeec7d275f1b87027fbc39d6dbd2adee840f44b6782df44a98828270d.png | complex | <table><tr><td>Species</td><td>Group</td><td>R<sub>G</sub></td><td>R<sub>T</sub></td><td>Skew<sup>1</sup></td></tr><tr><td colspan="5">Chromosomes with strongest overall skew</td></tr><tr><td>Candidatus <i>Blochmannia floridanus</i></td><td>Gammaproteobacteria</td><td>0.433</td><td>0.107</td><td>0.446</td></tr><tr><td><i>Clostridium acetobutylicum </i>ATCC 824</td><td>Firmicutes</td><td>0.426</td><td>-0.087</td><td>0.435</td></tr><tr><td><i>Ehrlichia canis str</i>. Jake</td><td>Alphaproteobacteria.</td><td>0.346</td><td>0.226</td><td>0.413</td></tr><tr><td><i>Ehrlichia ruminantium </i>str. Welgevonden</td><td>Alphaproteobacteria</td><td>0.360</td><td>0.191</td><td>0.408</td></tr><tr><td><i>Ehrlichia chaffeensis </i>str. Arkansas</td><td>Alphaproteobacteria</td><td>0.360</td><td>0.191</td><td>0.407</td></tr><tr><td><i>Ehrlichia ruminantium </i>str. Gardel</td><td>Alphaproteobacteria</td><td>0.353</td><td>0.190</td><td>0.401</td></tr><tr><td><i>Ehrlichia ruminantium </i>str. Welgevonden</td><td>Alphaproteobacteria</td><td>0.349</td><td>0.188</td><td>0.397</td></tr><tr><td><i>Lactobacillus salivarius subsp. salivarius </i>UCC118</td><td>Firmicutes</td><td>0.362</td><td>-0.121</td><td>0.382</td></tr><tr><td><i>Borrelia burgdorferi </i>B31</td><td>Spirochaetes</td><td>0.229</td><td>0.300</td><td>0.378</td></tr><tr><td><i>Clostridium perfringens </i>str. 13</td><td>Firmicutes</td><td>0.350</td><td>-0.086</td><td>0.360</td></tr><tr><td><i>Borrelia garinii </i>PBi</td><td>Spirochaetes</td><td>0.207</td><td>0.287</td><td>0.354</td></tr><tr><td><i>Xylella fastidiosa </i>Temecula1</td><td>Gammaproteobacteria</td><td>0.254</td><td>0.228</td><td>0.341</td></tr><tr><td><i>Bartonella quintana </i>str. Toulouse</td><td>Alphaproteobacteria</td><td>0.300</td><td>0.080</td><td>0.311</td></tr><tr><td><i>Clostridium tetani </i>E88</td><td>Firmicutes</td><td>0.273</td><td>-0.137</td><td>0.305</td></tr><tr><td><i>Bartonella henselae </i>str. Houston-1</td><td>Alphaproteobacteria</td><td>0.284</td><td>0.080</td><td>0.295</td></tr><tr><td><i>Xylella fastidiosa </i>9a5c</td><td>Gammaproteobacteria</td><td>0.197</td><td>0.218</td><td>0.294</td></tr><tr><td><i>Lactobacillus acidophilus </i>NCFM</td><td>Firmicutes</td><td>0.286</td><td>-0.024</td><td>0.287</td></tr><tr><td><i>Buchnera aphidicola </i>str. Bp</td><td>Gammaproteobacteria</td><td>0.254</td><td>0.124</td><td>0.282</td></tr><tr><td><i>Lactobacillus johnsonii </i>NCC 533</td><td>Firmicutes</td><td>0.260</td><td>-0.042</td><td>0.263</td></tr><tr><td><i>Carboxydothermus hydrogenoformans </i>Z-2901</td><td>Firmicutes</td><td>0.260</td><td>0.000</td><td>0.260</td></tr><tr><td colspan="5">Chromosomes with weakest overall skew</td></tr><tr><td><i>Corynebacterium efficiens </i>YS-314</td><td>Actinobacteria</td><td>0.023</td><td>0.019</td><td>0.030</td></tr><tr><td><i>Nostoc sp</i>. PCC 7120</td><td>Cyanobacteria</td><td>0.028</td><td>0.005</td><td>0.028</td></tr><tr><td><i>Sinorhizobium meliloti </i>1021 plasmid pSymA</td><td>Alphaproteobacteria</td><td>0.022</td><td>0.014</td><td>0.026</td></tr><tr><td><i>Mycobacterium avium subsp. paratuberculosis </i>K-10</td><td>Actinobacteria</td><td>0.002</td><td>0.025</td><td>0.025</td></tr><tr><td><i>Anaeromyxobacter dehalogenans </i>2CP-C</td><td>Deltaproteobacteria</td><td>0.022</td><td>-0.009</td><td>0.024</td></tr><tr><td><i>Mycoplasma hyopneumoniae </i>232</td><td>Firmicutes</td><td>0.017</td><td>0.016</td><td>0.023</td></tr><tr><td><i>Mycoplasma synoviae </i>53</td><td>Firmicutes</td><td>-0.012</td><td>0.016</td><td>0.020</td></tr><tr><td><i>Wigglesworthia glossinidia</i></td><td>Gammaproteobacteria</td><td>0.016</td><td>0.011</td><td>0.020</td></tr><tr><td><i>Mycoplasma mycoides subsp. mycoides </i>SC str. PG1</td><td>Firmicutes</td><td>0.017</td><td>0.009</td><td>0.019</td></tr><tr><td><i>Mycoplasma gallisepticum </i>R</td><td>Firmicutes</td><td>-0.014</td><td>0.009</td><td>0.016</td></tr><tr><td><i>Aquifex aeolicus </i>VF5</td><td>Aquificae</td><td>-0.006</td><td>-0.014</td><td>0.015</td></tr><tr><td><i>Mycoplasma hyopneumoniae </i>7448</td><td>Firmicutes</td><td>-0.012</td><td>-0.002</td><td>0.013</td></tr><tr><td><i>Thermosynechococcus elongatus </i>BP-1</td><td>Cyanobacteria</td><td>-0.005</td><td>-0.010</td><td>0.012</td></tr><tr><td><i>Synechocystis sp. PCC 6803</i></td><td>Cyanobacteria</td><td>0.010</td><td>-0.002</td><td>0.010</td></tr><tr><td><i>Synechococcus sp. JA-2-3B'a(2–13)</i></td><td>Cyanobacteria</td><td>0.009</td><td>-0.001</td><td>0.009</td></tr><tr><td><i>Baumannia cicadellinicola </i>str. Hc</td><td>Gammaproteobacteria</td><td>-0.003</td><td>-0.005</td><td>0.006</td></tr><tr><td><i>Anabaena variabilis </i>ATCC 29413</td><td>Cyanobacteria</td><td>-0.005</td><td>0.003</td><td>0.006</td></tr><tr><td><i>Mycoplasma pneumoniae </i>M129</td><td>Firmicutes</td><td>0.003</td><td>0.003</td><td>0.004</td></tr><tr><td><i>Synechococcus sp. JA-3-3Ab</i></td><td>Cyanobacteria</td><td>0.001</td><td>0.004</td><td>0.004</td></tr><tr><td><i>Gloeobacter violaceus </i>PCC 7421</td><td>Cyanobacteria</td><td>0.003</td><td>-0.002</td><td>0.004</td></tr></table> |
2c22effac1a443c60021ee4269c7ec243da714a9695d3f75f09c34db13f82554.png | simple | <table><tr><td>Measured parameters</td><td>Group</td><td>Pre-dose</td><td>1 month</td><td>2 month</td></tr><tr><td></td><td>Placebo</td><td>24.53 + 2.55</td><td>24.33 + 2.28</td><td>24.33 + 2.46</td></tr><tr><td>Grip strength (Rt) (kg)</td><td>KP25</td><td>25.06 + 3.01</td><td>25 + 2.97</td><td>24.86 + 3.18</td></tr><tr><td></td><td>KP90</td><td>23.93 + 3.30</td><td>24.6 + 3.13</td><td>24.8 + 3.14</td></tr><tr><td></td><td>Placebo</td><td>21.06 + 1.83</td><td>21.33 + 1.58</td><td>21.2 + 1.56</td></tr><tr><td>Grip strength (Lt) (kg)</td><td>KP25</td><td>22.06 + 1.86</td><td>21.66 + 1.5</td><td>21.26 + 1.48</td></tr><tr><td></td><td>KP90</td><td>20.86 + 2.72</td><td>21.6 + 2.02</td><td>21.6 + 1.84</td></tr><tr><td></td><td>Placebo</td><td>19.13 + 2.79</td><td>19.26 + 1.43</td><td>18.93 + 1.70</td></tr><tr><td>30-second chair stand test. (sec)</td><td>KP25</td><td>18.33 + 2.58</td><td>19 + 2.77</td><td>20 + 3.11</td></tr><tr><td></td><td>KP90</td><td>18.6 + 2.52</td><td>19.6 + 2.13</td><td>20.66 + 2.28<sup>#</sup></td></tr><tr><td></td><td>Placebo</td><td>567.33 + 33.52</td><td>598.73 + 31.57</td><td>571.26 + 32.05</td></tr><tr><td>6 min. walk test (m.)</td><td>KP25</td><td>571.26 + 33.68</td><td>570.33 + 38.32</td><td>575.53 + 36.04</td></tr><tr><td></td><td>KP90</td><td>572.8 + 32.65</td><td>575.46 + 34.29</td><td>601.26 + 33.70<sup>∗#</sup></td></tr><tr><td></td><td>Placebo</td><td>164.8 ± 12.34</td><td>163.06 ± 10.35</td><td>165.06 ± 9.80</td></tr><tr><td>Tandem test (Opened Eye, Right leg is in front) (sec)</td><td>KP25</td><td>161.8 ± 11.16</td><td>164.06 ± 9.63</td><td>162.26 ± 8.93</td></tr><tr><td></td><td>KP90</td><td>164 ± 10.50</td><td>166.6 ± 6.81</td><td>168.46 + 6.90</td></tr><tr><td></td><td>Placebo</td><td>112.33 ± 11.00</td><td>110.66 ± 10.01</td><td>109 + 10.20</td></tr><tr><td>Tandem test (Opened Eye, Left leg is in front) (sec)</td><td>KP25</td><td>111.93 ± 7.77</td><td>112.33 ± 11.39</td><td>111.8 + 10.16</td></tr><tr><td> </td><td>KP90</td><td>108.2 ± 11.32</td><td>109.33 ± 13.62</td><td>110.46 + 13.31</td></tr><tr><td></td><td>Placebo</td><td>33.8 ± 9.22</td><td>30.8 ± 10.74</td><td>31.66 + 10.41</td></tr><tr><td>Tandem test (Closed Eye, Right leg is in front) (sec)</td><td>KP25</td><td>31.86 ± 10.12</td><td>32.6 ± 7.44</td><td>32.73 + 7.67</td></tr><tr><td> </td><td>KP90</td><td>31.26 ± 11.09</td><td>31.86 ± 9.33</td><td>33.4 + 8.94</td></tr><tr><td></td><td>Placebo</td><td>18.8 + 3.60</td><td>19.86 + 5.01</td><td>21.2 + 4.57</td></tr><tr><td>Tandem test (Closed Eye, Left leg is in front) (sec)</td><td>KP25</td><td>20.93 + 3.41</td><td>21.33 + 3.79</td><td>21.26 + 3.19</td></tr><tr><td></td><td>KP90</td><td>20.46 + 4.24</td><td>21.26 + 4.58</td><td>22.06 + 3.93</td></tr></table> |
75bd3853902c335de22ae4a1b6f0fb3cb38c70cbb0413e52e73d0984cd540531.png | complex | <table><tr><td colspan="3">Adhesive systems</td></tr><tr><td>Name of the adhesive</td><td>Type of adhesives</td><td>Components</td></tr><tr><td rowspan="3">SBMP</td><td rowspan="3">ER, 3 steps</td><td>Phosphoric acid (35%)</td></tr><tr><td>Primer = HEMA, polyalkenoic acid copolymer, water</td></tr><tr><td>Bonding = HEMA, Bis-GMA, amines, photoinitiator</td></tr><tr><td rowspan="2">SB1</td><td rowspan="2">ER, 2 steps</td><td>Phosphoric acid (35%)</td></tr><tr><td>Adhesive (primer + bonding) = dimethacrylates, HEMA, polyalkenoic acid copolymer, silanized silicium, alcohol, water, photo-initiator</td></tr><tr><td rowspan="2">ADSE</td><td rowspan="2">SE, 2 steps</td><td>Primer = dimethacrylate, phosphonic acid acrylate, initiators, stabilizers</td></tr><tr><td>Bonding = HEMA, dimethacrylate, silicon dioxide, Initiators, stabilizers</td></tr><tr><td>ADSE-1</td><td>SE, 1 step</td><td>Derivates of bis-acrylamide, water, alcohol, bis-methacrylamide dihydrogen phosphate, amino acid acrylamide, hydroxyl alkyl methacrylamide, alkyl sulfonic acid acrylamide, highly dispersed silicon dioxide, initiators, stabilizers, and potassium fluoride</td></tr></table> |
a78b5afddfa1d4b184c6d445d22854b4f287c36beaa54b85409ebb681bfdd1ff.png | simple | <table><tr><td></td><td>2012 Logistic Regression Deviance</td><td>2012 Logistic Regression Deviance Rank</td><td>2013 Logistic Regression Deviance</td><td>2013 Logistic Regression Deviance Rank</td><td>2014 Logistic Regression Deviance</td><td>2014 Logistic Regression Deviance Rank</td><td>2012–2014 Logistic Regression Mean Deviance Rank</td></tr><tr><td>Age</td><td>17,739.3</td><td>1</td><td>16,378.7</td><td>1</td><td>15,230.7</td><td>1</td><td>1.0</td></tr><tr><td>Pneumococcal Vaccination</td><td>13,599.2</td><td>2</td><td>10,199.2</td><td>2</td><td>10,833.8</td><td>2</td><td>2.0</td></tr><tr><td>Time Since Last Checkup</td><td>8280.7</td><td>3</td><td>7738.6</td><td>3</td><td>7577.9</td><td>3</td><td>3.0</td></tr><tr><td>Number of Personal Doctors</td><td>1659.5</td><td>5</td><td>2014.3</td><td>4</td><td>1910.7</td><td>4</td><td>4.3</td></tr><tr><td>Employment</td><td>2244.6</td><td>4</td><td>1577.3</td><td>6</td><td>1749.8</td><td>5</td><td>5.0</td></tr><tr><td>Annual Household Income</td><td>1543.9</td><td>6</td><td>2013.3</td><td>5</td><td>1681.4</td><td>6</td><td>5.7</td></tr><tr><td>Smoking Status</td><td>680.7</td><td>8</td><td>785.3</td><td>7</td><td>772.3</td><td>8</td><td>7.7</td></tr><tr><td>Health Care Coverage</td><td>837.1</td><td>7</td><td>709.8</td><td>8</td><td>701</td><td>9</td><td>8.0</td></tr><tr><td>Highest Education Level Attained</td><td>616.5</td><td>9</td><td>707.6</td><td>9</td><td>773.2</td><td>7</td><td>8.3</td></tr></table> |
bdeae50d1767987cc584b680103451354951b01884023c0553a4a123577289eb.png | complex | <table><tr><td>Characteristics</td><td>Total164 (%)</td><td>Died<i>N</i> = 32(%)</td><td>Survived132(%)</td><td><i>p</i>-Value</td></tr><tr><td colspan="5">Maternal age</td></tr><tr><td>< 20 years</td><td>23 (14.0)</td><td>4 (17.4)</td><td>19 (82.6)</td><td></td></tr><tr><td>≥ 20 years</td><td>141 (86.0)</td><td>28 (20.0)</td><td>113 (80.0)</td><td>0.78</td></tr><tr><td colspan="5">Maternal education</td></tr><tr><td> None</td><td>7 (4.3)</td><td>2 (28.6)</td><td>5 (71.4)</td><td>0.54</td></tr><tr><td> Primary</td><td>49 (29.9)</td><td>6 (12.2)</td><td>43 (87.2)</td><td></td></tr><tr><td> Secondary</td><td>81 (49.4)</td><td>20 (24.7)</td><td>61 (75.3)</td><td>0.10</td></tr><tr><td> Tertiary</td><td>27 (16.5)</td><td>4 (14.8)</td><td>23 (85.2)</td><td></td></tr><tr><td colspan="5">Maternal income/month</td></tr><tr><td> Unemployed/nil</td><td>77 (47.0)</td><td>14 (18.2)</td><td>63 (81.8)</td><td></td></tr><tr><td> 30-100 K</td><td>84 (51.2)</td><td>3 (10.0)</td><td>27 (90.0)</td><td></td></tr><tr><td>> 100 k</td><td>3 (1.8)</td><td>15 (26.3)</td><td>42 (73.7)</td><td>0.11</td></tr><tr><td colspan="5">Maternal parity</td></tr><tr><td> Primiparous</td><td>52 (31.7)</td><td>10 (19.2)</td><td>42 (80.8)</td><td></td></tr><tr><td> 2–4</td><td>89 (54.3)</td><td>17 (19.1)</td><td>72 (80.9)</td><td></td></tr><tr><td>> 4</td><td>23 (14.0)</td><td>5 (21.7)</td><td>18 (78.3)</td><td>0.77</td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Male</td><td>71 (43.3)</td><td>18 (25.3)</td><td>53 (74.7)</td><td>0.10</td></tr><tr><td> Female</td><td>93 (56.7)</td><td>14 (15.0)</td><td>79 (85.0)</td><td></td></tr><tr><td colspan="5">Discharge weight</td></tr><tr><td>< 1000 g</td><td>37 (22.6)</td><td>13 (34.1)</td><td>24 (64.9)</td><td>0.008</td></tr><tr><td> 1000-1199 g</td><td>73 (44.5)</td><td>13 (17.8)</td><td>60 (82.2)</td><td></td></tr><tr><td>≥ 1200 g</td><td>54 (32.9)</td><td>6 (11.1)</td><td>48 (88.9)</td><td></td></tr><tr><td colspan="5">Postmenstrual age at discharge</td></tr><tr><td>< 35 weeks</td><td>95 (57.9)</td><td>25 (26.3)</td><td>70 (73.7)</td><td>0.012</td></tr><tr><td>≥ 35 weeks</td><td>69 (42.1)</td><td>7 (10.1)</td><td>62 (89.9)</td><td></td></tr><tr><td colspan="5">Period in KMC</td></tr><tr><td>< 1 Week</td><td>130 (79.3)</td><td>20 (15.4)</td><td>110 (84.6)</td><td></td></tr><tr><td> 1-2 weeks</td><td>29 (17.7)</td><td>9 (31.0)</td><td>20 (69.0)</td><td>0.09</td></tr><tr><td>> 2 weeks</td><td>5 (3.0)</td><td>3 (60.0)</td><td>2 (40.0)</td><td>0.04</td></tr><tr><td colspan="5">KMC support</td></tr><tr><td> Supported</td><td>34 (79.3)</td><td>5 (15.6)</td><td>29 (84.4)</td><td></td></tr><tr><td> Not supported</td><td>130 (20.7)</td><td>27 (20.7)</td><td>103 (79.3)</td><td>0.43</td></tr><tr><td colspan="5">HIV exposure</td></tr><tr><td> Yes</td><td>30 (18.3)</td><td>7 (23.3)</td><td>23 (76.6)</td><td>0.56</td></tr><tr><td> No</td><td>134 (81.7)</td><td>25 (18.6)</td><td>109 (81.3)</td><td></td></tr><tr><td colspan="5">Parents living together</td></tr><tr><td> Yes</td><td>139 (84.8)</td><td>24 (17.3)</td><td>115 (82.7)</td><td></td></tr><tr><td> No</td><td>25 (15.2)</td><td>8 (32.0)</td><td>17 (68.0)</td><td>0.09</td></tr><tr><td colspan="5">SGA</td></tr><tr><td> Yes</td><td>98 (59.8)</td><td>11 (11.2)</td><td>87 (88.8)</td><td></td></tr><tr><td> No</td><td>66 (40.2)</td><td>21 (31.8)</td><td>45 (68.2)</td><td>0.001</td></tr></table> |
674b99709f378d01f2fd608d3e292764a1466063bf3dd887a46566888422b66a.png | complex | <table><tr><td></td><td>PID with chlamydia (<i>N</i> = 175)</td><td>PID without chlamydia (<i>N</i> = 322)</td><td><i>P</i></td></tr><tr><td>Mean age (years)</td><td>27.9 ± 8.2</td><td>32.4 ± 8.3</td><td><0.0001</td></tr><tr><td>Married (%)</td><td>71 (40.6)</td><td>223 (69.3)</td><td><0.0001</td></tr><tr><td>Parity</td><td>0.7 ± 0.9</td><td>1.2 ± 1.0</td><td><0.0001</td></tr><tr><td>Abortion</td><td>1.0 ± 1.2</td><td>1.2 ± 1.5</td><td>0.36</td></tr><tr><td>Cesarean sections (%)</td><td>19 (10.9)</td><td>89 (27.6)</td><td><0.0001</td></tr><tr><td>Previous pelvic surgery (%)</td><td>35 (20.0)</td><td>65 (20.2)</td><td>0.530</td></tr><tr><td>History of PID</td><td>26 (14.9)</td><td>61 (18.9)</td><td>0.269</td></tr><tr><td>Use of IUD (%)</td><td>18 (10.3)</td><td>38 (11.8)</td><td>0.658</td></tr><tr><td>Barrier contraceptive use (%)</td><td>22 (12.6)</td><td>46 (14.3)</td><td>0.682</td></tr><tr><td colspan="4">Main symptoms (%)</td></tr><tr><td> Low abdominal pain</td><td>110 (62.9)</td><td>276 (85.7)</td><td>0.001</td></tr><tr><td> Acute abdomen</td><td>19 (10.9)</td><td>19 (5.9)</td><td>0.321</td></tr><tr><td> Vaginal discharge</td><td>5 (2.9)</td><td>6 (1.9)</td><td>0.320</td></tr><tr><td> Right upper quadrant pain</td><td>34 (19.4)</td><td>5 (1.6)</td><td><0.0001</td></tr><tr><td> Febril sensation</td><td>7 (4.0)</td><td>16 (5.0)</td><td>0.628</td></tr><tr><td colspan="4">Menstrual problem</td></tr><tr><td> Menorrhagia (%)</td><td>20 (14.0)</td><td>15 (9.2)</td><td>0.215</td></tr><tr><td> Dysmenorrhea (%)</td><td>20 (14.0)</td><td>15 (9.2)</td><td>0.215</td></tr><tr><td> Alcohol (%)</td><td>72 (41.1)</td><td>107 (33.2)</td><td>0.096</td></tr><tr><td> Smoking (%)</td><td>45 (25.7)</td><td>74 (22.3)</td><td>0.510</td></tr></table> |
448ec286e029d700a99265175799fc36198bd830121500299fc4e1a96bc0eb44.png | simple | <table><tr><td></td><td>Non-op</td><td>Plate</td><td>TEN</td></tr><tr><td>Number</td><td>37</td><td>41</td><td>24</td></tr><tr><td>Age in years (stand. dev.)</td><td>41 (18)</td><td>38 (15)</td><td>34 (14.5)</td></tr><tr><td>Robinson classification 2B1/B2</td><td>24/13</td><td>14/27</td><td>17/7</td></tr><tr><td>Non-union (%)</td><td>2 (5.4)</td><td>0</td><td>1 (4.2)</td></tr><tr><td>Open reduction (%)</td><td></td><td>41 (100)</td><td>11 (46)</td></tr><tr><td>Other complications</td><td></td><td>1 lateral plate tear out after 4 weeks because of non-compliance</td><td>1 delayed union (healed with ultrasound), 2 lateral dislocations of the TEN, 1 prominent nail medially: required shortening in local anesthesia</td></tr><tr><td>Revision rate in % (major)</td><td></td><td>2.4</td><td>8.4 (4.2)</td></tr></table> |
1fca184589a81c57adf3d96356357358c2d1f36699d8e558d68cc936d6915465.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="3">Number (%)</td></tr><tr><td>Male </td><td>Female</td><td>Total</td></tr><tr><td>Presence of diabetes related complications </td><td>48 (70.6)</td><td>141 (84.9)</td><td>189 (80.8)</td></tr><tr><td>Presence of two or more concurrent diabetes complications</td><td>18 (26.5)</td><td>115 (69.3)</td><td>133 (70.37) </td></tr><tr><td>Time of the diabetes related complication(s) diagnosis</td><td> </td><td> </td><td> </td></tr><tr><td> Before being diagnosed with diabetes</td><td>19 (27.9)</td><td>43 (25.9)</td><td>62 (32.8)</td></tr><tr><td> After being diagnosed with diabetes</td><td>29 (42.6)</td><td>98 (59.0)</td><td>127 (67.2)</td></tr><tr><td>Type of diabetes related complication(s)</td><td> </td><td> </td><td> </td></tr><tr><td> Neuropathy</td><td>45 (66.2)</td><td>97 (58.4)</td><td>142 (75.0)</td></tr><tr><td> Retinopathy</td><td>21 (30.9)</td><td>57 (34.3)</td><td>78 (41.4)</td></tr><tr><td> Cardiovascular complications </td><td>30 (44.1)</td><td>10 (6.0)</td><td>40 (21.1)</td></tr><tr><td> Foot ulcers </td><td>7 (10.3)</td><td>3 (1.8)</td><td>10 (5.1)</td></tr></table> |
d622620d8a4dc3e1bac62424d8e197702c95ec18df12a97b1bee0d9ecc9d96f1.png | simple | <table><tr><td>Medicine</td><td>Saving/unit (€)</td><td>Annual consumption</td><td>Annual saving (€)</td></tr><tr><td>IVIG</td><td>9.5/g</td><td>650 kg</td><td>6,175,000</td></tr><tr><td>Albumin</td><td>0.4/g</td><td>8,500 kg</td><td>1,360,000 (based on 40% market share)</td></tr><tr><td>FIX</td><td>0.04/IU</td><td>15 MIU</td><td>600,000</td></tr><tr><td>FVIII</td><td>0.02/IU</td><td>120 MIU</td><td>420,000 (based on 15% market share)</td></tr></table> |
6065e5040feb4dc2c870ab9cd641e156710882209a874e48217b4ed53f4242b0.png | complex | <table><tr><td></td><td colspan="3">Mortality</td></tr><tr><td></td><td>30-day</td><td>90-day</td><td>Overall</td></tr><tr><td>ICU cohort</td><td></td><td></td><td></td></tr><tr><td> Non-carrier</td><td>55/209 (26.3)</td><td>72/209 (34.4)</td><td>115/209 (55)</td></tr><tr><td> Carrier</td><td>11/28 (39.3)</td><td>14/28 (50)</td><td>23/28 (82.1)*</td></tr><tr><td>G1 cohort</td><td></td><td></td><td></td></tr><tr><td> Non-carrier</td><td>40/292 (13.7)</td><td>70/294 (24)</td><td>90/292 (30.8)</td></tr><tr><td> Carrier</td><td>5/23 (21.7)</td><td>8/23 (34.8)</td><td>8/23 (34.8)</td></tr><tr><td>G2 cohort</td><td></td><td></td><td></td></tr><tr><td> Non-carrier</td><td>80/494 (16.2)</td><td>113/494 (22.9)</td><td>275/494 (56.0)</td></tr><tr><td> Carrier</td><td>10/40 (25.0)</td><td>11/40 (27.5)</td><td>21/40 (52.5)</td></tr><tr><td>IPD cohort</td><td></td><td></td><td></td></tr><tr><td> Non-carrier</td><td>24/155 (15.5)</td><td>NA</td><td>NA</td></tr><tr><td> Carrier</td><td>1/8 (12.5)</td><td></td><td></td></tr></table> |
643cd4028de08d1f1b58888004ae8ebd4fc475f1a0d4280aa0db2d8dddc1b418.png | complex | <table><tr><td rowspan="3"><i>Grade</i></td><td colspan="4">Patients</td></tr><tr><td colspan="4">35</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Neutropenia (<i>n</i>, %)</td><td>8 (22.8)</td><td>5 (14.2)</td><td>4 (11.4)</td><td>–</td></tr><tr><td>Anemia (<i>n</i>, %)</td><td>3 (8.5)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Hypertension (<i>n</i>. %)</td><td>–</td><td>14 (40)</td><td>2 (5.7)</td><td>–</td></tr><tr><td>Epistaxis (<i>n</i>, %)</td><td>27 (77.1)</td><td>2 (5.7)</td><td>–</td><td>–</td></tr><tr><td>Proteinuria (<i>n</i>, %)</td><td>–</td><td>1 (2.8)</td><td>–</td><td>–</td></tr><tr><td>Stomatitis (<i>n</i>, %)</td><td>15 (42.8)</td><td>2 (5.7)</td><td>1 (2.8)</td><td>–</td></tr><tr><td>Gingivitis (<i>n</i>, %)</td><td>1 (2.8)</td><td>1 (2.8)</td><td>–</td><td>–</td></tr><tr><td>Rhinitis (<i>n</i>, %)</td><td>3 (8.5)</td><td>1 (2.8)</td><td>–</td><td>–</td></tr><tr><td>Conjunctivitis (<i>n</i>, %)</td><td>3 (8.5)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Fatigue (<i>n</i>, %)</td><td>26 (74.2)</td><td>2 (5.7)</td><td>1 (2.8)</td><td>–</td></tr><tr><td>Constipation (<i>n</i>, %)</td><td>6 (17)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Diarrhea (<i>n</i>, %)</td><td>8 (22.8)</td><td>3 (8.5)</td><td>1 (2.8)</td><td>–</td></tr><tr><td>Nausea (<i>n</i>, %)</td><td>4 (11.4)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Vomiting (<i>n</i>, %)</td><td>–</td><td>–</td><td>1 (2.8)</td><td>–</td></tr><tr><td>Neuropathy (<i>n</i>, %)</td><td>14 (40)</td><td>4 (11.4)</td><td>–</td><td>–</td></tr><tr><td>Headache (<i>n</i>, %)</td><td>5 (14.2)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Myalgia (<i>n</i>, %)</td><td>18 (51.4)</td><td>1 (2.8)</td><td>–</td><td>–</td></tr><tr><td>Allergic reactions (<i>n</i>, %)</td><td>1 (2.8)</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Onychodystrophy (<i>n</i>, %)</td><td>3 (8.5)</td><td>1 (2.8)</td><td>–</td><td>–</td></tr><tr><td>↑ Transaminase (<i>n</i>, %)</td><td>5 (14.2)</td><td>1 (2.8)</td><td>–</td><td></td></tr><tr><td>Alopecia (n, %)</td><td>–</td><td>–</td><td>–</td><td>35 (100)</td></tr></table> |
cc1080628806b3fa69f4d35213e00e57e78e6c2ce7387472b37d330d0870e210.png | simple | <table><tr><td>C+1354T single nucleotide polymorphism</td><td>Systemic sclerosis patients (<i>n</i> = 115)</td><td>Control individuals (<i>n</i> = 140)</td></tr><tr><td>Genotype*</td><td></td><td></td></tr><tr><td> CC</td><td>103 (89.6)</td><td>108 (77.1)</td></tr><tr><td> CT</td><td>12 (10.4)</td><td>30 (21.4)</td></tr><tr><td> TT</td><td>0 (0)</td><td>2 (1.4)</td></tr><tr><td>Allele**</td><td></td><td></td></tr><tr><td> C</td><td>218 (94.8)</td><td>246 (87.6)</td></tr><tr><td> T</td><td>12 (5.2)</td><td>34 (12.4)</td></tr></table> |
769847a3ce195c0f6d0dc62c355c0450f459ab19353a5915583a693f7c139624.png | complex | <table><tr><td>Metric</td><td></td><td>Observed</td><td>Predicted</td></tr><tr><td>Braiding intensity</td><td></td><td>6.8</td><td>6.4</td></tr><tr><td>Confluence node density, nodes km<sup>−2</sup></td><td></td><td>91</td><td>83</td></tr><tr><td rowspan="3">Least squares regression coefficient of determination, <i>R</i><sup>2</sup>, for relationship between:</td><td>Bar perimeter and bar area</td><td>0.986</td><td>0.985</td></tr><tr><td>Bar length and bar width</td><td>0.903</td><td>0.881</td></tr><tr><td>Bar convex perimeter</td><td>0.999</td><td>0.999</td></tr></table> |
d2fc6cebb3c8dd42a024d58ff01173222026dce36227b06d0076b36be532b9ff.png | complex | <table><tr><td colspan="4">β-catenin expression</td></tr><tr><td></td><td>Low (0–1)</td><td>High (2–3)</td><td></td></tr><tr><td>n(%)</td><td>53 (34.6)</td><td>100 (65.4)</td><td><i>p</i>-value</td></tr><tr><td>Age, years</td><td></td><td></td><td></td></tr><tr><td>< 65</td><td>28 (52.8)</td><td>48 (48.0)</td><td>0.613</td></tr><tr><td>≥ 65</td><td>25 (47.2)</td><td>52 (52.0)</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>32 (60.4)</td><td>52 (52.0)</td><td>0.394</td></tr><tr><td> Female</td><td>21 (39.6)</td><td>48 (48.0)</td><td></td></tr><tr><td>T</td><td></td><td></td><td></td></tr><tr><td> 1</td><td>3 (5.7)</td><td>8 (8.0)</td><td>0.602</td></tr><tr><td> 2</td><td>14 (26.4)</td><td>26 (26.0)</td><td></td></tr><tr><td> 3</td><td>34 (64.2)</td><td>65 (65.0)</td><td></td></tr><tr><td> 4</td><td>2 (3.8)</td><td>1 (1.0)</td><td></td></tr><tr><td>N</td><td></td><td></td><td></td></tr><tr><td> 0</td><td>15 (28.3)</td><td>32 (32.0)</td><td>0.714</td></tr><tr><td> 1</td><td>38 (71.7)</td><td>68 (68.0)</td><td></td></tr><tr><td>Stage (WHO)</td><td></td><td></td><td></td></tr><tr><td> IA</td><td>3 (5.7)</td><td>6 (6.0)</td><td>0.590</td></tr><tr><td> IB</td><td>6 (11.3)</td><td>12 (12.0)</td><td></td></tr><tr><td> IIA</td><td>5 (9.4)</td><td>14 (14.0)</td><td></td></tr><tr><td> IIB</td><td>37 (69.8)</td><td>67 (67.0)</td><td></td></tr><tr><td> III</td><td>2 (3.8)</td><td>1 (1.0)</td><td></td></tr><tr><td>Lymph node ratio</td><td></td><td></td><td></td></tr><tr><td>< 20 %</td><td>40 (75.5)</td><td>77 (78.6)</td><td>0.687</td></tr><tr><td>≥ 20 %</td><td>13 (24.5)</td><td>21 (21.4)</td><td></td></tr><tr><td> Missing</td><td></td><td>2</td><td></td></tr><tr><td>Grade</td><td></td><td></td><td></td></tr><tr><td> 1</td><td>5 (10.9)</td><td>17 (19.8)</td><td>0.025</td></tr><tr><td> 2</td><td>29 (63.0)</td><td>60 (69.8)</td><td></td></tr><tr><td> 3</td><td>12 (26.1)</td><td>9 (10.5)</td><td></td></tr><tr><td> Missing</td><td>7</td><td>14</td><td></td></tr><tr><td>Perineural invasion</td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>34 (77.3)</td><td>66 (77.6)</td><td>1.000</td></tr><tr><td> No</td><td>10 (22.7)</td><td>19 (22.4)</td><td></td></tr><tr><td> Missing</td><td>9</td><td>15</td><td></td></tr><tr><td colspan="4">Perivascular invasion</td></tr><tr><td> Yes</td><td>19 (43.2)</td><td>24 (30.0)</td><td>0.169</td></tr><tr><td> No</td><td>25 (56.8)</td><td>56 (70.0)</td><td></td></tr><tr><td> Missing</td><td>9</td><td>20</td><td></td></tr></table> |
2cdd39a37bba084e8a2c978942005d5a896991e5895fafb559c3cb1a2da230c0.png | simple | <table><tr><td>No.</td><td>ORF No.</td><td>Protein Name</td><td>MS/MASCOT Score</td><td>Mowse Score</td><td>% Coverage</td><td>Annotation</td><td>Putative kDa/pI</td><td>Calculated kDa/pI</td></tr><tr><td>1</td><td>2338</td><td><i>polA2*</i></td><td>15</td><td>39</td><td>13</td><td>DNA polymerase</td><td>150/4.38</td><td>148.9/4.39</td></tr><tr><td>2</td><td>2096</td><td><i>cctB</i></td><td>668</td><td></td><td>33</td><td>Thermosome β</td><td>70/4.12</td><td>69/4.1</td></tr><tr><td>3</td><td>2381</td><td><i>uvrC</i>*</td><td>40</td><td>51</td><td>18</td><td>Excision nuclease chain C</td><td>63.7/4.8</td><td>63/4.89</td></tr><tr><td>4</td><td>6363</td><td><i>Orc4/CDC6</i></td><td>82</td><td></td><td>30</td><td>Orc4/CDC6</td><td>58/4.51</td><td>58/4.52</td></tr><tr><td>5</td><td>715</td><td><i>thiC</i></td><td>57</td><td></td><td>28</td><td>Thiamine biosynthesis protein</td><td>51/4.15</td><td>51.5/4.15</td></tr><tr><td>6</td><td>1601</td><td><i>gcvP2</i>*</td><td>20</td><td>47</td><td>20</td><td>Glycine Dehydrogenase II</td><td>50/4.43</td><td>51/4.4</td></tr><tr><td>7</td><td>1356</td><td><i>fumC</i></td><td>378</td><td></td><td>27</td><td>Fumarate hydratase</td><td>50/4.4</td><td>50/4.38</td></tr><tr><td>8</td><td>2649</td><td><i>eef1A</i></td><td>158</td><td></td><td>18</td><td>Translation elongation factor α subunit</td><td>46/4.32</td><td>46.2/4.3</td></tr><tr><td>9</td><td>2606</td><td><i>thiD</i></td><td>83</td><td></td><td>21</td><td>Thiamine biosynthesis protein</td><td>45/4.2</td><td>47/4.17</td></tr><tr><td>10</td><td>95</td><td><i>gapB</i></td><td>220</td><td></td><td>13</td><td>Glyceraldehyde 3-PDH</td><td>35/4.26</td><td>35.5/4.2</td></tr><tr><td>11</td><td>903</td><td><i>yufN</i>*</td><td>20</td><td>47</td><td>8</td><td>ABC transporter</td><td>33/4.02</td><td>33.2/4.02</td></tr><tr><td>12</td><td>683</td><td><i>vng0683C</i>*</td><td>73</td><td>63</td><td>14</td><td>Hypothetical</td><td>28/4.69</td><td>28.9/4.6</td></tr><tr><td>13</td><td>2331</td><td><i>vng0309C</i>*</td><td>56</td><td>46</td><td>12</td><td>Hypothetical</td><td>25/4.48</td><td>26.9/4.31</td></tr><tr><td>14</td><td>1027</td><td><i>tpiA</i></td><td>50</td><td></td><td>13</td><td>Triosephosphate isomerase</td><td>21/3.97</td><td>21.3/4.01</td></tr><tr><td>15</td><td>2443</td><td><i>dpsA</i></td><td>60</td><td></td><td>19</td><td>Stress induced DNA binding protein</td><td>20/4.14</td><td>20.4/4.16</td></tr><tr><td>16</td><td>890</td><td><i>imD2</i></td><td>196</td><td></td><td>25</td><td>Inosine-5'-monophosphate dehydrogenase</td><td>20/4.76</td><td>20.1/4.8</td></tr><tr><td>17</td><td>1914</td><td><i>ppiA</i>*</td><td>20</td><td>45</td><td>11</td><td><underline>Peptidyl proryl isomerase</underline></td><td>20/4.02</td><td>21/4.1</td></tr><tr><td>18</td><td>633</td><td><i>purE</i></td><td>72</td><td></td><td>20</td><td>Phosphoribosylamino subunit</td><td>21/4</td><td>21.7/4.07</td></tr><tr><td>19</td><td>1180</td><td><i>msrA</i></td><td>71</td><td></td><td>38</td><td>Peptide methionine sulfoxide red.</td><td>19.4/4.2</td><td>21.1/4.18</td></tr><tr><td>20</td><td>1607</td><td><i>cheC2</i></td><td>76</td><td></td><td>12</td><td>Chemotaxis protein</td><td>21/4.23</td><td>21.7/4.2</td></tr><tr><td>21</td><td>2118</td><td><i>pyrE2</i>*</td><td>25</td><td>51</td><td>22</td><td>Orotatephosphoribosyl transferase</td><td>18/4.11</td><td>19.2/4.13</td></tr><tr><td>22</td><td>626</td><td><i>maoC2</i>*</td><td>27</td><td>52</td><td>22</td><td>Acyl Dehydratase</td><td>16.8/4.15</td><td>16.9/4.2</td></tr><tr><td>23</td><td>1807</td><td><i>vng1807H</i></td><td>55</td><td></td><td>38</td><td>Hypothetical</td><td>15/4.29</td><td>16/4.32</td></tr><tr><td>24</td><td>6254</td><td><i>vng6254</i>*</td><td>21</td><td>42</td><td>12</td><td>Conserved Hypothetical</td><td>11.4/3.85</td><td>12.2/3.9</td></tr><tr><td>25</td><td>1137</td><td><i>rpl18E</i>*</td><td>22</td><td>44</td><td>17</td><td>Ribosome assembly</td><td>12.5/5.6</td><td>12.1/5.62</td></tr><tr><td>26</td><td>1157</td><td><i>rphs6</i>*</td><td>30</td><td>47</td><td>12</td><td>Ribosome assembly</td><td>12.7/3.79</td><td>12.5/3.81</td></tr><tr><td>27</td><td>2467</td><td><i>rpl31E</i></td><td>110</td><td></td><td>71</td><td>Ribosome assembly</td><td>10/4.52</td><td>10.2/4.4</td></tr><tr><td>28</td><td>1922</td><td><i>trh5</i>*</td><td>32</td><td>54</td><td>26</td><td>Lrp like regulator</td><td>8.0/4.24</td><td>8.4/4.11</td></tr><tr><td>29</td><td>1300</td><td><i>vng1300H</i>*</td><td>49</td><td>71</td><td>91</td><td>Hypothetical</td><td>6.5/3.91</td><td>8.0/4.0</td></tr><tr><td>30</td><td>2047</td><td><i>rps27aE</i>*</td><td>30</td><td>49</td><td>10</td><td>Ribosome assembly</td><td>6/3.87</td><td>8.2/3.86</td></tr></table> |
907e4e56644af77bf5e6504517ccd3474aaf18a748673944f6f5cc89871de6bb.png | simple | <table><tr><td>Treatment groups (mg/kg)</td><td>% MNPCE (mean ± SD)</td><td>% PCE (mean ± SD)</td></tr><tr><td>Nondiabetic control</td><td>0.32 ± 0.08</td><td>48.4 ± 1.81</td></tr><tr><td>Nondiabetic + naringin (25)</td><td>0.30 ± 0.07</td><td>48.2 ± 2.16</td></tr><tr><td>Nondiabetic + naringin (50)</td><td>0.28 ± 0.08</td><td>49.0 ± 1.41</td></tr><tr><td>Diabetes</td><td>0.92 ± 0.13**</td><td>45.6 ± 3.97</td></tr><tr><td>Diabetes + naringin (25)</td><td>0.60 ± 0.12<sup>a</sup></td><td>47.0 ± 2.54</td></tr><tr><td>Diabetes + naringin (50)</td><td>0.44 ± 0.11<sup>b</sup></td><td>47.4 ± 2.40</td></tr></table> |
6e243b6ad4f784efb7a1a041a6887165d342630f8d3704d7ffbf6443f8d37cbf.png | complex | <table><tr><td>Organism</td><td>r</td><td>P-value</td></tr><tr><td>C185</td><td colspan="2">Constant</td></tr><tr><td>C212</td><td>0.791</td><td>0.034 *</td></tr><tr><td>C148</td><td>0.932</td><td>0.002 **</td></tr><tr><td>C119</td><td>0.791</td><td>0.034 *</td></tr><tr><td>C280</td><td>0.487</td><td>0.268</td></tr><tr><td>C238</td><td>-0.791</td><td>0.034 *</td></tr><tr><td>C216</td><td colspan="2">Constant</td></tr><tr><td>C149</td><td>0.277</td><td>0.547</td></tr><tr><td>C202</td><td>0.866</td><td>0.012*</td></tr><tr><td>C295</td><td>0.552</td><td>0.199</td></tr><tr><td>C274</td><td colspan="2">Not applicable</td></tr><tr><td>C222</td><td colspan="2">Constant</td></tr></table> |
299e3d1e567bf0aed69778456cb92e2fc0bae90f8e80b0e2c2e82a4003b0e459.png | complex | <table><tr><td>F0 male diet</td><td>CD</td><td>CD</td><td>HFD</td><td>HFD</td></tr><tr><td>F1 male diet</td><td>CD</td><td>HFD</td><td>CD</td><td>HFD</td></tr><tr><td>F<sub>1</sub> Male offspring</td><td><i>n </i>=<i> </i>14</td><td><i>n </i>=<i> </i>14</td><td><i>n </i>=<i> </i>20</td><td><i>n </i>=<i> </i>19</td></tr><tr><td> Total body weight (g)1</td><td>36.4 ± 0.8 a</td><td>39.8 ± 0.9 bc</td><td>37.7 ± 0.8 ab</td><td>42.1 ± 0.8 c</td></tr><tr><td colspan="5">Reproductive organs</td></tr><tr><td> Testes (g; L + R)</td><td>0.21 ± 0.01</td><td>0.20 ± 0.01</td><td>0.22 ± 0.01</td><td>0.22 ± 0.01</td></tr><tr><td> Seminal Vesicles (g; L + R)</td><td>0.36 ± 0.03 a</td><td>0.38 ± 0.04 ab</td><td>0.41 ± 0.03 ab</td><td>0.46 ± 0.03 b2</td></tr><tr><td> Gonadal fat depot (% TBW)</td><td>1.45 ± 0.21 a</td><td>2.68 ± 0.23 b</td><td>2.04 ± 0.21 a</td><td>3.91 ± 0.20 c</td></tr><tr><td colspan="5">Sex Hormone</td></tr><tr><td> Testosterone (ng ml<sup>−1</sup>)</td><td>2.51 ± 0.53</td><td>2.58 ± 0.41</td><td>2.41 ± 0.29</td><td>3.18 ± 0.28</td></tr></table> |
012e114152c06e5ab575cdbc5ac0ee7ef0656103fdde8b44ac234ec3ddfa8f23.png | complex | <table><tr><td rowspan="2">Groups</td><td colspan="2">Mean ± standard deviation (h)</td><td rowspan="2">p-value</td></tr><tr><td>Misoprostol</td><td>Foley catheter</td></tr><tr><td>Latent phase</td><td>8.5 ± 5.1</td><td>10 ± 6.8</td><td>> 0.1</td></tr><tr><td>Time to delivery</td><td>11.08 ± 5.6</td><td>13.6 ± 16.9</td><td>< 0.05</td></tr></table> |
94d6e85d7d5bd2136ed8ba937a0b8b39795da1dba09ffb5f63e7fd63edc89f09.png | complex | <table><tr><td>Group</td><td colspan="2">Severity Scale</td><td colspan="2">Weekly occurrence</td></tr><tr><td></td><td>< 21</td><td>≥ 21</td><td>< 4 day</td><td>≥ 4 day</td></tr><tr><td>Day workers (Group A), n (%)</td><td>11 (50)</td><td>11 (50)</td><td>13 (59.1)</td><td>9 (40.9)</td></tr><tr><td>Rotational shift workers, n (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> - Group B</td><td>14 (36.8)</td><td>24 (63.2)</td><td>16 (42.1)</td><td>22 (57.9)</td></tr><tr><td> - Group C</td><td>11 (28.9)</td><td>27 (71.1)</td><td>18 (47.4)</td><td>20 (52.6)</td></tr><tr><td> - Groups B and C</td><td>25 (32.9)</td><td>51 (67.1)</td><td>34 (44.7)</td><td>42 (55.3)</td></tr></table> |
da6f31b8bc42a4053365ac0bee090486e5904a04b8634e45859933d6c9d4c12d.png | complex | <table><tr><td rowspan="2">Microbial agent</td><td colspan="2">Relative rate of incidence, n (%)</td></tr><tr><td>Early infections (39 episodes)</td><td>Late infections (187 episodes)</td></tr><tr><td>Coagulase-negative Staphylococci</td><td>20 (51.3)</td><td>56 (29.9)</td></tr><tr><td>Pseudomonas species</td><td>10 (25.6)</td><td>47 (25.2)</td></tr><tr><td>Sternotrophomonas maltophylia</td><td>6 (15.4)</td><td>30 (16.1)</td></tr><tr><td>Escherichia coli</td><td>/</td><td>15 (8.0)</td></tr><tr><td>Staphylococcus aureus</td><td>3 (7.7)</td><td>14 (7.5)</td></tr><tr><td>Enterococcus faecalis</td><td>/</td><td>9 (4.8)</td></tr><tr><td>Candida species</td><td>/</td><td>8 (4.3)</td></tr><tr><td>Enterococcus</td><td>/</td><td>4 (2.1)</td></tr><tr><td>Klebsiella pneumoniae</td><td>/</td><td>4 (2.1)</td></tr></table> |
14e4b7ccd793184ad52d5f6e46cb0b827869b71f24fe17da14588098b67b7f38.png | simple | <table><tr><td>Drug [brand or alternative name(s)]</td><td>Common clinical formulation(s) (USA unless stated otherwise)</td><td>Classification; origin</td><td>Clinical use</td><td>Cellular target</td></tr><tr><td>Buprenorphine (e.g., Suboxone, Subutex, Buprenex)</td><td>Buprenorphine hydrochloride, buprenorphine naloxone (4:1)</td><td>Semisynthetic opiate; thebaine of the opium poppy (104)</td><td>Analgesia and maintenance therapy or opiate addiction treatment (Step 3 pain medication) (104)</td><td>Partial MOR agonist, KOR antagonist, nociceptin receptor agonist and antagonist (105, 106)</td></tr><tr><td>Fentanyl (e.g., Actiq, Duragesic, Fentora)</td><td>Fentanyl citrate</td><td>Synthetic opioid; <i>N</i>-phenethyl-piperidone (95)</td><td>Chronic and acute pain; administered orally, IV, transdermal patches (Step 3 pain medication) (107, 108)</td><td>Full MOR agonist, weak KOR agonist (109)</td></tr><tr><td>Heroin (i.e., diamorphine)</td><td>Diamorphine (UK) (110), diacetylmorphine (Canada/Switzerland) (111)</td><td>Opiate; morphine, and opium poppy (112)</td><td>Strong analgesic (Step 3 pain medication) (113, 114), opiate addiction treatment (Switzerland, Netherlands, Germany, England, Denmark) (115)</td><td>Partial MOR agonist (116) acts as prodrug (see active metabolites).</td></tr><tr><td>Hydrocodone (i.e., dihydrocodeinone) (e.g., Zohydro ER, Vicodin)</td><td>Hydrocodone bitartrate, hydrocodone bitartrate, and acetaminophen (117)</td><td>Semisynthetic opioid (118, 119); codeine (from opium poppy)</td><td>Chronic pain and opioid maintenance therapy (117)</td><td>Full MOR agonist (118)</td></tr><tr><td>Hydromorphone (e.g., Dilaudid)</td><td>Hydromorphone hydrochloride (120)</td><td>A semisynthetic opioid; the hydrogenated ketone of morphine (121)</td><td>Acute and chronic analgesia (Step 3 pain medication) (122), 5–8× more potent than morphine (123)</td><td>Full MOR agonist, partial DOR agonist, and weak KOR agonist (124, 125)</td></tr><tr><td>Methadone (e.g., Dolophine)</td><td>Methadone hydrochloride [(R) or racemic mixture] (126, 127)</td><td>Synthetic opioid (128); diphenylacetonitrile (129); and 1-dimethylamino-2-chloropropane (130)</td><td>Opioid dependence treatment (detoxification), chronic pain (131, 132)</td><td>Levo: full MOR agonist (109); dextro (d) NMDA antagonist (127).</td></tr><tr><td>Morphine (e.g., morphine sulfate ER, Roxanol, MsContin)</td><td>Morphine sulfate</td><td>Opiate; opium poppy (133)</td><td>Acute and chronic pain (Step 3 pain medication) (134)</td><td>Partial MOR agonist, weak DOR agonist (109, 135)</td></tr><tr><td>Oxycodone (e.g., Oxycontin, Norco, etc.)</td><td>Oxycodone hydrochloride, oxycodone acetaminophen, and oxycodone aspirin</td><td>Semisynthetic opiate; thebaine of the (136) opium poppy (137, 138)</td><td>Acute and chronic pain; may be superior than morphine for some types of pain (Step 3 pain medication) (139, 140)</td><td>Medium MOR agonist, partial KOR agonist (141), and partial DOR agonist (137, 142)</td></tr><tr><td>Remifentanil (e.g., Ultiva)</td><td>Remifentanil hydrochloride (always administered IV)</td><td>Synthetic opioid (143); derivative of fentanyl (144)</td><td>Acute pain or sedation (50–100× more potent than morphine) often used for surgical procedures (145–148)</td><td>Full MOR agonist (143)</td></tr><tr><td>Tramadol (e.g., Ultram)</td><td>Tramadol hydrochloride [racemic (+/−)], Tramadol hydrochloride, and acetaminophen</td><td>Synthetic opioid; salicylic acid with addition of 3-methoxyphenyl magnesium halide (149)</td><td>Moderate pain (Step 2 pain medication) (149, 150). Analgesic potency is 10% that of morphine (149)</td><td>(+/−) MOR agonist (151), (−) monoamine reuptake inhibitor (152)</td></tr></table> |
11eed28fab235253b7390e08800689e282a422e7fc58acaa65c5b75c54152e5b.png | simple | <table><tr><td>Difficulties</td><td>Frequency (n = 59)**</td><td>Percentage</td></tr><tr><td>Institutional related</td><td></td><td></td></tr><tr><td>Few staff & heavy workload</td><td>20</td><td>33.9</td></tr><tr><td>Lack of testing kits and other logistical support</td><td>12</td><td>20.3</td></tr><tr><td>Occupational hazards (pricking self and infections)</td><td>7</td><td>11.9</td></tr><tr><td>Lack of prior sensitization before referral for testing</td><td>6</td><td>10.2</td></tr><tr><td>Poor motivation of staff</td><td>3</td><td>5.1</td></tr><tr><td>Lack of ARVs</td><td>2</td><td>3.4</td></tr><tr><td>Lack of child-friendly environment</td><td>2</td><td>3.4</td></tr><tr><td>Caretaker related</td><td></td><td></td></tr><tr><td>Unwillingness of caretakers to disclose to child</td><td>15</td><td>25.4</td></tr><tr><td>Caretakers refusing children to be tested</td><td>7</td><td>11.9</td></tr><tr><td>Caretakers look at HIV-infected children as a burden</td><td>3</td><td>5.1</td></tr><tr><td>Sick and weak parents</td><td>3</td><td>5.1</td></tr><tr><td>Clients not sympathetic to health workers due to desperation</td><td>2</td><td>3.4</td></tr><tr><td>Some parents deny parenthood (stigma)</td><td>2</td><td>3.4</td></tr><tr><td>Lack of consistency by caregivers</td><td>2</td><td>3.4</td></tr><tr><td>Child related</td><td></td><td></td></tr><tr><td>Children cannot express themselves easily</td><td>8</td><td>13.6</td></tr><tr><td>Dependency nature of children</td><td>6</td><td>10.2</td></tr><tr><td>Children require more time for counselling</td><td>5</td><td>8.9</td></tr><tr><td>Most children are needy & orphans</td><td>4</td><td>6.8</td></tr><tr><td>Need a lot of support to adhere to treatment</td><td>3</td><td>5.1</td></tr><tr><td>Children have many fears - death and abandonment</td><td>2</td><td>3.4</td></tr><tr><td>Health worker related</td><td></td><td></td></tr><tr><td>Failure to cope with knowledge demand for HIV care</td><td>14</td><td>23.7</td></tr><tr><td>Lack of specialized skills in paediatric counselling & management</td><td>10</td><td>16.9</td></tr><tr><td>Difficult of dealing with non-parents</td><td>7</td><td>11.9</td></tr><tr><td>Difficult to draw blood from children</td><td>4</td><td>6.8</td></tr><tr><td>Difficult to disclose to children</td><td>3</td><td>5.1</td></tr><tr><td>Caretakers refuse other monitoring tests for ART</td><td>2</td><td>3.4</td></tr></table> |
6e6d4770f882e0786dba542fdeeba8fed869fa76aed1d469b8e1379f794528d0.png | complex | <table><tr><td></td><td colspan="2">Median pericardial volume</td><td colspan="3">Univariate analysis</td></tr><tr><td>Parameters</td><td>Grade 2, 3</td><td>Grade 0</td><td>Odds ratio<sup>a</sup></td><td>95% CI</td><td><i>P</i> value</td></tr><tr><td>V5 Gy (%)</td><td>79.7 (51.8–100.0)</td><td>66.5 (45.7–88.5)</td><td>1.08</td><td>1.03–1.13</td><td>0.0004</td></tr><tr><td>V10 Gy (%)</td><td>74.2 (46.5–97.6)</td><td>61.1 (40.8–84.7)</td><td>1.08</td><td>1.03–1.13</td><td>0.0003</td></tr><tr><td>V20 Gy (%)</td><td>68.2 (38.8–88.2)</td><td>53.4 (33–80.2)</td><td>1.08</td><td>1.03–1.13</td><td>0.0003</td></tr><tr><td>V30 Gy (%)</td><td>55.9 (32.1–83.3)</td><td>44.5 (19.5–74.3)</td><td>1.08</td><td>1.03–1.13</td><td>0.0005</td></tr><tr><td>V40 Gy (%)</td><td>43.8 (19.2–78.8)</td><td>34.2 (8.9–57.1)</td><td>1.06</td><td>1.02–1.11</td><td>0.0024</td></tr><tr><td>V50 Gy (%)</td><td>24.5 (10.9–47.3)</td><td>16.5 (6.7–35.8)</td><td>1.13</td><td>1.05–1.23</td><td>0.0009</td></tr><tr><td>V60 Gy (%)</td><td>8.0 (0.3–21.6)</td><td>4.5 (0.4–14.8)</td><td>1.19</td><td>1.04–1.39</td><td>0.0228</td></tr><tr><td>Mean dose (Gy)</td><td>31.7 (16.7–44.1)</td><td>25.6 (14.3–37.9)</td><td>1.16</td><td>1.06–1.28</td><td>0.0005</td></tr></table> |
2ccc259ce5519adb077fbfa8239988d549e431657cbdebee1c607758bb06d8c3.png | simple | <table><tr><td>Parameter</td><td>Value</td></tr><tr><td>Frequency</td><td>2.41 GHz</td></tr><tr><td>Transmitted Power Level</td><td>0 dBm</td></tr><tr><td>Antenna gain</td><td>5 dBi</td></tr><tr><td>Vertical plane angle resolution Δθ</td><td>1°</td></tr><tr><td>Horizontal plane angle resolution Δφ</td><td>1°</td></tr><tr><td>Reflections</td><td>5</td></tr></table> |
0fc3a968e0bb3f2569614f788f6c92ad4543cd36a47ecd12d4c8f955b8e1987a.png | complex | <table><tr><td rowspan="2">Parameter, n (%)</td><td>Treatment-naïve patients</td></tr><tr><td>(<i>N</i> = 39)</td></tr><tr><td>At any time during study</td><td></td></tr><tr><td> Increase from baseline ≥10 mm Hg</td><td>12 (30.8)</td></tr><tr><td> Post-baseline IOP ≥25 mm Hg</td><td>15 (38.5)</td></tr><tr><td> Post-baseline IOP ≥35 mm Hg</td><td>5 (12.8)</td></tr><tr><td>At final visit</td><td></td></tr><tr><td> Increase from baseline ≥10 mm Hg</td><td>4 (10.3)</td></tr><tr><td> IOP ≥25 mm Hg</td><td>4 (10.3)</td></tr><tr><td> IOP ≥35 mm Hg</td><td>0 (0)</td></tr><tr><td>Glaucoma surgery (laser/incisional)</td><td>0 (0)</td></tr><tr><td>IOP-lowering medication used secondary to retina treatment</td><td>12 (30.8)</td></tr></table> |
61613186f8b070a8211369e1dace54a02ab9837f69c303aa96d6a9777d9aff68.png | complex | <table><tr><td>Consequence of muscle paralysis</td><td>Options for intervention</td></tr><tr><td rowspan="2">Motor weakness</td><td>Tendon transfer if muscle of adequate power (Grade V on the MRC scale) is available</td></tr><tr><td>Bracing if muscle of adequate power is not available</td></tr><tr><td rowspan="2">Muscle imbalance</td><td>Tendon transfer from stronger side of the joint to the weaker side of the joint if muscle of adequate power is available</td></tr><tr><td>Weaken muscles on stronger side of the joint if muscle of adequate power is not available for transfer</td></tr><tr><td rowspan="4">Instability of joint</td><td>Tendon transfer if:(a) Muscle of adequate muscle power available for transfer, (b) Instability is unidirectional (possibly bi-directional around ankle and foot)</td></tr><tr><td>Osteotomy to alter the biomechanics and restore stability (e.g., shifting the axis of movement of the joint)</td></tr><tr><td>Bracing if tendon transfer or osteotomy is not feasible</td></tr><tr><td>Arthrodesis (appropriate only for spine, shoulder, wrist and foot)</td></tr><tr><td rowspan="3">Deformity</td><td>Soft tissue contracture release (release of tendons, fascia, joint capsule)</td></tr><tr><td>Osteotomy for residual deformity after soft tissue release</td></tr><tr><td>Ignore if deformity contributes to stability (e.g., mild genu recurvatum or mild equinus in child with quadriceps paralysis)</td></tr><tr><td rowspan="4">Shortening of lower limb</td><td>Lengthening of short lower limb</td></tr><tr><td>Growth arrest of long lower limb</td></tr><tr><td>Compensate with shoe lift (especially if orthosis is required for shorter limb)</td></tr><tr><td>Ignore shortening in the upper limb and if <2 cm in the lower limb</td></tr></table> |
09370fbb4b62a1dadeae9988cdf2f7dd7d4158648feb0a807ee58201c64a4ddf.png | complex | <table><tr><td> </td><td colspan="2">Effect of Dex</td></tr><tr><td> </td><td>Fold change of AQP5 mRNA</td><td>Fold change of AQP5 protein</td></tr><tr><td>Dividing cells</td><td> </td><td> </td></tr><tr><td> <70% confluent</td><td>↓ 0–2x</td><td>↓ 0–2x</td></tr><tr><td>Nondividing cells</td><td> </td><td> </td></tr><tr><td> 90–100% confluent</td><td>↓ 4–6x</td><td>↓ 4–6x</td></tr><tr><td> Matrigel treated cells</td><td>↓ 4–6x; after 2 h</td><td>↓ 4–6x; after 6 h</td></tr></table> |
033da487f2b78dcfcab72f8baf74480378739d0958ce541b710bc43c9b80b2b6.png | simple | <table><tr><td>Characteristic</td><td>Value</td></tr><tr><td>Age, years</td><td>71 (51; 78)</td></tr><tr><td>Height, cm</td><td>169 ± 7</td></tr><tr><td>Weight, kg</td><td>74 (72; 85)</td></tr><tr><td>Body mass index, kg/cm<sup>2</sup></td><td>26.4 (23.9; 30.1)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Male</td><td>21 (84%)</td></tr><tr><td>Female</td><td>4 (16%)</td></tr><tr><td>Simplified acute physiology score 2</td><td>29.2 ± 7.6</td></tr><tr><td>Type of surgery</td><td></td></tr><tr><td>Abdominal</td><td>10 (40%)</td></tr><tr><td>Vascular</td><td>5 (20%)</td></tr><tr><td>Endocrine</td><td>4 (16%)</td></tr><tr><td>Urologic</td><td>3 (12%)</td></tr><tr><td>Others</td><td>3 (12%)</td></tr><tr><td>Richmond agitation-sedation scale score</td><td></td></tr><tr><td>−1</td><td>9 (36%)</td></tr><tr><td>0</td><td>16 (64%)</td></tr><tr><td>Length of stay, days</td><td>2.6 ± 2.2</td></tr><tr><td>Length of mechanical ventilation, days</td><td>1.4 ± 0.9</td></tr></table> |
a1c96b4a5b127692642118c3dac169ee825d2f239e27223c79b7c4336da3cab9.png | simple | <table><tr><td></td><td>PDB Entry</td><td>5WZE</td></tr><tr><td>Data collection</td><td>Space group</td><td>P 21 21 21</td></tr><tr><td></td><td>Cell dimension</td><td></td></tr><tr><td></td><td><i>a, b, c (Å)</i></td><td>111.197,123.432,149.485</td></tr><tr><td></td><td>α, β, γ (°)</td><td>90, 90, 90</td></tr><tr><td></td><td>Wavelength</td><td>0.97776</td></tr><tr><td></td><td>Resolution (Å)</td><td>48.01–1.783 (1.847–1.783)</td></tr><tr><td></td><td>I/I</td><td>19.714 (2.167)</td></tr><tr><td></td><td>Completeness (%)</td><td>0.99</td></tr><tr><td></td><td><i>R</i><sub>merge</sub></td><td>0.099 (0.709)</td></tr><tr><td></td><td>Redundancy</td><td>8.9 (6.4)</td></tr><tr><td>Refinement</td><td>Resolution (Å)</td><td>48.01–1.783 (1.847–1.783)</td></tr><tr><td></td><td>No. of reflections</td><td>194404 (18600)</td></tr><tr><td></td><td>Rwork/Rfree</td><td>0.2105/0.2206</td></tr><tr><td></td><td>No. of atoms</td><td></td></tr><tr><td></td><td>Protein</td><td>1783</td></tr><tr><td></td><td>Ligand/ion</td><td>90</td></tr><tr><td></td><td>Water</td><td>1153</td></tr><tr><td></td><td>B-factor</td><td></td></tr><tr><td></td><td>Protein</td><td>27.37</td></tr><tr><td></td><td>Ligand/ion</td><td>38.94</td></tr><tr><td></td><td>Water</td><td>30.89</td></tr><tr><td></td><td><i>R.m.s. deviations</i></td><td></td></tr><tr><td></td><td>Bond lengths (Å)</td><td>0.011</td></tr><tr><td></td><td>Bond angles (°)</td><td>1.00</td></tr><tr><td></td><td>Ramachandran plot</td><td>98/1.5/0</td></tr></table> |
63e64b0ce8f5c499f5d8548a2338bb1dee6bbf767a0b73d3efef18d0fe8513d7.png | complex | <table><tr><td></td><td></td><td colspan="6">Test database MegaBLAST score</td></tr><tr><td>FAexpTRL</td><td>Annotation</td><td>Lp_MF</td><td>Zm_MF</td><td>Zm_TA</td><td>Hv_TA</td><td>Gm_TA</td><td>At_TA</td></tr><tr><td>LOC_Os04g16450</td><td>aquaporin PIP2.8, putative, expressed</td><td>470</td><td>357</td><td>351</td><td>838</td><td>121</td><td>121</td></tr><tr><td>LOC_Os04g16680</td><td>Sedoheptulose-1,7-bisphosphatase, chloroplast precursor, putative, expressed</td><td>289</td><td>995</td><td>1112</td><td>1112</td><td>184</td><td>129</td></tr><tr><td>LOC_Os04g16740</td><td>ATP synthase alpha chain, putative, expressed</td><td>1037</td><td>644</td><td>743</td><td>1126</td><td>856</td><td>815</td></tr><tr><td>LOC_Os04g16750</td><td>Photosystem I P700 chlorophyll a apoprotein A2, putative, expressed</td><td>613</td><td>868</td><td>644</td><td>628</td><td>470</td><td>462</td></tr><tr><td>LOC_Os04g16760</td><td>Photosystem I P700 chlorophyll a apoprotein A1, putative, expressed</td><td>503</td><td>1465</td><td>1100</td><td>323</td><td>357</td><td>252</td></tr><tr><td>LOC_Os04g16770</td><td>Photosystem Q, putative, expressed</td><td>936</td><td>190</td><td>539</td><td>1891</td><td>848</td><td>987</td></tr><tr><td>LOC_Os04g16780</td><td>Chloroplast 30S ribosomal protein S3, putative, expressed</td><td>129</td><td>287</td><td>474</td><td>498</td><td>97.6</td><td>141</td></tr><tr><td>LOC_Os04g16790</td><td>DNA-directed RNA polymerase alpha chain, putative, expressed</td><td>525</td><td>-</td><td>1086</td><td>1219</td><td>216</td><td>206</td></tr><tr><td>LOC_Os04g16819</td><td>DNA-directed RNA polymerase beta chain, putative, expressed</td><td>264</td><td>1265</td><td>410</td><td>394</td><td>105</td><td>188</td></tr><tr><td>LOC_Os04g16820</td><td>DNA-directed RNA polymerase beta chain, putative, expressed</td><td>1072</td><td>-</td><td>1096</td><td>460</td><td>266</td><td>-</td></tr><tr><td>LOC_Os10g21200</td><td>Photosystem Q, putative, expressed</td><td>936</td><td>1037</td><td>539</td><td>1883</td><td>840</td><td>979</td></tr><tr><td>LOC_Os10g21270</td><td>ATP synthase beta chain, putative, expressed</td><td>991</td><td>1524</td><td>1376</td><td>527</td><td>573</td><td>793</td></tr><tr><td>LOC_Os10g21280</td><td>Ribulose bisphosphate carboxylase large chain precursor, putative, expressed</td><td>936</td><td>591</td><td>1766</td><td>1701</td><td>531</td><td>981</td></tr><tr><td>LOC_Os10g21310</td><td>Photosystem II P680 chlorophyll A apoprotein, putative, expressed</td><td>561</td><td>287</td><td>551</td><td>170</td><td>206</td><td>-</td></tr><tr><td>LOC_Os10g21330</td><td>DNA-directed RNA polymerase alpha chain, putative, expressed</td><td>525</td><td>184</td><td>1070</td><td>1203</td><td>216</td><td>206</td></tr><tr><td>LOC_Os10g38229</td><td>Photosystem I P700 chlorophyll a apoprotein A1, putative, expressed</td><td>496</td><td>914</td><td>1092</td><td>323</td><td>357</td><td>252</td></tr><tr><td>LOC_Os10g38248</td><td>Photosystem I P700 chlorophyll a apoprotein A2, putative, expressed</td><td>1033</td><td>949</td><td>936</td><td>906</td><td>716</td><td>1076</td></tr><tr><td>LOC_Os10g38270</td><td>ATP synthase alpha chain, putative, expressed</td><td>1029</td><td>-</td><td>698</td><td>1098</td><td>848</td><td>815</td></tr><tr><td>LOC_Os10g38292</td><td>Chloroplast ATP synthase a chain precursor, putative, expressed</td><td>109</td><td>258</td><td>-</td><td>1096</td><td>545</td><td>614</td></tr><tr><td>Mean MegaBLAST score</td><td></td><td>214</td><td>260</td><td>504</td><td>473</td><td>155</td><td>151</td></tr></table> |
54a00c7d11abdf200e43c16a1a4cd05a0f4958e3e856bacbc8119bf19cebece0.png | complex | <table><tr><td></td><td>B</td><td>SE <sup>a</sup></td><td>Sig</td><td colspan="2">95% CI for B</td></tr><tr><td>Lifetime anxiety</td><td>­0.151</td><td>0.216</td><td>0.487</td><td>­0.590</td><td>0.287</td></tr><tr><td>Lifetime depression</td><td>0.006</td><td>0.136</td><td>0.964</td><td>­0.271</td><td>0.283</td></tr><tr><td>Age</td><td>0.004</td><td>0.003</td><td>0.142</td><td>­0.001</td><td>0.009</td></tr><tr><td>Employment<sup>b</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Unemployed</td><td>­0.080</td><td>0.142</td><td>0.574</td><td>­0.368</td><td>0.207</td></tr><tr><td>Not in labor force</td><td>­0.213</td><td>0.103</td><td>0.047</td><td>­0.423</td><td>­0.003</td></tr><tr><td>Education<sup>c</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>12 years</td><td>­0.068</td><td>0.080</td><td>0.396</td><td>­0.230</td><td>0.093</td></tr><tr><td>13 ­ 15 years</td><td>0.038</td><td>0.075</td><td>0.617</td><td>­0.114</td><td>0.189</td></tr><tr><td>16 years or more</td><td>0.123</td><td>0.113</td><td>0.283</td><td>­0.106</td><td>0.353</td></tr><tr><td>Marital status<sup>d</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Divorced / Separated / Widowed</td><td>­0.265</td><td>0.088</td><td>0.005</td><td>­0.443</td><td>­0.086</td></tr><tr><td>Never married</td><td>­0.316</td><td>0.079</td><td>< 0.001</td><td>­0.477</td><td>­0.156</td></tr><tr><td>Region<sup>e</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Midwest</td><td>0.200</td><td>0.181</td><td>0.278</td><td>­0.169</td><td>0.569</td></tr><tr><td>South</td><td>0.010</td><td>0.142</td><td>0.944</td><td>­0.278</td><td>0.298</td></tr><tr><td>West</td><td>­0.079</td><td>0.169</td><td>0.644</td><td>­0.423</td><td>0.265</td></tr><tr><td>Intercept</td><td>3.138</td><td>0.197</td><td>< 0.001</td><td>2.737</td><td>3.539</td></tr></table> |
d119a3e1f801473d0e5496b2a3f08ba4cf65b27f3af161004ea433887f5ac952.png | complex | <table><tr><td></td><td colspan="9">Subgroup 1 (<i>n</i> = 11) VPIT test performance without support</td></tr><tr><td>VPIT parameters</td><td>Test Mean ± SD</td><td>Retest Mean ± SD</td><td>Test-Retest Mean difference ± SD</td><td>Kendall’s tau correlation</td><td>Kendall’s tau correlation with transformed data</td><td>ICC (95 % CI)</td><td>SEM agreement</td><td>SDD</td><td>SDD%</td></tr><tr><td>T<sub>ex</sub> [s]</td><td>113.14 ± 64.54</td><td>83.56 ± 27.26</td><td>29.57 ± 61.17</td><td>.19<sup>a</sup></td><td>0.31<sup>c</sup></td><td>0.35 (−0.90–0.81)</td><td>37.01</td><td>102.50</td><td>682.87</td></tr><tr><td>N<sub>dp</sub></td><td>0.12 ± 0.23</td><td>0.12 ± 0.23</td><td>0.0 ± 0.34</td><td>0.0</td><td>-</td><td>0.25 (−6.04–0.69)</td><td>0.20</td><td>0.55</td><td>3.66</td></tr><tr><td>F<sub>g</sub> go [N]</td><td>10.49 ± 4.84</td><td>10.13 ± 4.09</td><td>0.36 ± 3.4</td><td>0.20<sup>a</sup></td><td>0.24<sup>c</sup></td><td>0.84 (0.40–0.96)</td><td>1.79</td><td>4.95</td><td>32.97</td></tr><tr><td>F<sub>g</sub> return [N]</td><td>1.74 ± 0.92</td><td>1.55 ± 1.22</td><td>0.19 ± 0.93</td><td>0.13<sup>a</sup></td><td>0.13<sup>d</sup></td><td>0.78 (0.18–0.94)</td><td>0.50</td><td>1.39</td><td>9.26</td></tr><tr><td>N<sub>zc [1/s]</sub> go</td><td>11.18 ± 1.79</td><td>10.79 ± 1.97</td><td>0.39 ± 1.21</td><td>0.06</td><td>-</td><td>0.89 (0.60–0.97)</td><td>0.62</td><td>1.73</td><td>11.53</td></tr><tr><td>N<sub>zc [1/s]</sub> return</td><td>11.72 ± 1.91</td><td>10.80 ± 1.83</td><td>0.92 ± 1.29</td><td>0.09</td><td>-</td><td>0.82 (0.28–0.95)</td><td>0.79</td><td>2.20</td><td>14.66</td></tr><tr><td rowspan="2">E<sub>traj</sub> go [cm]</td><td>0.56 ± 0.27</td><td>0.47 ± 0.15</td><td>0.09 ± 0.20</td><td rowspan="2">0.16<sup>a</sup></td><td rowspan="2">0.10<sup>b,c</sup></td><td>0.70 (0.00–0.92)</td><td>0.12</td><td>0.32</td><td>2.13</td></tr><tr><td>0.29 ± 0.18<sup>c</sup></td><td>0.35 ± 0.15<sup>c</sup></td><td>0.06 ± 0.11<sup>c</sup></td><td>0.83 (0.38–0.95)<sup>c</sup></td><td>0.07<sup>c</sup></td><td>0.19<sup>c</sup></td><td>1.27<sup>c</sup></td></tr><tr><td>E<sub>traj</sub> return [cm]</td><td>0.79 ± 0.28</td><td>0.75 ± 0.35</td><td>0.04 ± 0.42</td><td>0.06</td><td>-</td><td>0.18 (−2.80–0.80)</td><td>0.29</td><td>0.79</td><td>5.26</td></tr><tr><td>F<sub>cmean</sub> [N]</td><td>1.08 ± 0.72</td><td>1.18 ± 0.66</td><td>−0.10 ± 0.52</td><td>0.02</td><td>-</td><td>0.84 (0.41–0.96)</td><td>0.28</td><td>0.77</td><td>5.13</td></tr></table> |
9536b2473342be1967bd9a74d6ea39b4dceeb3175cf57234d5b4dec0d941777d.png | simple | <table><tr><td></td><td>SUL</td><td>PAF</td><td>PTV</td><td>PAD</td><td>PBT</td><td>BAU</td><td>BOB</td><td>BPN</td><td>BFL</td></tr><tr><td>Gene number</td><td>6</td><td>13</td><td>13</td><td>13</td><td>5</td><td>26</td><td>18</td><td>18</td><td>18</td></tr><tr><td>dS/t</td><td>1.5 × 10<sup>-10</sup></td><td>2.9 × 10<sup>-09</sup></td><td>3.6 × 10<sup>-09</sup></td><td>4.8 × 10<sup>-09</sup></td><td>1.3 × 10<sup>-08</sup></td><td>1.1 × 10<sup>-08</sup></td><td>7.9 × 10<sup>-08</sup></td><td>6.4 × 10<sup>-08</sup></td><td>8.9 × 10<sup>-08</sup></td></tr><tr><td>dN/t</td><td>5.8 × 10<sup>-11</sup></td><td>2.0 × 10<sup>-10</sup></td><td>2.4 × 10<sup>-10</sup></td><td>3.1 × 10<sup>-10</sup></td><td>9.5 × 10<sup>-10</sup></td><td>1.0 × 10<sup>-09</sup></td><td>5.2 × 10<sup>-09</sup></td><td>5.6 × 10<sup>-09</sup></td><td>7.9 × 10<sup>-09</sup></td></tr></table> |
4826b5c76d4aad712511560e79b561d99018a4bea14c1fdf98a5dbbc65f064ef.png | simple | <table><tr><td>Rank</td><td>Microbe</td><td>Evidence</td></tr><tr><td>1</td><td><i>Helicobacter pylori</i></td><td>PMID:24782613</td></tr><tr><td>2</td><td><i>Clostridium difficile</i></td><td>PMID:23734349</td></tr><tr><td>3</td><td><i>Prevotella</i></td><td>PMID:23613868</td></tr><tr><td>4</td><td><i>Actinobacteria</i></td><td>PMID:23613868</td></tr><tr><td>5</td><td><i>Staphylococcus aureus</i></td><td>PMID:16495627</td></tr><tr><td>6</td><td><i>Lachnospiraceae</i></td><td>unconfirmed</td></tr><tr><td>7</td><td><i>Staphylococcus</i></td><td>PMID:24385898</td></tr><tr><td>8</td><td><i>Haemophilus</i></td><td>unconfirmed</td></tr><tr><td>9</td><td><i>Bacteroides</i></td><td>PMID:20140211</td></tr><tr><td>10</td><td><i>Enterobacteriaceae</i></td><td>PMID:25759592</td></tr></table> |
6ca2093326dfb092ee373951f29e11677db5802158f2220c8d899296d9a39038.png | simple | <table><tr><td> </td><td>Pre (N=174)</td><td>During (N=116)</td><td>Post (N=174)</td><td>Overall (N=464)</td></tr><tr><td>Median age years (IQR)</td><td>76 (65–82)</td><td>74.5 (61–84)</td><td>75 (62–83)</td><td>75 (62–83)</td></tr><tr><td>Female (%)</td><td>81/174 (46.6)</td><td>63/116 (54.3)</td><td>97/174 (55.7)</td><td>241/464 (51.9)</td></tr><tr><td>Dispatched as stroke (%) (all diagnoses)</td><td>134/168 (79.8)</td><td>105/111 (94.6)</td><td>159/171 (93.0)</td><td>398/450 (88.4)</td></tr><tr><td>Final Diagnosis of stroke (%)</td><td>98/162 (60.5)</td><td>53/106 (50.0)</td><td>62/159 (39.0)</td><td>213/427 (49.9)</td></tr></table> |
156a5e4d1fd7e91202dc3411272cb14e7e7d0f986573c3d0baa0eccb404c82aa.png | simple | <table><tr><td>Variable</td><td>No.<sup>#</sup> N = 346</td><td>3-year OS (%)</td><td>p-value</td><td>3-year LRFS (%)</td><td>p-value</td><td>3-year DFS (%)</td><td>p-value</td></tr><tr><td>Age</td><td></td><td></td><td>0.002</td><td></td><td>0.001</td><td></td><td>0.008</td></tr><tr><td><50 y</td><td>225</td><td>87</td><td></td><td>97</td><td></td><td>80</td><td></td></tr><tr><td>≥50 y</td><td>121</td><td>75</td><td></td><td>87</td><td></td><td>69</td><td></td></tr><tr><td>N-stage</td><td></td><td></td><td>0.003</td><td></td><td>0.685</td><td></td><td>0.024</td></tr><tr><td>N0</td><td>63</td><td>92</td><td></td><td>94</td><td></td><td>84</td><td></td></tr><tr><td>N1</td><td>110</td><td>87</td><td></td><td>92</td><td></td><td>77</td><td></td></tr><tr><td>N2</td><td>113</td><td>84</td><td></td><td>94</td><td></td><td>77</td><td></td></tr><tr><td>N3</td><td>60</td><td>67</td><td></td><td>96</td><td></td><td>65</td><td></td></tr><tr><td>T-stage</td><td></td><td></td><td>0.105</td><td></td><td>0.838</td><td></td><td>0.050</td></tr><tr><td>T3</td><td>59</td><td>90</td><td></td><td>95</td><td></td><td>88</td><td></td></tr><tr><td>T4</td><td>287</td><td>82</td><td></td><td>93</td><td></td><td>74</td><td></td></tr><tr><td>Overall stage</td><td></td><td></td><td>0.038</td><td></td><td>0.684</td><td></td><td>0.024</td></tr><tr><td>III</td><td>53</td><td>92</td><td></td><td>94</td><td></td><td>91</td><td></td></tr><tr><td>IV</td><td>293</td><td>82</td><td></td><td>94</td><td></td><td>74</td><td></td></tr><tr><td>Chemotherapy</td><td></td><td></td><td>0.386</td><td></td><td>0.059</td><td></td><td>0.427</td></tr><tr><td>Yes</td><td>327</td><td>84</td><td></td><td>94</td><td></td><td>77</td><td></td></tr><tr><td>No</td><td>19</td><td>72</td><td></td><td>83</td><td></td><td>68</td><td></td></tr><tr><td>Prescribed dose</td><td></td><td></td><td>0.926</td><td></td><td>0.985</td><td></td><td>0.793</td></tr><tr><td>≤73.92 Gy</td><td>311</td><td>83</td><td></td><td>93</td><td></td><td>76</td><td></td></tr><tr><td>>73.92 Gy</td><td>35</td><td>85</td><td></td><td>94</td><td></td><td>75</td><td></td></tr><tr><td>Residual tumor*</td><td></td><td></td><td>0.007</td><td></td><td>0.002</td><td></td><td><0.001</td></tr><tr><td>No</td><td>205</td><td>90</td><td></td><td>97</td><td></td><td>82</td><td></td></tr><tr><td>Yes</td><td>141</td><td>73</td><td></td><td>89</td><td></td><td>67</td><td></td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.